"","pmid","doi","title","abstract","year","month","day","jabbrv","journal","keywords","lastname","firstname","address","email"
"1","34118731","10.1016/j.jiph.2021.04.001","Nonlinear dynamics for the spread of pathogenesis of COVID-19 pandemic.","Coronaviruses did not invite attention at a global level and responsiveness until the series of 2003-SARS contagion followed by year-2012 MERS plus, most recently, 2019-nCoV eruptions. SARS-CoV &amp;MERS-CoV are painstaking, extremely pathogenic. Also, very evidently, both have been communicated from bats to palm-civets &amp; dromedary camels and further transferred ultimately to humans. No country has been deprived of this viral genomic contamination wherever populaces reside and are interconne","2021","06","12","J Infect Public Health","Journal of infection and public health","COVID-19; Lyapunov exponents; Phase space; RNA genome; Time domainic analysis","Sharma","Sunil Kumar","Department of Information Technology, College of Computer and Information Sciences, Majmaah University, Majmaah, Saudi Arabia. Electronic address: s.sharma@mu.edu","s.sharma@mu.edu.sa"
"2","34118289","10.1016/j.ijbiomac.2021.06.015","Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides.","COVID-19 caused by SARS-CoV-2 corona virus has become a global pandemic. In the absence of drugs and vaccine, and premises of time, efforts and cost required for their development, natural resources such as herbs are anticipated to provide some help and may also offer a promising resource for drug development. Here, we have investigated the therapeutic prospective of Ashwagandha for the COVID-19 pandemic. Nine withanolides were tested in silico for their potential to target and inhibit (i) cell ","2021","06","12","Int J Biol Macromol","International journal of biological macromolecules","COVID-19; Main protease (M(pro)); SARS-CoV-2; Transmembrane protease serine 2 (TMPRSS2); Withanolides; Withanosides","Dhanjal","Jaspreet Kaur","Indraprastha Institute of Information Technology Delhi, Okhla Industrial Estate, Phase III, New Delhi 110 020, India. Electronic address: jaspreet@iiitd.ac","jaspreet@iiitd.ac.in"
"3","34117994","10.1007/s40120-021-00261-4","Emerging Infection, Vaccination, and Guillain-Barr.. Syndrome: A Review.","Guillain-Barr.. syndrome (GBS) is an autoimmune disorder of the peripheral nervous system that typically develops within 4..weeks after infection. In addition to conventional infectious diseases with which we are familiar, emerging infectious diseases, such as Zika virus infection and coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have also been suggested to be associated with GBS. GBS is mainly categorized into a demyelinating subtype","2021","06","12","Neurol Ther","Neurology and therapy","Adverse events; Clinical trials; Epidemiology; Glycolipids; Pathogenesis; Pathophysiology; Prevention; Treatment; Vaccine; World Health Organization","Koike","Haruki","Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan. koike-haruki@med.nagoya-u.ac","haruki@med.nagoya"
"4","34117979","10.1007/s10654-021-00767-z","Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program.","The Human Immunomics Initiative (HII), a joint project between the Harvard T.H. Chan School of Public Health and the Human Vaccines Project (HVP), focuses on studying immunity and the predictability of immuneresponsiveness to vaccines in aging populations. This paper describes the hypotheses and methodological approaches of this new collaborative initiative. Central to our thinking is the idea that predictors of age-related non-communicable diseases are the same as predictors for infectious dise","2021","06","12","Eur J Epidemiol","European journal of epidemiology","Aging-related diseases; Biological age; Immune aging; Vaccine responsiveness","Goudsmit","Jaap","Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA",NA
"5","34114939","10.1080/21645515.2021.1922060","A rational strategy to support approved COVID-19 vaccines prioritization.","The World Health Organization (WHO) proposed a set of criteria to be considered for the prioritization of COVID-19 candidate vaccines for further development of phase II/III clinical trials, thinking in a target audience that includes vaccine scientists, product developers, manufacturers, regulators, and funding agencies. In this paper, a knowledge-based or rational strategy is employed to perform a prioritization matrix of approved COVID-19 vaccines: BBIBP-CorV, JANSSEN, CORONAVAC, SPUTNIK V, M","2021","06","11","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","COVID-19 vaccines; SARS-CoV-2; formal concept analysis; vaccine prioritization","Burgos-Salcedo","Javier","Biomathematics Department, Corporaci..n para la Investigaci..n y la Innovaci..n-CIINAS, Colombia",NA
"6","34114884","10.4155/bio-2021-0065","Validation of high-throughput, semiquantitative solid phase SARS..coronavirus-2 serology assays in serum and dried blood spot matrices.","Aim: Serological assays for the detection of anti-SARS..coronavirus-2 (SARS-CoV-2) antibodies are essential to the response to the global pandemic. A ligand..binding-based serological assay..was validated for the semiquantitative detection of IgG, IgM, IgA and neutralizing antibodies (nAb) against SARS-CoV-2 in serum. Results: The assay demonstrated high levels of diagnostic specificity and sensitivity (85-99% for all analytes). Serum IgG, IgM, IgA and nAb correlated positively (R<","2021","06","11","Bioanalysis","Bioanalysis","COVID-19; ELISA; SARS-CoV-2; dried blood spot; neutralizing antibodies; serology","Maritz","Leo","Synexa Life Sciences, 4 Kunene Circle, Montague Gardens, Cape Town, 7441, South Africa",NA
"7","34112143","10.1186/s12889-021-11197-7","Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda.","Health experts agree that widespread use of safe and effective vaccines will rapidly contain the COVID-19 pandemic. The big question is whether these vaccines can easily be accepted by their end-users. Our study aimed at determining sociodemographic factors associated with acceptance of vaccines and clinical trials of COVID-19 in western Uganda. A simplified snowball sampling technique was used to select 1067 respondents of 18-70...years in western Uganda using an online questionnaire from July ","2021","06","13","BMC Public Health","BMC public health","Acceptance; COVID-19; Clinical trials; Western Uganda; vaccine","Echoru","Isaac","School of Medicine, Kabale University, Kabale, Uganda. echoruisaac@gmail","echoruisaac@gmail.com"
"8","34108276","","COVID-19 Eradication for Vaccine Equity in Low Income Countries.","The coronavirus disease 2019 (COVID-19) pandemic will transition into endemic phase with perpetual risk of severe disease and high mortality in vulnerable people - the elderly and those with co-morbidities, unless eradicated. Although several vaccines are already available to rich countries, low-income countries face gross vaccine inequity. We propose COVID-19 eradication to address both problems. An eradication program will ensure vaccine equity and international cooperation to establish public","2021","06","10","Indian Pediatr","Indian pediatrics",NA,"Dharmapalan","Dhanya","Pediatric Infectious Diseases, Apollo Hospitals, CBD Belapur, Navi Mumbai, Maharashtra. Correspondence to: Dr. Dhanya Dharmapalan, Consultant in Pediatric Infectious Diseases, Apollo Hospitals, CBD Belapur, Navi Mumbai 400 614, Maharashtra. drdhanyaroshan@gmail","drdhanyaroshan@gmail.com"
"9","34108186","10.1158/1078-0432.CCR-21-1133","A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes.","While COVID-19 vaccine distribution has addressed vulnerabilities related to age and co-morbidities, there is a need to ensure vaccination of cancer patients receiving experimental and routine treatment, where interruption of treatment by infection is likely to result in inferior outcomes. Among cancer patients, those undergoing neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (Adj chemo) for early breast cancer (EBC) are at particularly high risk for inferior outcomes, in part because op","2021","06","10","Clin Cancer Res","Clinical cancer research : an official journal of the American Association for Cancer Research",NA,"Potter","David A","Department of Medicine, Division of Hematology, Oncology, and Transplantation and the Masonic Cancer Center, University of Minnesota dapotter@umn","dapotter@umn.edu"
"10","34107529","10.1038/s41586-021-03681-2","Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.","The Ad26.COV2.S vaccine<sup>1-3</sup> has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies<sup>1</sup>. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase 1/2 clinical trial<sup>2</sup> against the original SARS-CoV-2","2021","06","09","Nature","Nature",NA,"Alter","Galit","Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA",NA
"11","34105996","10.1128/JVI.00617-21","V367F mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity.","The current pandemic of COVID-19 is caused by a novel coronavirus SARS-CoV-2. The SARS-CoV-2 spike protein receptor-binding domain (RBD) is the critical determinant of viral tropism and infectivity. To investigate whether naturally occurring RBD mutations during the early transmission phase have altered the receptor binding affinity and infectivity, firstly we analyzed in silico the binding dynamics between SARS-CoV-2 RBD mutants and the human ACE2 receptor. Among 32,123 genomes of SARS-C","2021","06","09","J Virol","Journal of virology",NA,"Ou","Junxian","Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, Guangdong 510515, China",NA
"12","34105617","10.1590/0102-311X00007221","Ethical issues in placebo-controlled trials of COVID-19 vaccines.",NA,"2021","06","11","Cad Saude Publica","Cadernos de saude publica","Brazil; COVID-19; COVID-19 Vaccines; Ethics, Medical; Humans; SARS-CoV-2","Oliveira","Ana Cecilia Amado Xavier de","Escola Nacional de Sa..de P..blica Sergio Arouca, Funda....o Oswaldo Cruz, Rio de Janeiro, Brasil",NA
"13","34104816","","Addressing the global surge of COVID-19 cases: Insights from diagnostics, improved treatment strategies, vaccine development and application.","As the rage of coronavirus disease 2019 (COVID-19) pandemic continues to spread globally, much effort is being directed to contain it through various efforts - genomic studies, drug discoveries, clinical trials, vaccine development, and the innovation of diagnostic techniques. However, some pertinent areas involving accurate and sensitive diagnostics, immunoglobulin specificity, evolution of mutant strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the drug combination ","2021","06","11","J Clin Transl Res","Journal of clinical and translational research","COVID-19 vaccines; SARS-CoV-2; antiviral drug; containment operation; diagnostics; immunotherapy","Adedokun","Kamoru A","Department of Oral Pathology, DUH, King Saud University Medical City, Riyadh, Saudi Arabia",NA
"14","34101990","10.1111/ajt.16713","Effectiveness of SARS-CoV-2 vaccination in fully-vaccinated solid organ transplant recipients.","The COVID-19 pandemic has disproportionately impacted immunosuppressed patients, including solid organ transplant recipients (SOTR). COVID-19-associated mortality among SOTR was estimated at 20.5% in the early phase of the pandemic(1). SARS-CoV-2 vaccination may help reduce the morbidity and mortality of COVID-19 among SOTR. Under emergency use authorization, the US Food Drug Administration approved two SARS-CoV-2 messenger RNA vaccines [BNT162b2 (Pfizer), mRNA-1273 (Moderna)] and an adenovirus ","2021","06","08","Am J Transplant","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons",NA,"Malinis","Maricar","Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA",NA
"15","34101922","10.1111/jpc.15588","Lessons learnt during the COVID-19 pandemic: Why Australian schools should be prioritised to stay open.","In 2020, school and early childhood educational centre (ECEC) closures affected over 1.5 billion school-aged children globally as part of the COVID-19 pandemic response. Attendance at school and access to ECEC is critical to a child's learning, well-being and health. School closures increase inequities by disproportionately affecting vulnerable children. Here, we summarise the role of children and adolescents in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and that o","2021","06","08","J Paediatr Child Health","Journal of paediatrics and child health",NA,"Koirala","Archana","National Centre for Immunisation Research and Surveillance Kids Research, Sydney Children's Hospitals Network, Westmead, New South Wales, Australia",NA
"16","34101005","10.1007/s00705-021-05132-9","Antibody response in COVID-19 patients with and without re-positive RT-PCR results during the convalescent phase.","Nucleic acid testing and antibody testing data from 143 recovered COVID-19 patients during the convalescent phase were retrospectively analyzed. A total of 23 (16.1%) recovered patients re-tested positive for SARS-CoV-2 RNA by RT-PCR. Three months after symptom onset, 100% and 99.3% of the patients remained positive for total and IgG antibodies, and the antibody levels remained high. IgM antibodies declined rapidly, with a median time to seroconversion of 67 (95% CI: 59, 75) days after onset. Ap","2021","06","10","Arch Virol","Archives of virology",NA,"Peng","Jing","Shenzhen Sami Medical Center, 1 Jinniu West Road, Pingshan District, Shenzhen, Guangdong Province, China",NA
"17","34100388","10.4103/sjg.sjg_223_21","Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.","Patients with chronic liver disease (CLD) and liver transplant recipients are at increased risk of morbidity and mortality from coronavirus disease 2019 (COVID-19). Although several studies demonstrated the safety and efficacy of COVID-19 vaccines in the general population, data in CLD patients and liver transplant recipients are lacking. Two COVID-19 vaccines were approved by the Saudi Food and Drug Authority and rolled out to several million recipients in Saudi Arabia. These vaccines are mRNA-","2021","06","08","Saudi J Gastroenterol","Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","COVID-19; Cirrhosis; SARS-CoV-2; liver disease; vaccine","Alqahtani","Saleh A","Liver Transplant Center, King Faisal Specialist Hospital and Research Center",NA
"18","34100150","10.1208/s12249-021-02058-y","Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.","Vaccination development and production was an essential question for the prevention and global control of COVID-19. The strong support from governing authorities such as Operation Warp Speed and robust funding has led to the development and authorization of the tozinameran (BNT162b2) vaccine. The BNT162b2 vaccine is a lipid nanoparticle-encapsulated mRNA that encodes for SARS-CoV-2 spike protein, the main site for neutralizing antibodies. Once it binds with the host cells, the lipid nanoparticle","2021","06","10","AAPS PharmSciTech","AAPS PharmSciTech","BNT162b1; BNT162b2; BioNTech; COVID-19; Pfizer; SARS-CoV-2; adolescents; adverse effects; antibody response; children; clinical trials; efficacy; phase 1 trials; phase 1/2 trials; phase 2 trials; phase 2/ 3 trials; phase 3 trials; preclinical trials; pregnant women; real-world outcomes; safety; tozinameran; vaccine","Khehra","Nimrat","Saint James School of Medicine, Arnos Vale, Saint Vincent and the Grenadines",NA
"19","34100017","10.1101/2021.06.01.446591","Structural basis for SARS-CoV-2 Nucleocapsid protein recognition by single-domain antibodies.","The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, is the most severe public health event of the twenty-first century. While effective vaccines against SARS-CoV-2 have been developed, there remains an urgent need for diagnostics to quickly and accurately detect infections. Antigen tests, particularly those that detect the abundant SARS-CoV-2 Nucleocapsid protein, are a proven method for detecting active SARS-CoV-2 infections. Here we report high-resolution crystal structures of three l","2021","06","10","bioRxiv","bioRxiv : the preprint server for biology",NA,"Ye","Qiaozhen",NA,NA
"20","34099541","10.1136/medethics-2020-107109","Do coronavirus vaccine challenge trials have a distinctive generalisability problem?","Notwithstanding the success of conventional field trials for vaccines against COVID-19, human challenge trials (HCTs) that could obtain more information about these and about other vaccines and further strategies against it are about to start in the UK. One critique of COVID-19 HCTs is their distinct paucity of information on crucial population groups. For safety reasons, these HCTs will exclude candidate participants of advanced age or with comorbidities that worsen COVID-19, yet a vaccine shou","2021","06","08","J Med Ethics","Journal of medical ethics","COVID-19; biostatistics; clinical trials; ethics; research ethics","Eyal","Nir","Center for Population-Level Bioethics, Department of Philosophy (SAS) and Department of HBSP (SPH), Rutgers University, New Brunswick, New Jersey, USA nir.eyal@rutgers","nir.eyal@rutgers.edu"
"21","34097570","10.1080/19420862.2021.1930636","A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.","Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10..days. Our lead antibody JMB2002, now in a Phase 1 clinica","2021","06","11","MAbs","mAbs","B.1.1.7; B.1.351; D614G; JMB2002; SARS-CoV-2; broad-spectrum; neutralizing antibody; phage-to-yeast; rhesus macaque disease model","Gu","Chunyin","Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China",NA
"22","34097044","10.1001/jamanetworkopen.2021.15985","Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.","The BNT162b2 vaccine showed high efficacy against COVID-19 in a phase III randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is needed. To assess the short-term effectiveness of the first dose of the BNT162b2-vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting. This comparative effectiveness study used data from a 2.6 million-member state-mandated health care system in Israel. Participants included all individuals aged ","2021","06","11","JAMA Netw Open","JAMA network open",NA,"Chodick","Gabriel","Maccabi Institute for Research &amp",NA
"23","34093548","10.3389/fimmu.2021.660298","Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.","In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral infections will continue to arise. Increasing evidence suggests a delayed, possibly suppressed, type 1 interferon (IFN-I) response occurs early during COVID-19 and other viral respiratory infections such as SARS and MERS. These observations prompt considering IFN-.. as a prophylactic or early intervention for respiratory viral infections. A rationale for developing and testing intranasal interferon beta (IF","2021","06","10","Front Immunol","Frontiers in immunology","COVID-19; coronavirus; emerging respiratory viral infection; nasopharyngeal; post-pandemic; prophylaxis; type-I interferon; Administration, Intranasal; Humans; Interferon Type I; Pre-Exposure Prophylaxis; Respiratory Tract Infections; Severity of Illness Index; Virus Diseases","Lee","Amos C","Bio-MAX Institute, Seoul National University, Seoul, South Korea",NA
"24","34086877","10.1093/cid/ciab517","Mathematical modeling to inform vaccination strategies and testing approaches for COVID-19 in nursing homes.","Nursing home residents and staff were included in the first phase of COVID-19 vaccination in the United States. Because the primary trial endpoint was vaccine efficacy (VE) against symptomatic disease, there are limited data on the extent to which vaccines protect against SARS-CoV-2 infection and the ability to infect others (infectiousness). Assumptions about VE against infection and infectiousness have implications for changes to infection prevention guidance for vaccinated populations, includ","2021","06","08","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Covid-19; Nursing Homes; Vaccine Efficacy","Kahn","Rebecca","Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA",NA
"25","34085281","10.1111/bph.15582","The Impact of COVID-19 on Pregnancy and Therapeutic Drug Development.","Emerging data shows pregnant women with COVID-19 are at significantly higher risk of severe outcomes compared to non-pregnant women of similar age. This review discusses the invaluable insight revealed from vaccine clinical trials in women who were vaccinated and inadvertently became pregnant during the trial period. It further explores a number of clinical avenues in their management and proposes a drug development strategy in-line with clinical trials for vaccines and drug treatments for the d","2021","06","04","Br J Pharmacol","British journal of pharmacology","COVID-19; pregnancy; cardiovascular diseases; clinical trials; drug development; preeclampsia; vaccines","Abbas-Hanif","Allyah","Mirzyme Therapeutics, Innovation Birmingham Campus, Faraday Wharf, Holt Street, Birmingham, B7 4BB, United Kingdom",NA
"26","34084669","10.7759/cureus.14741","Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine.","For the first time, the mRNA technology was utilized to produce a vaccine against COVID-19 after the unprecedented pandemic equally affected every part of the world. Pfizer-BioNTech (BNT162b2) mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was granted emergency use authorization (EUA) by Food and Drug Administration (FDA) in December 2020. EUA has been widely discussed in the medical literature and the general public. The safety of the BNT162b2 vaccine has been","2021","06","05","Cureus","Cureus","acute pancreatitis; bnt162b2 mrna; covid-19; pfizer-biontech","Parkash","Om","Internal Medicine, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, USA",NA
"27","34083395","10.1136/jnnp-2021-326405","Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives.","There is accumulating evidence of the neurological and neuropsychiatric features of infection with SARS-CoV-2. In this systematic review and meta-analysis, we aimed to describe the characteristics of the early literature and estimate point prevalences for neurological and neuropsychiatric manifestations.We searched MEDLINE, Embase, PsycINFO and CINAHL up to 18 July 2020 for randomised controlled trials, cohort studies, case-control studies, cross-sectional studies and case series. Studies report","2021","06","04","J Neurol Neurosurg Psychiatry","Journal of neurology, neurosurgery, and psychiatry","COVID-19; clinical neurology; meta-analysis; psychiatry; systematic reviews","Rogers","Jonathan P","Division of Psychiatry, University College London, London, UK jonathan.rogers@ucl.ac","jonathan.rogers@ucl.ac.uk"
"28","34081687","10.15585/mmwr.mm7022e2","Excess Death Estimates in Patients with End-Stage Renal Disease - United States, February-August 2020.","End-stage renal disease (ESRD) is a condition in which kidney function has permanently declined such that renal replacement therapy* is required to sustain life (1). The mortality rate for patients with ESRD in the United States has been declining since 2001 (2). However, during the COVID-19 pandemic, ESRD patients are at high risk for COVID-19-associated morbidity and mortality, which is due, in part, to weakened immune systems and presence of multiple comorbidities (3-5). The ESRD National Coo","2021","06","04","MMWR Morb Mortal Wkly Rep","MMWR. Morbidity and mortality weekly report","COVID-19; Humans; Kidney Failure, Chronic; Mortality; Risk Assessment; United States","Ziemba","Robert",NA,NA
"29","34081073","10.1001/jama.2021.8828","Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.","Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection from SARS-CoV-2 infection and COVID-19. To determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities. Randomized, double-blind, single-dose, phase 3 t","2021","06","03","JAMA","JAMA",NA,"Cohen","Myron S","Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill",NA
"30","34080997","10.20529/IJME.2020.104","Covid-19 vaccine trials and ethics: Protection delayed is protection denied.","The Covid-19 pandemic is raging, taking heavy toll of lives and livelihoods. The need for safe and effective vaccine(s) is urgent. Vaccine research has progressed rapidly and a few vaccine candidates have passed trial Phases 1 and 2, confirming reasonable safety and immunogenicity parameters. They are ready for large scale Phase 3 trials to quantify protective efficacy, if any, and to detect uncommon but serious adverse effects, if any. These developments present unprecedented opportunities and ","2021","06","07","Indian J Med Ethics","Indian journal of medical ethics",NA,"John","T Jacob","Retired Professor, Christian Medical College, Vellore, Tamil Nadu 632 002 INDIA",NA
"31","34080991","10.20529/IJME.2020.122","Emergency use authorisation of Covid-19 vaccines: An ethical conundrum.","Large-scale vaccination with a safe and effective vaccine against Covid-19 is the only way to conquer the ongoing lethal pandemic that has led to extraordinary social and economic upheaval globally. Fortunately, the world is on the verge of developing Covid-19 vaccines in an unprecedentedly short time. More than forty vaccines are in different stages of clinical trials, and a few are in the crucial phase III studies stage. A new demand for emergency use authorisation and rapid deployment of thes","2021","06","07","Indian J Med Ethics","Indian journal of medical ethics",NA,"Vashishtha","Vipin M","Director and Consultant Paediatrician, Department of Paediatrics, Mangla Hospital and Research Centre, Shakti Chowk, Bijnor 246 701 Uttar Pradesh INDIA",NA
"32","34080537","10.1051/medsci/2021094","[COVID-19: Warp Speed vaccines].","A vaccine is required to effectively control the COVID-19 pandemic in the mid and long term. The development of vaccines against SARS-CoV-2 was initiated as soon as the genetic sequence of the virus was published, and has evolved at an unprecedented speed, with a first clinical trial launched in March 2020. One year later, more than a dozen of vaccines based on different concepts, with some having been evaluated only in clinical trials so far, are authorized under emergency procedures. Here, we ","2021","06","03","Med Sci (Paris)","Medecine sciences : M/S",NA,"Feraoun","Yanis","Immunologie des maladies virales, auto-immunes, h..matologiques et bact..riennes (IMVA-HB), D..partement IDMIT (Infectious Disease Models and Innovative Therapies), UMR 1184, Universit.. Paris-Saclay, Unit.. Inserm 1184, CEA, 18 route du Panorama, 92265 Fontenay-aux-Roses, France",NA
"33","34079692","10.5501/wjv.v10.i3.97","Impact of COVID-19 in patients with lymphoid malignancies.","The first cases of coronavirus disease 2019 (COVID-19) were detected in Wuhan, China, in December 2019. Since this time a concerted global effort of research and observational data gathering has meant that a great deal has been learnt about the impact of COVID-19 in patients with lymphoid malignancies. Approximately one-third of patients with lymphoid malignancies who acquire COVID-19 and have it severely enough to require hospital assessment will die from this infection. Major risk factors for ","2021","06","05","World J Virol","World journal of virology","COVID-19; Chemoimmunotherapy; Hemopoietic stem cell transplantation; Leukemia; Lymphoma; Vaccination","Riches","John Charles","Centre for Haemato-Oncology, Barts Cancer Institute - a Cancer Research UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. j.riches@qmul.ac","j.riches@qmul.ac.uk"
"34","34078415","10.1186/s13027-021-00376-1","Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.","Patients with non-hodgkin lymphomas (NHL) represent a population of special interest during the current Coronavirus disease-19 (COVID-19) pandemics. NHLs are associated with disease- and treatment-related immunodeficiencies which may generate unusual COVID-19 dynamics and pose unique management challenges. We report the unusual clinical course of COVID-19 in a patient with mantle cell lymphoma (MCL) exposed to nine doses of Rituximab shortly before infection with severe acute respiratory syndrom","2021","06","06","Infect Agent Cancer","Infectious agents and cancer","Anti-CD20 antibodies; COVID-19; Mantle cell lymphoma; Rituximab","Marcacci","Gianpaolo","Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy",NA
"35","34077664","","Vaccines for COVID-19: An Overview.","The advent of the COVID-19 pandemic in the final months of 2019 prompted an extraordinary response on the part of the scientific community, with fundamental research on the biology of the virus and the human immune response, and development of testing, therapeutics, and vaccines occurring on an unprecedentedly short timescale. Within a year after the worldwide outbreak of the disease, more than 40 vaccine candidates had emerged, with 21 candidates in phase 3 trials or already being used on an em","2021","06","04","Compend Contin Educ Dent","Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995)","COVID-19; COVID-19 Vaccines; Humans; Pandemics; SARS-CoV-2","Lane","Thomas F","Department of Radiology and Biomedical Imaging, School of Medicine, University of California San Francisco, San Francisco, California",NA
"36","34077467","10.1371/journal.pone.0252332","Tracking COVID-19 vaccine hesitancy and logistical challenges: A machine learning approach.","In this study, we use an effective word embedding model (word2vec) to systematically track 'vaccine hesitancy' and 'logistical challenges' associated with the Covid-19 vaccines, in the USA. To that effect, we use news articles from reputed media sources and create dictionaries to estimate different aspects of vaccine hesitancy and logistical challenges. Using machine learning and natural language processing techniques, we have developed (i) three sub-dictionaries that indicate vaccine hesitancy,","2021","06","07","PLoS One","PloS one",NA,"Dutta","Shantanu","Telfer School of Management, University of Ottawa, Ottawa, Ontario, Canada",NA
"37","34075361","10.1016/j.ijnsa.2021.100030","Experiences of cancer care during COVID-19: Phase 1 results of a longitudinal qualitative study.","Healthcare services have responded to the challenges of service delivery during COVID-19 with telehealth and hybrid models of care. However, there is limited understanding of the experiences of care amongst people affected by cancer and how their experiences may change and evolve against the shifting landscape of COVID-19 incidence, mortality, vaccination and refinements in service delivery. This study explores the experiences of cancer care amongst people affected by cancer in Ireland during th","2021","06","09","Int J Nurs Stud Adv","International journal of nursing studies advances","COVID-19; Cancer; Cancer care; Distress; Ehealth; Experiences of care; Models of care; Resilience; Telemedicine; Unmet needs","Drury","Amanda","School of Nursing, Midwifery and Health Systems, University College Dublin, Belfield, Dublin 4, Ireland",NA
"38","34075245","10.1038/d41586-021-01470-5","COVID: treatment trials are still urgent.",NA,"2021","06","07","Nature","Nature","SARS-CoV-2; Therapeutics; Vaccines; COVID-19; COVID-19 Vaccines; Humans; Immunization Programs; India; Pandemics; Patient Selection; Randomized Controlled Trials as Topic; SARS-CoV-2; Time Factors; United States","Rauchman","Steve",NA,NA
"39","34074880","10.1097/QCO.0000000000000739","Coronavirus disease 2019 vaccination in transplant recipients.","Coronavirus disease 2019 (COVID-19) vaccination is considered one of the most promising and socioeconomically sustainable strategy to help control the pandemic and several vaccines are currently being distributed in nationwide mass immunization campaigns. Very limited data are available on benefits and risks of COVID-19 vaccination in immunocompromised patients and in particular in solid organ or hematopoietic stem cell transplant recipients as they were excluded from phase III trials. This revi","2021","06","02","Curr Opin Infect Dis","Current opinion in infectious diseases",NA,"Eberhardt","Christiane S","Center for Vaccinology, University Hospitals of Geneva Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland Emory Vaccine Center, Emory University, Atlanta, Georgia, USA Department of Health Sciences (DISSAL), University of Genoa Division of Infectious Diseases, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School Centre for Individualised Infection Medicine (CiiM), A Joint Venture of Helmholtz Centre for Infection Research and Hannover Medical School German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany",NA
"40","34069412","10.3390/nu13051714","COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents.","Insufficient blood levels of the neurohormone vitamin D are associated with increased risk of COVID-19 severity and mortality. Despite the global rollout of vaccinations and promising preliminary results, the focus remains on additional preventive measures to manage COVID-19. Results conflict on vitamin D's plausible role in preventing and treating COVID-19. We examined the relation between vitamin D status and COVID-19 severity and mortality among the multiethnic population of the United Arab E","2021","06","08","Nutrients","Nutrients","COVID-19; SARS-CoV-2; United Arab Emirates; mortality; severity; vitamin D; Adult; COVID-19; Disease-Free Survival; Female; Humans; Male; Middle Aged; SARS-CoV-2; Severity of Illness Index; Survival Rate; United Arab Emirates; Vitamin D; Vitamin D Deficiency","AlSafar","Habiba","Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates",NA
"41","34068474","10.3390/healthcare9050557","An Examination of COVID-19 Medications' Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review.","Background: The review seeks to shed light on the administered and recommended COVID-19 treatment medications through an evaluation of their efficacy. Methods: Data were collected from key databases, including Scopus, Medline, Google Scholar, and CINAHL. Other platforms included WHO and FDA publications. The review's literature search was guided by the WHO solidarity clinical trials for COVID-19 scope and trial-assessment parameters. Results: The findings indicate that the u","2021","06","13","Healthcare (Basel)","Healthcare (Basel, Switzerland)","COVID-19; SARS-CoV-2; efficacy; medication; side-effects","Al-Masaeed","Mahmoud","Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia",NA
"42","34066475","10.3390/vaccines9050467","Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","The current study systematically reviewed, summarized and meta-analyzed the clinical features of the vaccines in clinical trials to provide a better estimate of their efficacy, side effects and immunogenicity. All relevant publications were systematically searched and collected from major databases up to 12 March 2021. A total of 25 RCTs (123 datasets), 58,889 cases that received the COVID-19 vaccine and 46,638 controls who received placebo were included in the meta-analysis. In total, mRNA-base","2021","06","13","Vaccines (Basel)","Vaccines","COVID-19; SARS-CoV-2; efficacy; meta-analysis; randomized clinical trial; side effect; vaccines","Pormohammad","Ali","Department of Biological Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada",NA
"43","34063476","10.3390/ijerph18105272","Willingness to Be Vaccinated against COVID-19 in Spain before the Start of Vaccination: A Cross-Sectional Study.","Vaccine hesitancy has increased in the past few years, influenced by the socio-cultural differences, political populism, or concerns related to the effectiveness and safety of some vaccines, resulting a feeling of distrust. This feeling can become a barrier against the achievement of the immunity necessary to stop the expansion of COVID-19. The aim of this study was to evaluate the acceptance of the vaccine against COVID-19 in Spain, as well as to identify the factors that have an influence on t","2021","06","04","Int J Environ Res Public Health","International journal of environmental research and public health","COVID-19; SARS-CoV-2; immunization program; vaccination campaign; vaccine acceptance; vaccine hesitancy; vaccines; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Humans; Male; SARS-CoV-2; Spain; Vaccination","Rodr..guez-Blanco","Noelia","Department of Obstetrics and Gynaecology, Marina Baixa University Hospital, Av. Alcalde En Jaume Botella Mayor, 7, 03570 Villajoyosa, Spain",NA
"44","34063327","10.3390/ijerph18094864","Willing or Hesitant? A Socioeconomic Study on the Potential Acceptance of COVID-19 Vaccine in Japan.","The worldwide COVID-19 vaccination program is already underway, raising hopes and aspirations to contain the spread of the COVID-19 pandemic that halted economic and social activities. However, the issue of vaccine effectiveness and its side-effects is influencing the potential acceptance of vaccines. In this uncertain situation, we used data from a nationwide survey in Japan during February 2021, following the Japanese government's initial phase of COVID-19 vaccination. Our results show that 47","2021","06","04","Int J Environ Res Public Health","International journal of environmental research and public health","COVID-19 pandemic; Japan; socioeconomic factors; vaccine; COVID-19; COVID-19 Vaccines; Child; Humans; Japan; Pandemics; SARS-CoV-2; Socioeconomic Factors; Vaccination","Kadoya","Yoshihiko","School of Economics, Hiroshima University, Higashi-Hiroshima 739-8525, Japan",NA
"45","34062137","10.1016/S0140-6736(21)01198-3","Africa's need for more COVID-19 clinical trials.",NA,"2021","06","07","Lancet","Lancet (London, England)","Africa; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Comorbidity; HIV Infections; Humans; Pandemics; Patient Selection; SARS-CoV-2; Treatment Outcome; Tuberculosis","Makoni","Munyaradzi",NA,NA
"46","34062110","10.1080/07391102.2021.1931451","Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications.","In view of many European countries and the USA leading to the second wave of COVID-19 pandemic, winter season, the evolution of new mutations in the spike protein, and no registered drugs and vaccines for COVID-19 treatment, the discovery of effective and novel therapeutic agents is urgently required. The degrees and frequencies of COVID-19 clinical complications are related to uncontrolled immune responses, secondary bacterial infections, diabetes, cardiovascular disease, hypertension, and chro","2021","06","04","J Biomol Struct Dyn","Journal of biomolecular structure &amp; dynamics","COVID-19; FDA/passed phase-1 inhibitors; molecular docking; molecular dynamics; multi-targeting compounds","Naik","Biswajit","Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Ajmer, India",NA
"47","34060379","10.1177/10760296211021498","An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination.","Today the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global health problem. After more than a year with the pandemic, although our knowledge has progressed on COVID-19, there are still many unknowns in virological, pathophysiological and immunological aspects. It is obvious that the most efficient solution to end this pandemic are safe and efficient vaccines. This manuscript summarizes the pathophysiological and throm","2021","06","03","Clin Appl Thromb Hemost","Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","COVID-19; SARS-CoV-2; heparin induced thrombocytopenia; safety and efficacy; thrombocytopenia; thrombosis; Autoantibodies; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Disseminated Intravascular Coagulation; Drug Approval; Female; Genetic Vectors; Glycosaminoglycans; Humans; Male; Models, Cardiovascular; Pandemics; Platelet Factor 4; SARS-CoV-2; Safety; Sinus Thrombosis, Intracranial; Thrombosis; Vaccines, Inactivated; Vaccines, Synthetic","Kantarcioglu","Bulent","Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA",NA
"48","34060334","10.1128/mBio.00696-21","Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.","The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with spike protein mutations raises concerns that antibodies elicited by natural infection or vaccination and therapeutic monoclonal antibodies will become less effective. We show that convalescent-phase sera neutralize pseudotyped viruses with the B.1.1.7, B.1.351, B.1.1.248, COH.20G/677H, 20A.EU2, and mink cluster 5 spike proteins with only a minor loss in titer. Similarly, antibodies elicited by","2021","06","01","mBio","mBio","20A.EU2; B.1.1.248; B.1.1.7; B.1.351; COH.20G/677H; Pfizer BNT162b2; REGN10933; REGN10987; SARS-CoV-2; mink cluster 5; neutralization; spike protein","Tada","Takuya","Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA",NA
"49","34057040","10.1080/22221751.2021.1937328","Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.","Neutralizing antibodies in the subjects of an inactivated SARS-CoV-2 vaccine clinical trial showed a decreasing trend over months. An investigation studying the third immunization suggested that the waning of neutralizing antibodies in individuals administered two doses of inactivated vaccine does not mean the disappearance of immunity.","2021","06","10","Emerg Microbes Infect","Emerging microbes &amp; infections","COVID-19; SARS-CoV-2; antibody waning; immune memory; inactivated vaccine","Liao","Yun","Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China",NA
"50","34056571","10.1016/j.metop.2021.100096","Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic.","Remdesivir (GS-5734), a drug initially developed to treat hepatitis C and Ebola virus disease, was the first approved treatment for severe coronavirus disease 2019 (COVID-19). However, apart from remdesivir, there is a paucity of other specific anti-viral agents against SARS-CoV-2 infection. In 2017, researchers had documented the anti-coronavirus potential of remdesivir in animal models. At the same time, trials performed during two Ebola outbreaks in Africa showed that the drug was safe. Altho","2021","06","10","Metabol Open","Metabolism open","Antiviral treatment; Baricitinib; COVID-19; Favipiravir; Molnupiravir; Monoclonal antibodies; Nanobodies; Plitidepsin; Protease inhibitors; Ribavirin; SARS-CoV-2; Zotatifin; boceprevir","Vallianou","Natalia G","First Department of Internal Medicine, Evangelismos General Hospital, 45-47 Ipsilantou str, 10676, Athens, Greece",NA
"51","34056559","10.1093/jamiaopen/ooab032","How the clinical research community responded to the COVID-19 pandemic: an analysis of the COVID-19 clinical studies in ClinicalTrials.gov.","In the past few months, a large number of clinical studies on the novel coronavirus disease (COVID-19) have been initiated worldwide to find effective therapeutics, vaccines, and preventive strategies for COVID-19. In this study, we aim to understand the landscape of COVID-19 clinical research and identify the issues that may cause recruitment difficulty or reduce study generalizability. We analyzed 3765 COVID-19 studies registered in the largest public registry-ClinicalTrials.gov, leveraging na","2021","06","01","JAMIA Open","JAMIA open","COVID-19; clinical trial; eligibility criteria; natural language processing","He","Zhe","School of Information, Florida State University, Tallahassee, Florida, USA",NA
"52","34054532","10.3389/fphar.2021.652335","Multi-Omics Approach in the Identification of Potential Therapeutic Biomolecule for COVID-19.","COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has a disastrous effect on mankind due to the contagious and rapid nature of its spread. Although vaccines for SARS-CoV-2 have been successfully developed, the proven, effective, and specific therapeutic molecules are yet to be identified for the treatment. The repurposing of existing drugs and recognition of new medicines are continuously in progress. Efforts are being made to single out plant-based novel the","2021","06","01","Front Pharmacol","Frontiers in pharmacology","COVID-19; SARS-CoV-2; biomolecules; coronavirus; multi-omics; therapeutic molecules","Singh","Rachana","Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow, India",NA
"53","34053848","10.1016/j.ejim.2021.05.010","SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors.","Elucidating the characteristics of human immune response against SARS-CoV-2 is of high priority and relevant for determining vaccine strategies. We report the results of a follow-up evaluation of anti-SARS-CoV-2 antibodies in 148 convalescent plasma donors who participated in a phase 2 study at a median of 8.3 months (range 6.8-10.5 months) post first symptom onset. Monitoring responses over time, we found contraction of antibody responses for all four antigens tested, with Spike antibodies show","2021","06","08","Eur J Intern Med","European journal of internal medicine","Antibodies; COVID-19; Immunity; Neutralizing; SARS-CoV-2; Spike","Terpos","Evangelos","Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece. Electronic address: eterpos@med.uoa","eterpos@med.uoa.gr"
"54","34053446","10.1186/s12879-021-06092-w","A data-driven metapopulation model for the Belgian COVID-19 epidemic: assessing the impact of lockdown and exit strategies.","In response to the ongoing COVID-19 pandemic, several countries adopted measures of social distancing to a different degree. For many countries, after successfully curbing the initial wave, lockdown measures were gradually lifted. In Belgium, such relief started on May 4th with phase 1, followed by several subsequent phases over the next few weeks. We analysed the expected impact of relaxing stringent lockdown measures taken according to the phased Belgian exit strategy. We developed a stochasti","2021","06","02","BMC Infect Dis","BMC infectious diseases","Behavioral changes; COVID-19; Epidemic modeling; Metapopulation; Mixing patterns; Spatial transmission; Belgium; COVID-19; Communicable Disease Control; Hospitalization; Humans; Models, Theoretical; Pandemics; Physical Distancing; Schools; Workplace","Coletti","Pietro","Data Science Institute, I-Biostat, Hasselt University, Agoralaan Gebouw D, Diepenbeek, 3590, Belgium. pietro.coletti@uhasselt","pietro.coletti@uhasselt.be"
"55","34046552","10.12688/hrbopenres.13185.2","ReStOre@Home: Feasibility study of a virtually delivered 12-week multidisciplinary rehabilitation programme for survivors of upper gastrointestinal (UGI) cancer - study protocol.","Background: Exercise rehabilitation programmes, traditionally involving supervised exercise sessions, have had to rapidly adapt to virtual delivery in response to the coronavirus disease 2019 (COVID-19) pandemic to minimise patient contacts. In the absence of an effective vaccine, the pandemic is likely to persist in the medium term and during this time it is important that the feasibility and effectiveness of remote solutions is considered. ..We have previously established the feasibilit","2021","05","31","HRB Open Res","HRB open research","Virtual delivery; diet; education; exercise; multidisciplinary rehabilitation; upper gastrointestinal cancer","O'Neill","Linda","Discipline of Physiotherapy, Trinity College Dublin, the University of Dublin, Dublin, Ireland",NA
"56","34046170","10.12688/f1000research.23524.3","Revisiting early-stage COVID-19 strategy options.","Background: Early-stage interventions in a potential pandemic are important to understand as they can make the difference between runaway exponential growth that is hard to turn back and stopping the spread before it gets that far. COVID19 is an interesting case study because there have been very different outcomes in different localities. These variations are best studied after the fact if precision is the goal; while a pandemic is still unfolding less precise analysis is of value in att","2021","06","02","F1000Res","F1000Research","COVID-19; asymptomatic transmission; early-stage pandemic intervention; COVID-19; Contact Tracing; Humans; Pandemics; Quarantine; SARS-CoV-2","Machanick","Philip","Computer Science, Rhodes University, Makhanda, Eastern Cape, 6140, South Africa",NA
"57","34051840","10.1186/s13063-021-05323-4","Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations.","Chemoprophylactics against emerging epidemic and pandemic infectious diseases offer potential for prevention but require efficacy and safety analysis before widespread use can be recommended. Chemoprophylaxis with repurposed drugs enables deployment ahead of development of novel vaccines. It may have particular utility as a stopgap ahead of vaccine deployment or when vaccines become less effective on virus variants, in countries where there may be structural inaccessibility to vaccines or in spe","2021","06","04","Trials","Trials","Adaptive design; COVID-19; Chemoprophylaxis; Chloroquine; Coronavirus; Hydroxychloroquine; SARS-CoV-2; Systematic review","Manoharan","Lakshmi","Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine University of Oxford, Old Road Campus, Roosevelt Dr, Oxford, OX3 7LG, UK",NA
"58","34051181","10.1016/S1473-3099(21)00274-7","Vaccine development lessons between HIV and COVID-19.",NA,"2021","06","02","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Vasan","Sandhya","US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA",NA
"59","34049688","10.1016/j.therap.2021.05.004","Efficacy of COVID-19 vaccines: From clinical trials to real life.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread around the globe leading to the COVID-19 pandemic. To mitigate the effects of the virus on public health and the global economy, vaccines were rapidly developed. In less than one year, with respect to usual clinical development rules, several vaccines have been put on the market and mass vaccination campaigns have been deployed. During the phase I to phase III clinical trials, most of these vaccines have demonstrated","2021","05","31","Therapie","Therapie","Adenoviral vector; COVID-19; Clinical trials; Efficacy; SARS-CoV-2; Vaccine; mRNA","Deplanque","Dominique","Universit.. de Lille, Inserm, CHU Lille, CIC 1403 - Clinical Investigation Center, 59000 Lille, France.",NA
"60","34046443","10.3389/fvets.2021.647308","Did the COVID-19 Pandemic Spark a Public Interest in Pet Adoption?","This study aimed to determine if there has been an increase of global interest on pet adoption immediately after the WHO declaration of the pandemic and if the effect has been sustainable in 8 months on. We conducted a Google Trends search using keywords related to pet adoption. Relative search volume (RSV) was scored between 0 and 100 for the lowest and the highest, respectively. Top countries contributing to the dataset included Australia, the United States, Canada, New Zealand, the United Kin","2021","05","30","Front Vet Sci","Frontiers in veterinary science","COVID-19; Google trend; animal welfare; companion animal; epidemiology; infodemiology; pet adoption; public health","Ho","Jeffery","Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China",NA
"61","34046139","10.11604/pamj.2021.38.234.25964","Comparing knowledge, attitudes and practices regarding COVID-19 amongst Cameroonians living in urban versus rural areas.","adherence to preventive measures to curb the spread of COVID-19 depends on the people..s knowledge, attitudes and practices (KAP) towards COVID-19. Living in rural areas may be associated with poor KAP towards COVID-19. This study compares the KAP regarding COVID-19 of people living in rural and urban areas in Cameroon. this was a comparative cross-sectional study, using data obtained through an online survey of 1,345 Cameroonians amongst which were 828 urban and 517 rural dwellers. The survey q","2021","06","07","Pan Afr Med J","The Pan African medical journal","COVID-19; attitudes; knowledge; practices; rural areas; urban areas; Adult; COVID-19; Cameroon; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Rural Population; Urban Population; Young Adult","Njingu","Atabong Emmanuel","Faculty of Health Sciences, University of Buea, Buea, Cameroon",NA
"62","34046036","10.3389/fimmu.2021.666223","Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis.","SARS, MERS, and COVID-19 share similar characteristics. For instance, the genetic homology of SARS-CoV-2 compared to SARS-CoV and MERS-CoV is 80% and 50%, respectively, which may cause similar clinical features. Moreover, uncontrolled release of proinflammatory mediators (also called a cytokine storm) by activated immune cells in SARS, MERS, and COVID-19 patients leads to severe phenotype development. This systematic review and meta-analysis aimed to evaluate the inflammatory cytokine profile as","2021","06","07","Front Immunol","Frontiers in immunology","COVID-19; MERS; SARS; SARS-CoV-2; cytokine storm; inflammatory cytokines; Animals; Blood Circulation; Chemokines; Coronavirus; Coronavirus Infections; Cytokine Release Syndrome; Cytokines; Humans; Inflammation; Randomized Controlled Trials as Topic","Zawawi","Ayat","Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia",NA
"63","34046033","10.3389/fimmu.2021.660019","Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2.","SARS-CoV-2 is the cause of a recent pandemic that has led to more than 3 million deaths worldwide. Most individuals are asymptomatic or display mild symptoms, which raises an inherent question as to how does the immune response differs from patients manifesting severe disease? During the initial phase of infection, dysregulated effector immune cells such as neutrophils, macrophages, monocytes, megakaryocytes, basophils, eosinophils, erythroid progenitor cells, and Th17 cells can alter the trajec","2021","06","07","Front Immunol","Frontiers in immunology","Immune memory; Immune system; Immunological memory; Pathogen; SARS...CoV-2; T cells; Vaccine; Vaccine design; Animals; Antibodies, Neutralizing; Antibodies, Viral; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Disease Resistance; Epitopes, T-Lymphocyte; Humans; Immunity, Cellular; Immunologic Memory; SARS-CoV-2","Ahluwalia","Pankaj","Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, United States",NA
"64","34044465","10.1055/a-1509-8916",NA,"Innovative and effective vaccination strategies are the most important lever to address the global SARS-COV2 pandemic. Within months scientists all over the world have developed promising new vaccines, many of which use adenoviral vectors to incorporate immunogenic molecules of SARS-coronavirus in order to elicit effective immune responses. The Gamaleya institute developed the COVID-19 vaccine named Sputnik (Gam-COVID-Vac) using adenoviral vectors ad 26 and ad5 to incorporate a full SARS-Spike P","2021","05","27","Laryngorhinootologie","Laryngo- rhino- otologie",NA,"Klimek","L","Zentrum f..r Rhinologie und Allergologie, Wiesbaden",NA
"65","34044428","10.1038/s41586-021-03653-6","BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.","BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavirus disease-19 (COVID-19)<sup>1</sup>. Here we extend our previous phase 1/2 trial report<sup>2</sup> and present BNT162b2 prime/boost induced immune response data from a second phase 1/2 trial in healthy adults (18-","2021","05","27","Nature","Nature",NA,"Sahin","Ugur","BioNTech, An der Goldgrube 12, 55131, Mainz, Germany. Ugur.Sahin@biontech","Ugur.Sahin@biontech.de"
"66","34043894","10.1056/NEJMoa2107456","Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.","Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socialization, and contribute to herd immunity. In this ongoing multinational, placebo-controlled, observer-blinded trial, we randomly assigned participants in a 1:1 ratio to receive two injections, 21 days apart, of 30 ","2021","06","05","N Engl J Med","The New England journal of medicine",NA,"Frenck","Robert W","From Cincinnati Children's Hospital, Cincinnati (R.W.F.)",NA
"67","34043693","10.1371/journal.pone.0251992","Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda.","Healthcare workers (HCWs) are at high risk of acquiring SARS-CoV-2 and COVID-19 and may therefore be a suitable population for COVID-19 vaccine trials. We conducted a survey to evaluate willingness-to-participate in COVID-19 vaccine trials in a population of HCWs at three hospitals in Uganda. The survey was conducted between September and November 2020. Using a standardised questionnaire, data were collected on socio-demographics, previous participation in health research, COVID-19 information s","2021","06","07","PLoS One","PloS one","Adult; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Female; Health Personnel; Humans; Male; Motivation; Patient Acceptance of Health Care; SARS-CoV-2; Uganda","Kitonsa","Jonathan","Medical Research Council / Uganda Virus Research Institute &amp",NA
"68","34042990","10.1001/jamanetworkopen.2021.11629","Factors Associated With Racial/Ethnic Group-Based Medical Mistrust and Perspectives on COVID-19 Vaccine Trial Participation and Vaccine Uptake in the US.","The impact of COVID-19 in the US has been far-reaching and devastating, especially in Black populations. Vaccination is a critical part of controlling community spread, but vaccine acceptance has varied, with some research reporting that Black individuals in the US are less willing to be vaccinated than other racial/ethnic groups. Medical mistrust informed by experiences of racism may be associated with this lower willingness. To examine the association between race/ethnicity and rejection of CO","2021","06","03","JAMA Netw Open","JAMA network open","Adolescent; Adult; African Americans; Aged; Asian Americans; Attitude to Health; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Continental Population Groups; Cross-Sectional Studies; European Continental Ancestry Group; Female; Hispanic Americans; Humans; Male; Michigan; Middle Aged; Patient Acceptance of Health Care; Trust; Vaccination Refusal; Young Adult","Thompson","Hayley S","Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan",NA
"69","34041932","10.1177/17407745211018613","COVID-19 vaccine trials: The potential for &quot;hybrid&quot; analyses.","Although several COVID-19 vaccines have been found to be effective in rigorous evaluation and have emerging availability in parts of the world, their supply will be inadequate to meet international needs for a considerable period of time. There also will be continued interest in vaccines that are more effective or have improved scalability to facilitate mass vaccination campaigns. Ongoing clinical testing of new vaccines also will be needed as variant strains continue to emerge that may elude so","2021","05","27","Clin Trials","Clinical trials (London, England)","COVID-19; SARS-CoV-2; active comparator; margin; non-inferiority; placebo-controlled; vaccines","Fleming","Thomas R","Department of Biostatistics, University of Washington, Seattle, WA, USA",NA
"70","34041136","10.4103/jfmpc.jfmpc_2151_20","Epidemiological characteristics, reinfection possibilities and vaccine development of SARS CoV2: A global review.","According to the World Health Organization (WHO), there are 37,704,153 cases and 10,79,029 deaths due to COVID-19 till the 13th October 2020 in the world. Day by day, rise in the number of COVID-19 deaths has created great pressure on health facilities, governmental bodies, and health workers. There is a need for knowledge regarding lifecycle, transmission, and different strains of SARSCoV2, so that countries can stop the disease as early as possible. The present study was conducted to review va","2021","05","28","J Family Med Prim Care","Journal of family medicine and primary care","Basic case reproduction rate; COVID-19; SARSCoV2; reinfection; vaccine","Yadav","Ramakant","Department of Neurology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, Uttar Pradesh, India",NA
"71","34041132","10.4103/jfmpc.jfmpc_2200_20","Health care of the elderly during Covid-19 pandemic-All a family physician should know.","Elderly people account for more than 9% of the global population, and more than 6% of the Indian population. Covid-19 has badly affected the older population, identification of risk factors for severe disease and early intervention results in reduced mortality. Older adults may have a varied spectrum of presentation which ranges from mild to severe disease. Milder diseases are more in older adults without prior comorbidities whereas severity increases with increase in number of illness. Till dat","2021","05","28","J Family Med Prim Care","Journal of family medicine and primary care","Covid-19; multimorbidity; older adults","Klanidhi","Kamal Bandhu","Department of Geriatric Medicine, All India Institute of Medical Sciences, New Delhi, India",NA
"72","34040921","10.7759/cureus.14623","Factors Associated With Adherence to COVID-19 Preventive Measures Among Saudi Arabians.","Background A recent outbreak of..COVID-19 which was initially reported in Wuhan City, China, has become a worldwide pandemic. This global public health threat drew the attention of the medical and scientific community to make the necessary research efforts to combat the spread of the virus. Predictors of preventive behaviors could be of considerable..importance relevant to identifying high-risk groups to manage their..behavior. We aimed to investigate the association between people's perception ","2021","05","28","Cureus","Cureus","adherence to preventive measures; coronavirus; covid-19 pandemic; perception of susceptibility; seriousness","Alshammari","Abdullah S","Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Riyadh, SAU",NA
"73","34039479","10.1016/j.clinthera.2021.04.010","Exploration and Ethical Analysis of Open-Label Pediatric Vaccine Trials in a Pandemic.","Young children will ultimately need to be vaccinated to stop the spread of coronavirus disease 2019 (COVID-19). Initial studies of vaccine were performed in adults. Randomized controlled trials are the gold standard. In the COVID-19 pandemic, many questions need to be answered about the ethics and feasibility of these trials. Given the harms of the COVID-19 pandemic and the now-known efficacy of the vaccines in adults and teens, the question of whether clinical equipoise exists for a placebo-con","2021","05","29","Clin Ther","Clinical therapeutics",NA,"Wolfe","Ian D","Children's Minnesota, Minneapolis, Minnesota. Electronic address: wolfe370@umn","wolfe370@umn.edu"
"74","34037666","10.1001/jama.2021.8565","Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.","Although effective vaccines against COVID-19 have been developed, additional vaccines are still needed. To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines. Prespecified interim analysis of an ongoing randomized, double-blind, phase 3 trial in the United Arab Emirates and Bahrain among adults 18 years and older without known history of COVID-19. Study enrollment began on July 16, 2020. Data sets used for the interim analysis of efficacy and adverse events were locked o","2021","06","10","JAMA","JAMA",NA,"Al Kaabi","Nawal","Sheikh Khalifa Medical City, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates",NA
"75","34036720","10.1111/ajt.16701","Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.","According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS-CoV-2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside","2021","05","26","Am J Transplant","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons",NA,"Cucchiari","David","Department of Nephrology and Kidney Transplantation, Hospital Cl..nic, Barcelona, Spain",NA
"76","34035902","10.12688/f1000research.23480.1","Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications.","This article proposes that one should explore whether the pulmonary complications of Covid-19 can be reduced or avoided by bypassing the airway entry of the SARS-CoV-2 virus. This could possibly be achieved by injecting live SARS-CoV-2 virus intradermal (ID), subcutaneous, intra-muscular (IM) or intra-peritoneal (IP), or by targeting the virus to the digestive tract... The effectiveness and innocuity of using those various routes could be tested very rapidly in animal models, such as Macaques, H","2021","05","28","F1000Res","F1000Research","SARS-CoV-2; clinical trial; vaccination; Aerosols; Animals; COVID-19; COVID-19 Vaccines; Cats; Cricetinae; Humans; Incidence; Lung; Models, Animal; SARS-CoV-2","Joly","Etienne","Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, 31000, France",NA
"77","34035111","10.1136/bmjopen-2021-050114","Equity in vaccine trials for higher weight people? Protocol for a rapid review of inclusion and exclusion criteria for higher weight people in clinical trials for COVID-19.","Vaccination is a public health strategy that aims to reduce the burden of viral illness, especially important for populations known or likely to be at increased risk for inequitable outcomes due to the disease itself or disparities in care accessed and received. The role of weight status in COVID-19 susceptibility and disease burden remains unclear. Despite this, higher weight is frequently described as a definitive risk factor for both susceptibility and disease severity. Therefore, COVID-19 va","2021","05","31","BMJ Open","BMJ open","COVID-19; clinical trials; protocols &amp; guidelines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Eligibility Determination; Humans; Overweight; Review Literature as Topic; SARS-CoV-2; Treatment Outcome; Vaccines","Campbell","Jessica","Otago Medical School, University of Otago, Christchurch, New Zealand",NA
"78","34031383","10.1038/s41421-021-00279-w","Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication.","Treatment options for COVID-19 remain limited, especially during the early or asymptomatic phase. Here, we report a novel SARS-CoV-2 viral replication mechanism mediated by interactions between ACE2 and the epigenetic eraser enzyme LSD1, and its interplay with the nuclear shuttling importin pathway. Recent studies have shown a critical role for the importin pathway in SARS-CoV-2 infection, and many RNA viruses hijack this axis to re-direct host cell transcription. LSD1 colocalized with ACE2 at t","2021","05","28","Cell Discov","Cell discovery",NA,"Tu","Wen Juan","Gene Regulation and Translational Medicine Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia",NA
"79","34031153","10.1136/ejhpharm-2021-002794","Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results.",NA,"2021","05","25","Eur J Hosp Pharm","European journal of hospital pharmacy : science and practice","COVID-19; allergy and immunology; dermatology; drug-related side effects and adverse reactions; immunization","Cebeci","Filiz","Department of Dermatology, Istanbul Medeniyet University, Istanbul, Turkey cebecifiliz@yahoo","cebecifiliz@yahoo.com"
"80","34029345","10.1371/journal.pone.0251963","Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults.","The success of vaccination efforts to curb the COVID-19 pandemic will require broad public uptake of immunization and highlights the importance of understanding factors associated with willingness to receive a vaccine. U.S. adults aged 65 and older enrolled in the HeartlineTM clinical study were invited to complete a COVID-19 vaccine assessment through the HeartlineTM mobile application between November 6-20, 2020. Factors associated with willingness to receive a COVID-19 vaccine were evaluated ","2021","06","02","PLoS One","PloS one","Aged; Aged, 80 and over; COVID-19; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Mass Vaccination; Patient Participation; Socioeconomic Factors; United States; Vaccination Refusal","Nikolovski","Janeta","Janssen Pharmaceutical Companies of Johnson &amp",NA
"81","34028468","10.1016/j.imu.2021.100604","The journey of antimalarial drugs against SARS-CoV-2: Review article.","The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop COVID-19 infection are being investigated vigorously worldwide. Currently, some specific drugs have been authorized for COVID-19, but the improvement of antivirals requires time. Hence, a faster way of ","2021","05","26","Inform Med Unlocked","Informatics in medicine unlocked","Anti-malarial drugs; COIVD-19; Combination therapy; Drug repurposing","Sarhan","Amany A","Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt",NA
"82","34025393","10.3389/fphar.2021.584940","The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.","The emergence and rapid spread of novel coronavirus disease (COVID-19) has posed a serious challenge to global public health in 2020. The speed of this viral spread together with the high mortality rate has caused an unprecedented public health crisis. With no antivirals or vaccines available for the treatment of COVID-19, the medical community is presently exploring repositioning of clinically approved drugs for COVID-19. Chloroquine (CQ) and hydroxychloroquine (HCQ) have emerged as potential c","2021","05","26","Front Pharmacol","Frontiers in pharmacology","COVID-19; SARS-CoV-2; chloroquine; coronavirus; hydroxychloroquine","Manivannan","Elangovan","School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore, India",NA
"83","34022375","10.1016/j.micinf.2021.104841","Development of leading first-generation vaccines against SARS-CoV-2.","SARS-CoV-2 has infected more than 152 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need.","2021","05","24","Microbes Infect","Microbes and infection","Covid-19; SARS-CoV-2; animal models; clinical trials; vaccines","Perera","Pin-Yu","Pathology and Laboratory Medicine, Veterans Affairs Medical Center, Washington, District of Columbia, USA. Electronic address: Pin-Yu.Perera@va",NA
"84","34021278","10.1038/s41591-021-01363-0","Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.",NA,"2021","05","22","Nat Med","Nature medicine",NA,"Ewer","Katie J","The Jenner Institute, University of Oxford, Oxford, UK. katie.ewer@ndm.ox.ac","katie.ewer@ndm.ox.ac.uk"
"85","34020485","10.1055/a-1423-8961","Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.","Since the end of 2019, the novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has been spreading worldwide and has caused severe health and economic issues on a global scale. By the end of February 2021, more than 100..million SARS-CoV-2 cases had been reported worldwide. SARS-CoV-2 causes the coronavirus disease 2019 (COVID-19) that can be divided into three phases: An early phase with fever and cough (phase I), a pulmonary vascular disease (phase II) and a hyperinflammator","2021","05","25","Klin Monbl Augenheilkd","Klinische Monatsblatter fur Augenheilkunde","Antiviral Agents; COVID-19; COVID-19 Vaccines; Humans; Immunization, Passive; SARS-CoV-2; Vaccination","Bormann","Maren","Klinik f..r Infektiologie, Westdeutsches Zentrum f..r Infektiologie, Universit..tsmedizin Essen, Universit..t Duisburg-Essen, Essen, Deutschland",NA
"86","34019801","10.1016/S1473-3099(21)00263-2","Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.","Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2 and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates. The effect will be particularly acute in high-income countries where the entire adult or older population could be vaccinated by late 2021. Regrettably, only a small proportion of the population in many low-income and middle-income countries will have access to available vaccines. Sponsors of COVID-19 vaccine candidates current","2021","05","24","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Dal-R..","Rafael","Epidemiology Unit, Health Research Institute-Fundaci..n Jim..nez D..az University Hospital, Universidad Aut..noma de Madrid, Madrid, Spain. Electronic address: rafael.dalre@quironsalud","rafael.dalre@quironsalud.es"
"87","34019218","10.1007/s10787-021-00820-z","A brief, highly selective history of acute phase proteins as indicators of infection, inflammation and injury.","There is an array of plasma protein alterations that occur in a wide variety of species, including humans in response to trauma, inflammation and infections, seemingly irrespective of etiologic agent. In numerous species, these plasma proteins are part of the innate immune response. In addition, it appears that a number of the plasma proteins in this array can be predictive of morbidity and/or mortality. We propose that based on historic use, selected acute phase proteins should be included in o","2021","05","25","Inflammopharmacology","Inflammopharmacology","Acute phase proteins; Animal models of disease; C-reactive protein; Chronic disease; Covid-19; Innate immunity; Morbidity and mortality; Trauma and sepsis; Vaccination","Powanda","Michael C","M/P Biomedical Consultants LLC, 402 Live Oak Drive, Mill Valley, CA, 94941, USA. powanda@mpbiomed","powanda@mpbiomed.com"
"88","34015363","10.1016/j.virusres.2021.198454","The COVID-19 vaccine development: A pandemic paradigm.","COVID-19 pandemic has resulted in millions of deaths and a social-economic crisis. A worldwide effort was made to develop efficient vaccines for this disease. A vaccine should produce immune responses with specific and neutralizing antibodies, and without harmful effects such as the antibody-dependent enhancement that may be associated with severe acute respiratory syndrome. Vaccine design involves the selection of platforms that includes viral, viral-vector, protein, nucleic acid, or trained im","2021","06","13","Virus Res","Virus research","Coronavirus; Emergency use; SARS-CoV-2; Vaccine safety; Vaccine strategies","Carneiro","Diego C","Federal University of Bahia, Health Sciences Institute, Department of Biochemistry and Biophysics, Salvador, Bahia, Brazil",NA
"89","34015240","10.1080/21645515.2021.1928463","Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.","With the progress of COVID-19 vaccination programs worldwide, some new adverse events associated with the available vaccines may unfold, especially in subpopulations, representatives of whom were not included in phase I, II, and III clinical trials of these vaccines, such as patients with autoimmune diseases, including multiple sclerosis (MS). A 34-year-old woman presented with severe right hemiplegia and ataxia. She was diagnosed with relapsing-remitting MS (RRMS) 13..years ago and treated with","2021","05","20","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","COVID-19; COVID-19 vaccines; SARS-CoV-2; multiple sclerosis; vaccines","Etemadifar","Masoud","Department of Neurosurgery, Isfahan University of Medical Sciences, Isfahan, Iran",NA
"90","34013223","10.5152/TurkArchPediatr.2020.20255","Coronavirus infections in childhood and vaccine studies.","In late December 2019, a new coronavirus (CoV) called the severe acute respiratory syndrome CoV 2 (SARS-CoV-2), which had not been detected in humans before, caused a worldwide pandemic. Owing to the highly infectious nature of this virus, it spread rapidly from person to person despite the warnings of the World Health Organization and all the measures taken by the governments. Although it has been reported that SARS-CoV-2 is more likely to infect the elderly, all age groups are susceptible to t","2021","05","22","Turk Arch Pediatr","Turkish archives of pediatrics","Children; coronavirus disease 2019; vaccine","Ayg..n","Deniz","Department of Pediatrics, Division of Pediatric Infectious Diseases, ..stanbul University-Cerrahpa..a, Cerrahpa..a Faculty of Medicine, ..stanbul, Turkey",NA
"91","34012335","10.14745/ccdr.v47i03a01","Vaccine against SARS-CoV-2: Challenges and considerations.","It is essential to consider challenges previously faced and addressed while developing a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the severity of the health crisis that SARS-CoV-2 has caused worldwide, and with so little known about the virus, our focus should be drawn towards approaches that can bring better development outcomes in a relatively short period of time. This commentary discusses the use of nucleic acid (deoxyribonucleic acid and ribo","2021","05","22","Can Commun Dis Rep","Canada communicable disease report = Releve des maladies transmissibles au Canada","SARS-CoV-2; nucleic acid; vaccine","Chaube","Ruchi","Regulatory Operations and Enforcement Branch, Health Canada, Edmonton, AB","ruchi.chaube@canada.ca"
"92","34012121","10.1038/d41586-020-01534-y","Daily briefing: Hope and caution greet coronavirus vaccine trial results.",NA,"2021","05","20","Nature","Nature",NA,"Stoye","Emma",NA,NA
"93","34008027","10.1093/infdis/jiab263","Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials.","To speed the development of vaccines against SARS-CoV-2, the United States federal government has funded multiple phase 3 trials of candidate vaccines. A single 11-member data and safety monitoring board (DSMB) monitors all government-funded trials to ensure coordinated oversight, promote harmonized designs, and allow shared insights related to safety across trials. DSMB reviews encompass 3 domains: 1) the conduct of trials, including overall and subgroup accrual and data quality and completenes","2021","05","19","J Infect Dis","The Journal of infectious diseases","COVID19; Clinical trials; Data and safety monitoring; SARS-CoV-2; Vaccines","Joffe","Steven","Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States",NA
"94","34007998","10.1093/infdis/jiab262","BNT162b2 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary report.","In the pre-registration trial, data on the efficacy of the BNT162b2 mRNA vaccine against SARS-CoV-2 infection were not collected. The aim of this study was to evaluate vaccine effectiveness (VE) against documented infection. Bari Policlinico University-Hospital healthcare workers (HCWs) who completed the vaccination schedule were matched with HCWs who had refused vaccination. The VE for documented infection was 61.9% (95%CI=19.2-82.0%) 14-20 days after the first dose, 87.9% (95%CI=51.7-97.0%) 21","2021","05","19","J Infect Dis","The Journal of infectious diseases","COVID-19; documented infection; healthcare workers; vaccine effectiveness","Bianchi","Francesco Paolo","Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy",NA
"95","34007358","10.14740/jocmr4490","Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus causing a global pandemic. Coronaviruses are a large family of single-stranded ribonucleic acid (RNA) viruses. The virus has four essential structural proteins which include the spike (S) glycoprotein, matrix (M) protein, nucleocapsid (N) protein and small envelope (E) protein. Different technologies are being used for vaccine development to battle the pandemic. There are messenger ribonucleic acid (mRNA)-based v","2021","05","20","J Clin Med Res","Journal of clinical medicine research","COVID-19; Janssen; Moderna; Pfizer-BioNTech; SARS-CoV-2; Vaccines","Vasireddy","Deepa","Department of Pediatrics, Pediatric Group of Acadiana, Lafayette, LA, USA",NA
"96","34007070","10.1038/s41591-021-01370-1","Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.","Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ). The co-primary out","2021","05","19","Nat Med","Nature medicine",NA,"Ward","Brian J","Medicago Inc., Quebec City, Quebec, Canada. wardb@medicago","wardb@medicago.com"
"97","34006847","10.1038/s41392-021-00611-6","Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study.","Our understanding of the protective immunity, particularly the long-term dynamics of neutralizing antibody (NAbs) response to SARS-CoV-2, is currently limited. We enrolled a cohort of 545 COVID-19 patients from Hubei, China, who were followed up up to 7 months, and determined the dynamics of NAbs to SARS-CoV-2 by using a surrogate virus neutralization test (sVNT). In our validation study, sVNT IC50 titers and the neutralization rate measured at a single dilution (1:20) were well corre","2021","05","31","Signal Transduct Target Ther","Signal transduction and targeted therapy","Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; Female; Humans; Male; Middle Aged; SARS-CoV-2; Severity of Illness Index; Time Factors","Xu","Xin","State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangdong Provincial Clinical Research Center for Kidney Disease, Nanfang Hospital, Southern Medical University, Guangzhou, China",NA
"98","34006597","10.1126/science.abg8985","Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2.","The identification of CD4<sup>+</sup> T cell epitopes is instrumental for the design of subunit vaccines for broad protection against coronaviruses. Here we demonstrate in COVID-19-recovered individuals a robust CD4<sup>+</sup> T cell response to naturally processed SARS-CoV-2 spike (S) and nucleoprotein (N), including effector, helper, and memory T cells. By characterizing 2943 S-reactive T cell clones from 34 individuals, we found that 34% of clones and 93% of individuals recognized a conserve","2021","06","05","Science","Science (New York, N.Y.)",NA,"Low","Jun Siong","Institute for Research in Biomedicine, Universit.. della Svizzera Italiana, 6500 Bellinzona, Switzerland",NA
"99","34003294","10.5271/sjweh.3960","Return-to-work, disabilities and occupational health in the age of COVID-19.","We have read with great interest the two editorials by Burdorf et al: &quot;The COVID-19 pandemic: one year later - an occupational perspective&quot; (1) and &quot;The COVID-19 (Coronavirus) pandemic: consequences for occupational health&quot; (2). The authors highlight the importance of the societal consequences of the outbreak and changes in the world of work to manage occupational health. The key points identified - such as individual socio-economic factors, psychological effects and occupati","2021","05","18","Scand J Work Environ Health","Scandinavian journal of work, environment &amp; health",NA,"Godeau","Diane",NA,NA
"100","34001183","10.1186/s13045-021-01090-6","Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.","Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies (MPM) (20 chronic myeloid leukemias and 30 myeloproliferative neoplasms), all of them on active anti-cancer treatment, in comparison with 36 elderly controls not suffering from cancer. Subjects serologically and/or molecularly (by nasal/throat swab) positives at basal for SARS-CoV-2 were e","2021","05","25","J Hematol Oncol","Journal of hematology &amp; oncology","COVID-19; Hematological malignancy; mRNA vaccine; Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Female; Humans; Immunogenicity, Vaccine; Immunoglobulin G; Male; Middle Aged; Multiple Myeloma; Myeloproliferative Disorders; Preliminary Data; Prospective Studies; SARS-CoV-2","Pimpinelli","Fulvia","Microbiology and Virology Unit, Dermatological Clinical and Research Department, IRCCS San Gallicano Institute, Rome, Italy",NA
"101","33999399","10.17269/s41997-021-00505-8","At-home HIV self-testing during COVID: implementing the GetaKit project in Ottawa.","In March 2020, COVID-19 shuttered access to many healthcare settings offering HIV testing and there is no licensed HIV self-test in Canada. A team of nurses at the University of Ottawa and Ottawa Public Health and staff from the Ontario HIV Treatment Network (OHTN) obtained Health Canada's Special Access approval on April 23, 2020 to distribute bioLytical's INSTI HIV self-test in Ottawa; we received REB approval on May 15, 2020. As of July 20, 2020, eligible participants (...18 years old, HIV-ne","2021","05","20","Can J Public Health","Canadian journal of public health = Revue canadienne de sante publique","Access; HIV; Implementation; Self-testing","O'Byrne","Patrick","School of Nursing, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, K1H 8M5, Canada. pjobyrne@uottawa","pjobyrne@uottawa.ca"
"102","33999127","10.1093/cid/ciab438","The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data.","COVID-19 mRNA vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing SARS-CoV-2 infection and COVID-19-related hospitalization and mortality. This historical cohort study included members of a large health provider in Israel that were vaccinated with at least one dose of BNT162b2. The","2021","05","17","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","BNT162b2; COVID-19; Effectiveness; Real-world data; Vaccine","Chodick","Gabriel","Maccabi Institute for Research &amp",NA
"103","33998379","10.1080/14767058.2021.1920916","COVID-19 vaccination in pregnancy and postpartum.","To identify whether COVID-19 vaccines should be administered in pregnant and breastfeeding women by reviewing the guidance and other evidence. We reviewed the COVID-19 vaccination guidance for pregnant and breastfeeding women published to date and evidence from preclinical experimental and observational clinical studies, and discuss their implications. Pregnant women were excluded from the initial phase 3 clinical trials of COVID-19 vaccines resulting in limited data on their efficacy and safety","2021","05","17","J Matern Fetal Neonatal Med","The journal of maternal-fetal &amp; neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians","COVID-19 Vaccine; SARS-CoV-2; breastfeeding; coronavirus disease 2019; pregnancy","Brillo","Eleonora","Center for Research in Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy",NA
"104","33998108","10.1111/ijcp.14364","Parents' willingness and attitudes concerning the COVID-19 vaccine: A cross-sectional study.","This study aimed to evaluate the parents' willingness and attitudes concerning the COVID-19 vaccine. This cross-sectional study was performed using a self-administered online survey, covering parents' and their children's characteristics, parents' willingness and attitudes towards the COVID-19 vaccine. A total of 1035 parents participated. Analysis showed that 36.3% of parents were willing to have their children receive the COVID-19 vaccine and that 59.9% were willing to receive it themselves. I","2021","05","29","Int J Clin Pract","International journal of clinical practice",NA,"Y..lmaz","Meltem","Pazar Integrated District Hospital, Tokat, Turkey",NA
"105","33997827","10.1016/j.xinn.2021.100116","Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review.","COVID-19 has spread globally to over 200 countries with more than 40 million confirmed cases and one million deaths as of November 1, 2020. The SARS-CoV-2 virus, leading to COVID-19, shows extremely high rates of infectivity and replication, and can result in pneumonia, acute respiratory distress, or even mortality. SARS-CoV-2 has been found to continue to rapidly evolve, with several genomic variants emerging in different regions throughout the world. In addition, despite intensive study of the","2021","06","04","Innovation (N Y)","Innovation (New York, N.Y.)","COVID-19; SARS-CoV-2; SARS-CoV-2 vaccine; infection mechanism; origin tracing","Li","Tianbao","Genetic Testing Center, Academician Workstation, Changsha Medical University, Changsha 410219, China",NA
"106","33993845","10.1080/22221751.2021.1931466","Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.","ABSTRACTCOVID-19 vaccines are being developed urgently worldwide. Here, we constructed two adenovirus vectored COVID-19 vaccine candidates of Sad23L-nCoV-S and Ad49L-nCoV-S carrying the full-length gene of SARS-CoV-2 spike protein. The immunogenicity of two vaccines was individually evaluated in mice. Specific immune responses were observed by priming in a dose-dependent manner, and stronger responses were obtained by boosting. Furthermore, five rhesus macaques were primed with 5 .. 10<su","2021","06","07","Emerg Microbes Infect","Emerging microbes &amp; infections","COVID-19 vaccines; human adenovirus 49 vector; mice and non-human primates; prime-boost vaccination; simian adenovirus 23 vector; Adenoviridae; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Female; Genetic Vectors; HEK293 Cells; Humans; Immunization, Secondary; Macaca mulatta; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; SARS-CoV-2; T-Lymphocytes","Luo","Shengxue","Department of Pediatrics, Shenzhen Hospital, Southern Medical University, Shenzhen, People's Republic of China",NA
"107","33993685","10.36233/0507-4088-40","[Reactivation of Epstein-Barr virus (<i>Herpesviridae: Lymphocryptovirus</i>, HHV-4) infection during COVID-19: epidemiological features].","Immunodeficiency underlying the development of severe forms of new coronavirus infection may be the result of mixed infection with SARS-CoV-2 and other pathogens, including Epstein-Barr virus (EBV).The aim is to study the prevalence and epidemiological features of co-infection with SARS-CoV-2 and EBV. A cross-sectional randomized study was conducted in Moscow region from March to May 2020. Two groups were examined for EBV-markers: hospital patients (n = 95) treated for SARS-CoV-2 infection and b","2021","05","24","Vopr Virusol","Voprosy virusologii","Adolescent; Adult; COVID-19; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Male; Middle Aged; SARS-CoV-2; Virus Activation","Solomay","T V","Interregional Department No. 1 of the Federal Medical and Biological Agency",NA
"108","33991482","10.1016/S2468-2667(21)00096-7","Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial.","The effectiveness of the COVID-19 vaccination programme depends on mass participation: the greater the number of people vaccinated, the less risk to the population. Concise, persuasive messaging is crucial, particularly given substantial levels of vaccine hesitancy in the UK. Our aim was to test which types of written information about COVID-19 vaccination, in addition to a statement of efficacy and safety, might increase vaccine acceptance. For this single-blind, parallel-group, randomised cont","2021","06","02","Lancet Public Health","The Lancet. Public health","Adolescent; Adult; Aged; Aged, 80 and over; COVID-19 Vaccines; Female; Health Communication; Humans; Male; Middle Aged; Persuasive Communication; Single-Blind Method; United Kingdom; Vaccination; Young Adult","Freeman","Daniel","Department of Psychiatry, University of Oxford, Oxford, UK","daniel.freeman@psych.ox.ac.uk"
"109","33991474","10.1016/S0140-6736(21)00894-1","Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply.",NA,"2021","05","27","Lancet","Lancet (London, England)","COVID-19; COVID-19 Vaccines; Humans; Research Report; Russia; SARS-CoV-2","Logunov","Denis Y","Federal State Budget Institution &quot","ldenisy@gmail.com"
"110","33989091","10.1177/00368504211016936","Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review.","The current COVID-19 pandemic situation has stimulated an unplanned clinical research paradigm which is evident from the surge of clinical trial registrations and the increasing number of COVID-related publications. We aimed to explore the standards for research conduction, publications and retraction of articles related to COVID-19 pharmacotherapy research during the pandemic. We analysed data from the contemporary literatures on studies reporting pharmacological agents for COVID-19 using MEDLI","2021","05","26","Sci Prog","Science progress","COVID-19 pandemic; pharmaceutical studies; publications; research ethics; retraction; Antiviral Agents; Biomedical Research; COVID-19; Humans; Peer Review; Publishing; Retraction of Publication as Topic; SARS-CoV-2","El-Menyar","Ayman","Clinical Medicine, Weill Cornell Medical College, Doha, Qatar",NA
"111","33988334","10.1097/TP.0000000000003755","The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression.","The ability of transplant (Tx)-patients to generate a protective antiviral response under immunosuppression is pivotal in COVID-19 infection. However, analysis of immunity against SARS-COV-2 is currently lacking. Here, we analyzed T cell immunity directed against SARS-CoV-2 spike-, membrane-, and nucleocapsid-protein by flow cytometry and spike-specific neutralizing antibodies in ten Tx in comparison to 26 nonimmunosuppressed (non-Tx) COVID-19 patients. Tx-patients (seven renal, one lung, and tw","2021","05","14","Transplantation","Transplantation",NA,"Thieme","Constantin J","Charit.. - Universit..tsmedizin Berlin, Corporate Member of Freie Universit..t Berlin, Humboldt-Universit..t zu Berlin, and Berlin Institute of Health, Berlin-Brandenburg Center for Regenerative Therapies, and Institute of Medical Immunology, Germany 2Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Germany 3Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Germany 4Department of Anesthesiology, University Hospital Essen, University Duisburg-Essen, Germany 5Department of Immunology, Labor Berlin GmbH, Berlin, Germany 6Ruhr-University Bochum, University Hospital Knappschaftskrankenhaus Bochum, Department of Surgery, Bochum, Germany",NA
"112","33986272","10.1038/s41541-021-00336-1","Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.","As SARS-CoV-2 vaccines are deployed worldwide, a comparative evaluation is important to underpin decision-making. We here report a systematic literature review and meta-analysis of Phase I/II/III human trials and non-human primates (NHP) studies, comparing reactogenicity, immunogenicity and efficacy across different vaccine platforms for comparative evaluation (updated to March 22, 2021). Twenty-three NHP and 32 human studies are included. Vaccines result in mostly mild, self-limiting adverse ev","2021","05","16","NPJ Vaccines","NPJ vaccines",NA,"McDonald","Ian","Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK",NA
"113","33984466","10.1016/j.micpath.2021.104933","Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.","The recent outbreak of viral infection and its transmission has highlighted the importance of its slowdown for the safeguard of public health, globally. The identification of novel drugs and efficient therapies against these infectious viruses is need of the hour. The eruption of COVID-19 is caused by a novel acute respiratory syndrome virus SARS-CoV-2 which has taken the whole world by storm as it has transformed into a global pandemic. This lethal syndrome is a global health threat to general ","2021","06","07","Microb Pathog","Microbial pathogenesis","COVID-19; Coronaviruses; Natural products; RNA; Spike proteins","Khursheed","Aadil","Department of Chemistry, Madhyanchal Professional University, Ratibad, Bhopal, 462044, Madhya Pradesh, India",NA
"114","33983745","10.1021/acs.molpharmaceut.1c00291","The Possible Role of Sex As an Important Factor in Development and Administration of Lipid Nanomedicine-Based COVID-19 Vaccine.","Nanomedicine has demonstrated a substantial role in vaccine development against severe acute respiratory syndrome coronavirus (SARS-CoV-2 and COVID-19). Although nanomedicine-based vaccines have now been validated in millions of individuals worldwide in phase 4 and tracking of sex-disaggregated data on COVID-19 is ongoing, immune responses that underlie COVID-19 disease outcomes have not been clarified yet. A full understanding of sex-role effects on the response to nanomedicine products is esse","2021","06","09","Mol Pharm","Molecular pharmaceutics","COVID-19; nanomedicine; sex-specific response; vaccine","Vulpis","Elisabetta","Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy",NA
"115","33983379","10.1001/jama.2021.7563","Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.","Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety and immunogenicity in these populations are therefore limited. To evaluate the immunogenicity of COVID-19 messenger RNA (mRNA) vaccines in pregnant and lactating women, including against emerging SARS-CoV-2 variants of concern. An exploratory, descriptive, prospective cohort study enrolled 103 women who received a COVID-19 vaccine f","2021","05","27","JAMA","JAMA",NA,"Collier","Ai-Ris Y","Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts",NA
"116","33983086","10.1177/03915603211016321","Urology practice during the COVID-19 vaccination campaign.","The current scenario of the COVID-19 pandemic is significantly different from that of the first, emergency phase. Several countries in the world are experiencing a second, or even a third, wave of contagion, while awaiting the effects of mass vaccination campaigns. The aim of this report was to provide an update of previously released recommendations on prioritization and restructuring of urological activities. A large group of Italian urologists directly involved in the reorganization of their ","2021","05","18","Urologia","Urologia","COVID-19; Coronavirus; clinical practice guidelines; endourology; pandemic; surgery; urology; vaccine","Ficarra","Vincenzo","Department of Human and Pediatric Pathology &quot",NA
"117","33980657","10.1136/medethics-2021-107229","COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement.","In spring, summer and autumn 2020, one abiding argument against controlled human infection (CHI) studies of SARS-CoV-2 vaccines has been their impact on local communities. Leading scientists and bioethicists expressed concern about undue usage of local residents' direly needed scarce resources at a time of great need and even about their unintended infection. They recommended either avoiding CHI trials or engaging local communities before conducting any CHIs. Similar recommendations were not mad","2021","05","15","J Med Ethics","Journal of medical ethics","COVID-19; clinical trials; ethics; public health ethics; research ethics","Lee","Kyungdo","Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, New Jersey, USA",NA
"118","33980601","10.1128/JVI.00294-21","Host-virus chimeric events in SARS-CoV2 infected cells are infrequent and artifactual.","Pathogenic mechanisms underlying severe SARS-CoV2 infection remain largely unelucidated. High throughput sequencing technologies that capture genome and transcriptome information are key approaches to gain detailed mechanistic insights from infected cells. These techniques readily detect both pathogen and host-derived sequences, providing a means of studying host-pathogen interactions. Recent studies have reported the presence of host-virus chimeric (HVC) RNA in RNA-seq data from SARS-CoV2 infec","2021","06","05","J Virol","Journal of virology",NA,"Yan","Bingyu","Department of Biochemistry, Purdue University, West Lafayette, IN, USA",NA
"119","33979495","10.1056/NEJMe2108162","Audio Interview: Vaccination and Variants in the U.S. and South Africa.",NA,"2021","05","18","N Engl J Med","The New England journal of medicine","Antibodies, Neutralizing; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Industry; Female; HIV Infections; Health Personnel; Health Services Accessibility; Humans; Immunogenicity, Vaccine; In Vitro Techniques; Patient Acuity; Pregnancy; Pregnancy Complications, Infectious; Prisoners; SARS-CoV-2; South Africa; Tuberculosis; United States; Vaccination Refusal","Rubin","Eric J",NA,NA
"120","33978261","10.1002/hpm.3191","Employing medical anthropology approach as an additional public health strategy in promoting COVID-19 vaccine acceptance in Bhutan.","Bhutan has been commended for their COVID-19 vaccination campaign, in which the country became the fastest in the world to inoculate nearly all of its adult population in just a few weeks. As a profoundly religious Buddhist kingdom in South Asia, the country successfully utilized a very unique strategy in promoting COVID-19 vaccine acceptance nationwide. Bhutan incorporated religion, culture, and tradition in their campaign wherein the royal government collaborated with the Zhung Dratsang, the c","2021","05","12","Int J Health Plann Manage","The International journal of health planning and management","Bhutan; COVID-19; medical anthropology; public health strategy; vaccine acceptance","Rocha","Ian Christopher N","School of Medicine, Centro Escolar University, Manila, Philippines",NA
"121","33976879","10.1002/cti2.1281","Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals.","Although the adaptive immune response to SARS-CoV-2 has been characterised in the acute and early convalescent phase of the disease, few studies explore whether natural infection elicits long-lasting immunological memory in recovered individuals. In this work, we aimed to assess the maintenance of immunological memory to SARS-CoV-2. We evaluated the long-term virus-specific cellular and humoral immune response in the members of an Italian Serie A football team, <AbstractText Label=""Results"" NlmC","2021","05","14","Clin Transl Immunology","Clinical &amp; translational immunology","SARS...CoV...2; T cells; immunoglobulins; immunological memory","Mazzoni","Alessio","Department of Experimental and Clinical Medicine University of Florence Florence Italy",NA
"122","33976088","","FDA authorizes Johnson &amp; Johnson COVID-19 vaccine.",NA,"2021","05","24","Med Lett Drugs Ther","The Medical letter on drugs and therapeutics","COVID-19; Vaccines; adverse effects; dosage; efficacy; lactation; pregnancy; safety; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Humans; United States; United States Food and Drug Administration",NA,NA,NA,NA
"123","33974610","10.37757/MR2021.V23.N2.17","Indian contribution toward biomedical research and development in COVID-19: A systematic review. Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center.","COVID-19 pandemic led to an unprecedented collaborative effort among industry, academia, regulatory bodies, and governments with huge financial investments. Scientists and researchers from India also left no stone unturned to find therapeutic and preventive measures against COVID-19. Indian pharmaceutical companies are one of the leading manufacturers of vaccine in the world, are utilizing its capacity to its maximum, and are one among the forerunners in vaccine research against COVID-19 across ","2021","05","19","Indian J Pharmacol","Indian journal of pharmacology","Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomedical Research; Biotechnology; COVID-19; COVID-19 Vaccines; Cuba; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Kaur","Hardeep","Department of Pediatric, Postgraduate Institute of Medical Education and Research, Chandigarh, India",NA
"124","33974607","10.37757/MR2021.V23.N2.16","COVID-19 Requires Innovation, Regulation and Rigor: Amaylid Arteaga-Garc..a MD MS Director, National Clinical Trials Coordinating Center (CENCEC).","The effects and implications of COVID-19 are global, comprehensive and long-term. The pandemic has exposed inequities, the fragility of economic and political systems, and in many cases, skewed priorities. Population health, not to mention planetary health, is suffering as a result. Nevertheless, the global health crisis in which we are embroiled has provided opportunities for effective collaboration, scientific innovation and real dialog around health and equity. Dr Amaylid Arteaga-Garc..a, dir","2021","05","24","MEDICC Rev","MEDICC review","COVID-19; Clinical Trials as Topic; Communicable Disease Control; Cuba; Humans; Pandemics; SARS-CoV-2","Aguilar","Tania L",NA,NA
"125","33973197","10.1007/978-3-030-63761-3_29","Dietary Supplements for COVID-19.","Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease that can rapidly escalate to respiratory failure and death. It has infected millions of people worldwide. The trajectory of this disease continues to progress in some areas of the United States and worldwide. The Institute for Health Metrics now predicts a resurgence of infections in the fall of 2020. The pathogenesis of COVID-19 includes an inflammatory phase with either resolution or the potential to accelerate to a ","2021","05","12","Adv Exp Med Biol","Advances in experimental medicine and biology","COVID-19; Cytokine storm; Inflammasome; Melatonin; SARS-CoV-2; Vitamin C; Vitamin D; Zinc; COVID-19; Dietary Supplements; Humans; Pandemics; SARS-CoV-2; United States; Vitamin D","Mullin","Gerard E","The Johns Hopkins School of Medicine, Baltimore, MD, USA. gmullin1@jhmi","gmullin1@jhmi.edu"
"126","33972565","10.1038/s41541-021-00315-6","ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.","Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via t","2021","05","14","NPJ Vaccines","NPJ vaccines",NA,"Marsh","Glenn A","CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia",NA
"127","33966930","10.1016/j.ejim.2021.04.019","SARS-CoV-2 vaccines: Lights and shadows.","Vaccines to prevent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicit an immune neutralizing response. Some concerns have been raised regarding the safety of SARS-CoV-2 vaccines, largely based on case-reports of serious thromboembolic events after vaccination. Some mechanisms have been suggested which might explain the adverse cardiovascular reactions to SARS-CoV-2 vaccines. Different vaccine platforms are currently available which include live attenuated vaccines, inactivat","2021","06","02","Eur J Intern Med","European journal of internal medicine","ACE2; Adverse event; COVID-19; Renin-angiotensin-aldosterone system; SARS-CoV-2; Thrombosis; Vaccines; COVID-19; COVID-19 Vaccines; Humans; SARS-CoV-2; Thrombosis","Angeli","Fabio","Department of Medicine and Surgery, University of Insubria, Varese and Department of Medicine and Cardiopulmonary Rehabilitation, Maugeri Care and Research Institute, IRCCS Tradate, Varese, Italy. Electronic address: angeli.internet@gmail","angeli.internet@gmail.com"
"128","33960659","10.1111/1751-7915.13818","COVID-19: vaccine's progress.","Under the pressure of the COVID-19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus-vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical t","2021","05","07","Microb Biotechnol","Microbial biotechnology",NA,"Br..ssow","Harald","Department of Biosystems, Laboratory of Gene Technology, KU Leuven, Leuven, Belgium",NA
"129","33960398","10.1111/bph.15452","Therapeutic strategies to fight COVID-19: Which is the status artis?","COVID-19 is a complex disease, and many difficulties are faced today especially in the proper choice of pharmacological treatments. The role of antiviral agents for COVID-19 is still being investigated and evidence for immunomodulatory and anti-inflammatory drugs is quite conflicting, whereas the use of corticosteroids is supported by robust evidence. The use of heparins in hospitalized critically ill patients is preferred over other anticoagulants. There are conflicting data on the use of conva","2021","05","07","Br J Pharmacol","British journal of pharmacology","clinical research; covid-19; repurposing drugs; review; vaccines","Scavone","Cristina","Department of Experimental Medicine, Universit.. degli studi della Campania 'Luigi Vanvitelli', Naples, Italy",NA
"130","33958800","10.1038/s41591-021-01372-z","Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.",NA,"2021","05","09","Nat Med","Nature medicine",NA,"Barrett","Jordan R","The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK",NA
"131","33957320","10.1016/j.jmoldx.2021.04.005","Clinical Validation of a Sensitive Test for Saliva Collected in Healthcare and Community Settings with Pooling Utility for Severe Acute Respiratory Syndrome Coronavirus 2 Mass Surveillance.","The clinical performance of saliva compared with nasopharyngeal swabs (NPSs) has shown conflicting results in healthcare and community settings. In the present study, a total of 429 matched NPS and saliva sample pairs, collected in either healthcare or community setting, were evaluated. Phase-1 (protocol U) tested 240 matched NPS and saliva sample pairs; phase 2 (SalivaAll protocol) tested 189 matched NPS and saliva sample pairs, with an additional sample homogenization step before RNA extractio","2021","06","13","J Mol Diagn","The Journal of molecular diagnostics : JMD",NA,"Sahajpal","Nikhil S","Department of Pathology, Medical College of Georgia, Augusta University, Augusta, Georgia",NA
"132","33956667","10.1172/JCI149154","One dose of SARS-CoV-2 vaccine exponentially increases antibodies in recovered individuals with symptomatic COVID-19.","Currently used COVID-19 vaccines require two doses to achieve optimal vaccination, and there is no indication as to whether individuals who have been exposed to SARS-CoV-2 should be vaccinated, or should receive one or two vaccine doses. Here, we tested the antibody response developed after administration of the Pfizer/BioNTech vaccine in 124 healthcare professionals of which 57 had a previous history of SARS-CoV-2 exposure (SARS-CoV-2-Exp), with or without symptoms. Post-vaccine antibodies in S","2021","05","06","J Clin Invest","The Journal of clinical investigation","Adaptive immunity; Immunoglobulins; Immunology; Vaccines","Levi","Riccardo","Department of Biomedical Sciences, Humanitas University, Milan, Italy",NA
"133","33953551","10.2147/CIA.S295522","Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist.","The COVID-19 pandemic has disproportionately impacted frail older adults, especially residents of long-term care (LTC) facilities. This has appropriately led to prioritization of frail older adults and LTC residents, and those who care for them, in the vaccination effort against COVID-19. Older adults have distinct immunological, clinical, and practical complexity, which can be understood through a lens of frailty. Even so, frailty has not been considered in studies of COVID-19 vaccines to date,","2021","05","19","Clin Interv Aging","Clinical interventions in aging","COVID-19; SARS-CoV-2; frail elderly; frailty; geriatrics; vaccine; Aged; Biomedical Research; COVID-19; COVID-19 Vaccines; Frail Elderly; Frailty; Geriatricians; Humans; Male; Pandemics; Physician's Role; Public Health; SARS-CoV-2","Andrew","Melissa K","Department of Medicine, Division of Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada",NA
"134","33952445","10.1136/bmj.n1114","Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.","To assess rates of cardiovascular and haemostatic events in the first 28 days after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S in Denmark and Norway and to compare them with rates observed in the general populations. Population based cohort study. Nationwide healthcare registers in Denmark and Norway. All people aged 18-65 years who received a first vaccination with ChAdOx1-S from 9 February 2021 to 11 March 2021. The general populations of Denmark (2016-18) and Norway (2018-19) s","2021","05","17","BMJ","BMJ (Clinical research ed.)","Adolescent; Adult; Aged; COVID-19 Vaccines; Cerebral Arterial Diseases; Denmark; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Norway; Registries; Thrombocytopenia; Venous Thromboembolism; Venous Thrombosis; Young Adult","Potteg..rd","Anton","Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark apottegaard@health.sdu","apottegaard@health.sdu.dk"
"135","33951913","10.1021/acs.bioconjchem.1c00208","Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.","SARS-CoV-2 caused the COVID-19 pandemic that lasted for more than a year. Globally, there is an urgent need to use safe and effective vaccines for immunization to achieve comprehensive protection against SARS-CoV-2 infection. Focusing on developing a rapid vaccine platform with significant immunogenicity as well as broad and high protection efficiency, we designed a SARS-CoV-2 spike protein receptor-binding domain (RBD) displayed on self-assembled ferritin nanoparticles. In a 293i cells eukaryot","2021","06","02","Bioconjug Chem","Bioconjugate chemistry","Animals; Antibodies, Neutralizing; Binding Sites; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Ferritins; Immunity, Humoral; Macaca mulatta; Male; Nanoparticles; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Ultracentrifugation","Li","Heng","Institute of Medical Biology, Chinese Academy of Medical Sciences &amp",NA
"136","33951417","10.1016/j.immuni.2021.04.009","CD8<sup>+</sup> T..cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity.","To better understand primary and recall T..cell responses during coronavirus disease 2019 (COVID-19), it is important to examine unmanipulated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T..cells. By using peptide-human leukocyte antigen (HLA) tetramers for direct ex..vivo analysis, we characterized CD8<sup>+</sup> T..cells specific for SARS-CoV-2 epitopes in COVID-19 patients and unexposed individuals. Unlike CD8<sup>+</sup> T..cells directed toward subdominant epitope","2021","05","21","Immunity","Immunity","COVID-19; SARS-CoV-2-specific CD8+; T cells; TCR; immunodominant; Adult; Aged; Amino Acid Motifs; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; Child; Convalescence; Coronavirus Nucleocapsid Proteins; Epitopes, T-Lymphocyte; Female; Humans; Immunodominant Epitopes; Male; Middle Aged; Phenotype; Phosphoproteins; Receptors, Antigen, T-Cell; Receptors, Antigen, T-Cell, alpha-beta; SARS-CoV-2; Spike Glycoprotein, Coronavirus","Nguyen","Thi H O","Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia",NA
"137","33951374","10.1056/NEJMoa2103055","Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.","The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) pandemic. In a phase 1-2 trial involving healthy adults, the NVX-CoV2373 nanoparticle vaccine had an acceptable safety profile and was associated with strong neutralizing-antibody and antigen-specific polyfunctional CD4+ T-cell responses. Evaluation of vaccine efficacy was needed in a setting of ongoing SARS-CoV-2 transmission. In thi","2021","05","25","N Engl J Med","The New England journal of medicine","Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; COVID-19; COVID-19 Serological Testing; COVID-19 Vaccines; Double-Blind Method; HIV Seronegativity; HIV Seropositivity; Humans; Immunogenicity, Vaccine; Middle Aged; SARS-CoV-2; South Africa; Young Adult","Shinde","Vivek","From Novavax, Gaithersburg, MD (V.S., L. Fries, S.C.-C., M.Z., C.B., G.A., E.F., J.S.P., A.R., S.N., I.C., G.M.G., F.D.)",NA
"138","33951370","10.1056/NEJMe2107728","Audio Interview: India's Covid-19 Crisis.",NA,"2021","05","13","N Engl J Med","The New England journal of medicine","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Communicable Disease Control; Disease Transmission, Infectious; Health Care Rationing; Health Resources; Humans; Immunization Programs; Immunogenicity, Vaccine; India; Oxygen; Oxygen Inhalation Therapy; Physicians; Public Health Administration; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Treatment Outcome","Rubin","Eric J",NA,NA
"139","33950586","","[COVID-19 Diagnosis].","The need to curb the circulation of SARS-CoV-2 virus in the community and to diagnose those at risk of developing complications implies that an appropriate test should be chosen according to the epidemiological and clinical context. Rapid antigen tests, either nasopharyngeal or nasal, have the advantage of reflecting contagiousness better than PCR and giving an immediate result, reason why they are used as first-line for community diagnosis and screening. A rapid test allows immediate management","2021","05","10","Rev Med Suisse","Revue medicale suisse","COVID-19; COVID-19 Testing; Humans; Mass Screening; Nasopharynx; SARS-CoV-2","Schwob","Jean-Marc","Policlinique de m..decine tropicale, voyages et vaccinations, Unisant.., 1015 Lausanne",NA
"140","33948908","10.1007/s40615-021-01051-2","Coronavirus Vaccine Distribution: Moving to a Race Conscious Approach for a Racially Disparate Problem.","Strikingly ignoring the critical impact of systemic racism in vulnerabilities to the deadly coronavirus, phase one of the vaccine rollout is not reaching the Black population that has suffered the most from COVID. An urgent need exists for a race-conscious approach that ensures equitable opportunities to both access and receive the vaccines.","2021","05","07","J Racial Ethn Health Disparities","Journal of racial and ethnic health disparities","Blacks; COVID-19; Comorbidities; Hyper-segregation; Legacy pollutants; Poverty; Race-blind vaccine rollout; Reputational equity","Johnson","James H","Kenan-Flagler Business School, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA",NA
"141","33948031","10.1038/d41586-021-01146-0","China's COVID vaccines are going global - but questions remain.",NA,"2021","05","17","Nature","Nature","Biotechnology; SARS-CoV-2; Vaccines; Aged; Bahrain; Brazil; COVID-19; COVID-19 Vaccines; Child; China; Clinical Trials as Topic; Female; Healthcare Disparities; Humans; Incidence; Information Dissemination; Internationality; Patient Safety; Pregnancy; Quality Control; Reproducibility of Results; Uncertainty; United Arab Emirates; Vaccines, Inactivated; World Health Organization","Mallapaty","Smriti",NA,NA
"142","33946736","10.3390/vaccines9050436","Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm.","Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a severe pandemic of the current century. The vicious tentacles of the disease have been disseminated worldwide with unknown complications and repercussions. Advanced COVID-19 syndrome is characterized by the uncontrolled and elevated release of pro-inflammatory cytokines and suppressed immunity, leading to the cytokine storm. The uncontrolled and dysregulated secretion of inflammatory","2021","06","12","Vaccines (Basel)","Vaccines","COVID-19; cytokine storm; genomics; immunomodulatory drugs; immunopathology; inflammatory cytokines","Rabaan","Ali A","Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia",NA
"143","33942351","10.1111/risa.13726","Exploring Risks of Human Challenge Trials For COVID-19.","Human challenge trials (HCTs) are a potential method to accelerate development of vaccines and therapeutics. However, HCTs for COVID-19 pose ethical and practical challenges, in part due to the unclear and developing risks. In this article , we introduce an interactive model for exploring some risks of a severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) dosing study, a prerequisite for any COVID-19 challenge trials. The risk estimates we use are based on a Bayesian evidence synthesis ","2021","06","01","Risk Anal","Risk analysis : an official publication of the Society for Risk Analysis","Bayesian meta-analysis; COVID-19; human challenge trial; informed consent; interactive models; risk communication; Antiviral Agents; Bayes Theorem; COVID-19; COVID-19 Vaccines; Ethics, Research; Humans; Risk Assessment; SARS-CoV-2","Manheim","David","DaySooner, Wilmington, DE, USA",NA
"144","33941657","10.4049/jimmunol.2001369","Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients.","Serological tests for detection of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Abs in blood are expected to identify individuals who have acquired immunity against SARS-CoV-2 and indication of seroprevalence of SARS-CoV-2 infection. Many serological tests have been developed to detect Abs against SARS-CoV-2. However, these tests have considerable variations in their specificity and sensitivity, and whether they can predict levels of neutralizing activity is yet to be determ","2021","05","17","J Immunol","Journal of immunology (Baltimore, Md. : 1950)","Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; Antibody Specificity; Antigens, Viral; COVID-19; COVID-19 Nucleic Acid Testing; Female; Humans; Immunoglobulin Isotypes; Male; Middle Aged; SARS-CoV-2","Fujigaki","Hidetsugu","Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan fujigaki@fujita-hu.ac",NA
"145","33937730","10.1016/j.eclinm.2021.100841","Mumbai mayhem of COVID-19 pandemic reveals important factors that influence susceptibility to infection.","COVID-19 severity is disproportionately high in the elderly and people with comorbidities. However, other factors that predispose individuals to increased chances of infection are unclear. Data from 18,600 people screened for COVID-19 in Mumbai during the outbreak's initial phase, March 7 to June 30, 2020, were used to assess risk factors associated with COVID-19 using the odds ratio analysis. Males aged ...60 years having both diabetes and hypertension were at the highest risk of COVID-19 infec","2021","05","04","EClinicalMedicine","EClinicalMedicine",NA,"Yadav","Radha","Department of Mathematics, Indian Institute of Technology Bombay, Mumbai 400076, India",NA
"146","33935504","10.2147/JAA.S303309","Pediatric Vaccine Hesitancy and the Utilization of Antibody Measurements: A Novel Strategy with Implications for COVID 19.","Vaccine hesitancy is a well researched area with implications for both public health and the health of children and their families The factors leading to vaccine hesitancy are often complex and involve fear of the healthcare system and the process of vaccine development, cultural viewpoints and experiences. Pediatric patients often rely on parental guidance and decision making, and this may result in a lack of immunization for some children. The availability of the COVID 19 vaccine has been wide","2021","05","04","J Asthma Allergy","Journal of asthma and allergy","antibody; immunization; vaccine","Dosanjh","Amrita","Pediatric Respiratory, San Diego, CA, USA",NA
"147","33934060","10.1016/j.ejca.2021.03.030","Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).","The impacts of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a high risk of death from coronavirus disease 2019 (COVID-19) in patients with cancer treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the rate of severe COVID-19 cases in patients with cancer and also to restore normal cancer care. Patients with cancer to be targeted for vaccination are difficult to define owing to the limited contribut","2021","05","28","Eur J Cancer","European journal of cancer (Oxford, England : 1990)","COVID-19; Chemotherapy; Coronavirus; Radiotherapy; SARS-CoV-2; Solid cancers; Vaccination; COVID-19; COVID-19 Vaccines; Humans; Neoplasms; SARS-CoV-2","Tougeron","David","Hepatology and Gastroenterology Department, Poitiers University Hospital and University of Poitiers, FFCD, Poitiers, France. Electronic address: david.tougeron@chu-poitiers",NA
"148","33932943","10.1055/s-0041-1726390","COVID-19 Vaccine Considerations during Pregnancy and Lactation.",NA,"2021","05","12","Am J Perinatol","American journal of perinatology","Breast Feeding; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Female; Humans; Lactation; Milk, Human; Patient Selection; Pregnancy; Risk Assessment; SARS-CoV-2","Blumberg","Dean","Department of Pediatrics, UC Davis Children's Hospital, Sacramento, California",NA
"149","33930855","10.1016/j.dsx.2021.04.004","Development and validation of a questionnaire to assess knowledge, attitude, practices, and concerns regarding COVID-19 vaccination among the general population.","There seems to be hesitation in the general population in accepting COVID 19 vaccine because of associated myths and/or misinformation. This study is dedicated to develop and validate a tool to interpret vaccine acceptance and/or hesitancy by assessing the knowledge, attitude, practices, and concerns regarding the COVID vaccine. Mixed methods study design was used. In phase 1, the questionnaire was developed through literature review, focus group discussion, expert evaluation, and pre-testing. I","2021","05","31","Diabetes Metab Syndr","Diabetes &amp; metabolic syndrome","Acceptance; COVID-19; Concerns; Hesitancy; KAP; Pandemic; Questionnaire; Vaccine","Kumari","Archana","Department of Obstetrics &amp",NA
"150","33930764","10.1016/j.compbiomed.2021.104420","Immunogenomics guided design of immunomodulatory multi-epitope subunit vaccine against the SARS-CoV-2 new variants, and its validation through in silico cloning and immune simulation.","Reports of the novel and more contagious strains of SARS-CoV-2 originating in different countries have further aggravated the pandemic situation. The recent substitutions in spike protein may be critical for the virus to evade the host's immune system and therapeutics that have already been developed. Thus, this study has employed an immunoinformatics pipeline to target the spike protein of this novel strain to construct an immunogenic epitope (CTL, HTL, and B cell) vaccine against the new varia","2021","06","02","Comput Biol Med","Computers in biology and medicine","Immune simulation; In silico cloning; New variant; SARS-CoV-2; Vaccine designing","Khan","Abbas","Department of Bioinformatics and Biological Statistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, PR China",NA
"151","33930321","10.1016/S1473-3099(21)00264-4","Symptom study app provides real-world data on COVID-19 vaccines.",NA,"2021","05","02","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Drury","Ruth E","Department of Paediatrics, University of Oxford, Oxford, UK",NA
"152","33930320","10.1016/S1473-3099(21)00224-3","Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.","The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community setting. In this prospective observational study, we examined the proportion and probability of self-reported systemic and local side-effects within 8 days of vaccination in individuals using the COVID Symptom Study app who received one or two doses of the ","2021","05","02","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Menni","Cristina","Department of Twin Research &amp","cristina.menni@kcl.ac.uk"
"153","33929280","10.1080/08820139.2021.1904977","Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines.","COVID-19, the disease caused by the novel severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), was first detected in December 2019 and has since morphed into a global pandemic claiming over 2.4 million human lives and severely impacting global economy. The race for a safe and efficacious vaccine was thus initiated with government agencies as well as major pharmaceutical companies as frontrunners. An ideal vaccine would activate multiple arms of the adaptive immune system to g","2021","05","07","Immunol Invest","Immunological investigations","COVID-19; SARS-CoV-2; clinical trial; formulation; vaccine","Hofman","Kirk","Department of Pharmaceutical Sciences, SUNY University at Buffalo, Buffalo, New York, USA",NA
"154","33928916","10.1097/CM9.0000000000001573","Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.","The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. Phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC were conducted in healthy Chinese adults aged 18 to 59 years. The participants in the phase 1 trial were randomiz","2021","06","03","Chin Med J (Engl)","Chinese medical journal","Adult; COVID-19; COVID-19 Vaccines; Double-Blind Method; Humans; SARS-CoV-2; Vaccines, Inactivated","Pan","Hong-Xing","NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu 210009, China",NA
"155","33928745","10.1111/1462-2920.15549","COVID-19: vaccination problems.","This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccinati","2021","05","14","Environ Microbiol","Environmental microbiology",NA,"Br..ssow","Harald","Department of Biosystems, Laboratory of Gene Technology, KU Leuven, Leuven, Belgium",NA
"156","33928668","10.1002/sim.9014","Replicability of studies following a dual-criterion design.","Replicability of results is regarded as the corner stone of science. Recent research seems to raise doubts about whether this requirement is generally fulfilled. Often, replicability of results is defined as repeating a statistically significant result. However, since significance may not imply scientific relevance, dual-criterion study designs that take both aspects into account have been proposed and investigated during the last decade. Originally developed for proof-of-concept trials, the des","2021","04","30","Stat Med","Statistics in medicine","COVID-19 vaccine trials; clinical relevance; dual-criterion design; proof-of-concept; replicability","Rosenkranz","Gerd K","L..rrach, Germany",NA
"157","33928660","10.1002/sim.9001","Assessing vaccine durability in randomized trials following placebo crossover.","Randomized vaccine trials are used to assess vaccine efficacy (VE) and to characterize the durability of vaccine-induced protection. If efficacy is demonstrated, the treatment of placebo volunteers becomes an issue. For COVID-19 vaccine trials, there is broad consensus that placebo volunteers should be offered a vaccine once efficacy has been established. This will likely lead to most placebo volunteers crossing over to the vaccine arm, thus complicating the assessment of long term durability. W","2021","04","30","Stat Med","Statistics in medicine","COVID-19; proportional hazards regression; vaccine efficacy; vaccine trial design","Fintzi","Jonathan","Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, 5601, Maryland, USA",NA
"158","33926540","10.1186/s13063-021-05277-7","The impact of theory-based messages on COVID-19 vaccination intentions: a structured summary of a study protocol for a randomised controlled trial.","Uptake of vaccination against COVID-19 is key to controlling the pandemic. However, a significant proportion of people report that they do not intend to have a vaccine, often because of concerns they have about vaccine side effects or safety. This study will assess the impact of theory-based messages on COVID-19 vaccination intention, drawing on the Necessity-Concerns framework to address previously reported beliefs and concerns about COVID-19 vaccination, and assess whether hypothesised variabl","2021","06","04","Trials","Trials","COVID-19; Necessity-Concerns Framework; illness beliefs; messaging; protocol; randomised controlled trial; treatment beliefs; vaccination; vaccine hesitancy; Adult; COVID-19; COVID-19 Vaccines; Humans; Intention; Prospective Studies; Psychological Theory; Randomized Controlled Trials as Topic; Scotland; Treatment Outcome; Vaccination","Young","Ben","University of Glasgow, Glasgow, UK. ben.young@glasgow.ac","ben.young@glasgow.ac.uk"
"159","33925526","10.3390/vaccines9050433","An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.","Since the worldwide COVID-19 pandemic was declared a year ago, the search for vaccines has become the top priority in order to restore normalcy after 2.5 million deaths worldwide, overloaded sanitary systems, and a huge economic burden. Vaccine development has represented a step towards the desired herd immunity in a short period of time, owing to a high level of investment, the focus of researchers, and the urge for the authorization of the faster administration of vaccines. Nevertheless, this ","2021","05","27","Vaccines (Basel)","Vaccines","COVID-19; SARS-CoV-2; adenovirus-based vaccines; coronavirus; inactivated virus vaccines; mRNA vaccines; pandemic management; vaccination programs; vaccine acceptance; vaccine hesitancy","Garc..a-Montero","Cielo","Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal.., 28801 Alcal.. de Henares, Spain",NA
"160","33923363","10.3390/vaccines9050428","Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.","We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual's HLA molecules. The second set consisted of ten peptides predicted to bind promiscuously to several HLA-DR allotypes. The vaccine formulation contained the new TLR 1/2 agonist XS15 and was administered as an emulsion in Montanide as a single su","2021","05","27","Vaccines (Basel)","Vaccines","COVID-19; SARS-CoV-2; adjuvant; high-risk patient; lipopeptide; peptide vaccine","Rammensee","Hans-Georg","Department of Immunology, Institute for Cell Biology, University of T..bingen, Auf der Morgenstelle 15, 72076 T..bingen, Germany",NA
"161","33920489","10.3390/microorganisms9040806","A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.","COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (n = 59) to a control group (n = 59). Sixty patients received CP within a median time of ","2021","05","18","Microorganisms","Microorganisms","COVID-19; SARS-CoV-2 antibodies; convalescent plasma; efficacy","Pappa","Vasiliki","Hematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital &quot",NA
"162","33916427","10.3390/vaccines9040348","What Is the State-of-the-Art in Clinical Trials on Vaccine Hesitancy 2015-2020?","Vaccine hesitancy is related to a delay in acceptance or refusal of vaccination. to perform a systematic review of clinical trials on vaccine hesitancy (2015-2020). a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria (PRISMA). Five databases were screened-PubMed, Cochrane Library, DOAJ, SciELO and b-on-which comprise multiple resources. &quot;Vaccine hesitancy&quot; and (&quot;randomized controlled trial&quot; or &quot;clinical trial&quot","2021","05","02","Vaccines (Basel)","Vaccines","clinical trial; hesitancy determinants; immunization; randomized controlled trial; vaccination; vaccine hesitancy; vaccine refusal","Pires","Carla","Research Center for Biosciences and Health Technologies, CBIOS-Universidade Lus..fona de Humanidades e Tecnologias-Escola de Ci..ncias e Tecnologias da Sa..de, Campo Grande 376, 1740-024 Lisboa, Portugal",NA
"163","33916222","10.3390/vaccines9040341","Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials.","To date, there is still a paucity of data from Phase III trials concerning the efficacy of vaccines against COVID-19. Furthermore, no studies investigated the variables that may modulate the efficacy of vaccination. The aim of this analysis was to assess whether there are modifying factors that may potentially influence the clinical efficacy of COVID-19 vaccines. A quantitative synthesis of data from Phase III trials was performed via pairwise and network meta-analyses, along with meta-regressio","2021","05","02","Vaccines (Basel)","Vaccines","COVID-19; SARS-Cov-2; efficacy; meta-regression; modifying factors; vaccine","Calzetta","Luigino","Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy",NA
"164","33912499","10.4103/jrpp.JRPP_20_71","Pharmacological and Nonpharmacological Studies on Coronavirus Disease 2019: A Mini-review of the Recent Evidence.","Coronavirus 19 (COVID-19) is an extremely transmittable microbial infection that has emerged in Wuhan (China) in late 2019, leading to severe acute respiratory syndrome coronavirus 2 syndrome, and caused a pandemic all over the globe. This study is a systematic review of all 927 clinical trial studies performed worldwide from the beginning of the COVID-19 mysterious pandemic in China. These researches have registered in different databases. According to the best of our knowledge, China (74.82%),","2021","04","30","J Res Pharm Pract","Journal of research in pharmacy practice","2019-novel coronavirus; clinical trials; outcome; review; severe acute respiratory syndrome-coronavirus 2","Bahmani","Amir Hossein Alizadeh","Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran",NA
"165","33910617","10.1186/s13063-021-05282-w","Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.","The aim of this trial is to evaluate the antiviral efficacy, clinical efficacy, and safety of nelfinavir in patients with asymptomatic and mild COVID-19. The study is designed as a multicenter, open-label, blinded outcome assessment, parallel group, investigator-initiated, exploratory, randomized (1:1 ratio) controlled clinical trial. Asymptomatic and mild COVID-19 patients will be enrolled in 10 university and teaching hospitals in Japan. The inclusion and exclusion criteria are as follows: Inc","2021","05","02","Trials","Trials","COVID-19; SARS-CoV-2; asymptomatic; blinded outcome assessment; mild; nelfinavir; protocol; randomized controlled trial","Hosogaya","Naoki","Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan",NA
"166","33909052","10.1001/jamanetworkopen.2021.10843","Assessment of Length and Readability of Informed Consent Documents for COVID-19 Vaccine Trials.","Informed consent is a fundamental element of research ethics. The COVID-19 vaccine trials are high profile trials that have enrolled more than 100...000 participants. Consent documents must be succinct and understandable to ensure informed voluntary participation. To assess how well informed consent documents of the COVID-19 vaccine trials achieve the ideal of being succinct and understandable, and to create a shorter, more readable document. This quality improvement study collected and analyzed","2021","05","14","JAMA Netw Open","JAMA network open","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Comprehension; Consent Forms; Humans; Informed Consent; Language; Randomized Controlled Trials as Topic; Reading; SARS-CoV-2","Emanuel","Ezekiel J","Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia",NA
"167","33908359","10.20529/IJME.2021.014","Problematic Covid-19 vaccine trials in times of vaccine nationalism.","Thanks to an impressive R&amp;D effort, three vaccines for Covid-19 have been conditionally approved by stringent regulators as of February 2021, and sixteen have entered the WHO evaluation process. However, they all need to keep on being evaluated in clinical trials. The WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine suggested that countries with limited or no access to an effective vaccine could ethically permit placebo-controlled trials, even if effective vaccines were already","2021","05","12","Indian J Med Ethics","Indian journal of medical ethics","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Ethics, Medical; Guidelines as Topic; Humans; Pandemics; Placebos; SARS-CoV-2","Ravinetto","Raffaella","Department of Public Health, Institute of Tropical Medicine, Antwerp, BELGIUM",NA
"168","33908358","10.20529/IJME.2021.015","Placebo-controlled trials of Covid-19 vaccines - Are they still ethical?","A World Health Organization (WHO) Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation recently recommended placebo-controlled trials (PCT) of Covid-19 vaccines. PCTs are ethically acceptable when there is no proven effective and safe treatment for a certain condition. However, there are already some vaccines that have been approved and which have high levels of efficacy and safety. Any new vaccine under development must be tested against the most effective vaccines available. P","2021","05","12","Indian J Med Ethics","Indian journal of medical ethics","Biomedical Research; COVID-19; COVID-19 Vaccines; Ethics, Medical; Guidelines as Topic; Humans; Pandemics; Placebos; SARS-CoV-2","Ortiz-Mill..n","Gustavo","Institute for Philosophical Research, National Autonomous University of Mexico, Circuito Mario de la Cueva s/n Ciudad Universitaria, Coyoac..n, Mexico City 04510 MEXICO",NA
"169","33908356","10.20529/IJME.2021.019","&quot;No&quot; to placebo-controlled trials of Covid-19 vaccines.","Recently the WHO Ad Hoc Expert Group proposed that it is ethical to continue placebo-controlled Covid-19 vaccine trials in countries where vaccines are not available even if this vaccine is marketed and being used elsewhere. The reason for this proposal is the usual scientific argument claiming that these trials are the most efficient method to obtain reliable results, and individuals in these countries will continue to get the local standard of care, meaning no vaccination, and thus participant","2021","05","12","Indian J Med Ethics","Indian journal of medical ethics","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Ethics, Medical; Guidelines as Topic; Human Rights; Humans; Pandemics; Placebos; SARS-CoV-2","Ahmad","Aasim","Dean and Chief Nephrologist, Member WHO Ethics &amp",NA
"170","33908355","10.20529/IJME.2021.021","Double standards redux.","It is fair to say that nothing is more pressing in today's world than bringing an end to the Covid-19 pandemic. Or to be more precise, if not an end, then the quickest and most effective reduction of mortality and morbidity from the disease in every country where infections exist. The forthcoming theme issue of IJME explores a long-standing ethical concern in research with human beings, focused mainly on a question posed about vaccine research for prevention of Covid-19. Contributors from six co","2021","04","30","Indian J Med Ethics","Indian journal of medical ethics","COVID-19; COVID-19 Vaccines; Humans; Pandemics; Reference Standards; SARS-CoV-2; Vaccines","Macklin","Ruth","Distinguished University Professor Emerita, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461 USA",NA
"171","33908353","10.20529/IJME.2021.022","Placebo control in Covid-19 trials: A missed opportunity for international guidance.","Vaccines preventing Covid-19 have been approved in several countries. Is it still ethically acceptable to use placebo controls during the development of other vaccine options? If two of the most influential international guidelines of biomedical research are consulted, the Declaration of Helsinki and the CIOMS-guidelines, the answer is &quot;no&quot;. We discuss the implications for ongoing vaccine research, and how placebo controls might be justified nevertheless. However, the ethical conflict ","2021","05","12","Indian J Med Ethics","Indian journal of medical ethics","Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Ethics, Medical; Female; Guidelines as Topic; Humans; International Cooperation; Male; Middle Aged; Pandemics; Placebos; SARS-CoV-2","Wiesing","Urban","Director, Institut f..r Ethik und Geschichte der Medizin, Gartenstrasse, T..bingen, GERMANY",NA
"172","33908352","10.20529/IJME.2021.023","Trials for second generation Covid-19 vaccines: Revisiting the debate over placebo use in developing country clinical trials.","This article compares the current debate over the use of placebos in developing country clinical trials of second generation Covid-19 vaccines with the debates over previous paradigmatic cases raising similar issues. Compared to the earlier zidovudine and Surfaxin trials, Covid-19 vaccine trials are likely to confer lower risk to placebo groups and to offer a greater number and variety of alternative study designs. However, turning to the developing world to conduct studies that would be unaccep","2021","05","12","Indian J Med Ethics","Indian journal of medical ethics","Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Developing Countries; Ethics, Medical; Female; Guidelines as Topic; Humans; Male; Middle Aged; Pandemics; Patient Rights; Placebos; Risk Factors; SARS-CoV-2","Lurie","Peter","Center for Science in the Public Interest, 1220 L Street, NW, Suite 300, Washington, DC 20005, USA",NA
"173","33908350","10.20529/IJME.2021.027","Ethical limits to placebo use and access to Covid-19 vaccines as a human right.","The world is currently facing another severe pandemic, Covid-19, just four decades after the start of AIDS, and the still increasing incidence of HIV infection continues to be one of the greatest global health challenges. The way the latter was confronted is of fundamental importance for a serious discussion on global health, ethics and human rights, and this experience could and can still be applied to Covid-19. The Covid-19 pandemic has specific characteristics and these will be discussed, in ","2021","05","12","Indian J Med Ethics","Indian journal of medical ethics","Biomedical Research; COVID-19; COVID-19 Vaccines; Ethics, Medical; Guidelines as Topic; Health Services Accessibility; Human Rights; Humans; Pandemics; Placebos; SARS-CoV-2","Greco","Dirceu B","Professor Emeritus, Infectious Diseases and Bioethics, Federal University of Minas Gerais, Belo Horizonte, BRAZIL",NA
"174","33907509","10.7150/ijbs.59170","Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces.","A year after the initial outbreak of Covid-19 pandemic, several Phase III clinical trials investigating vaccine safety and efficacy have been published. These vaccine candidates were developed by different research groups and pharmaceutical companies with various vaccine technologies including mRNA, recombinant protein, adenoviral vector and inactivated virus-based platforms. Despite numerous successful clinical trials, participants enrolled in these trials are limited by trial inclusion and exc","2021","05","20","Int J Biol Sci","International journal of biological sciences","Different subgroups; Pandemic; SARS-CoV-2; Vaccination; Viral Variants; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Humans; SARS-CoV-2","Kwok","Hang Fai","Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR",NA
"175","33907329","10.1038/d41586-021-01120-w","Peru scandal: gaps in oversight of COVID vaccine trial.",NA,"2021","04","28","Nature","Nature","Ethics; Government; Medical research; Vaccines","C..ceres","Carlos F",NA,NA
"176","33907209","10.1038/s41598-021-88153-3","A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials.","The year 2020 witnessed a heavy death toll due to COVID-19, calling for a global emergency. The continuous ongoing research and clinical trials paved the way for vaccines. But, the vaccine efficacy in the long run is still questionable due to the mutating coronavirus, which makes drug re-positioning a reasonable alternative. COVID-19 has hence fast-paced drug re-positioning for the treatment of COVID-19 and its symptoms. This work builds computational models using matrix completion techniques to","2021","05","11","Sci Rep","Scientific reports","Algorithms; Antiviral Agents; Area Under Curve; COVID-19; Databases, Factual; Drug Repositioning; Evolution, Molecular; Humans; Mutation; ROC Curve; SARS-CoV-2","Mongia","Aanchal","Department of CSE, IIIT-Delhi, New Delhi, 110020, India",NA
"177","33906067","10.1016/j.ebiom.2021.103348","A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests.","Antibody tests are essential tools to investigate humoral immunity following SARS-CoV-2 infection or vaccination. While first-generation antibody tests have primarily provided qualitative results, accurate seroprevalence studies and tracking of antibody levels over time require highly specific, sensitive and quantitative test setups. We have developed two quantitative, easy-to-implement SARS-CoV-2 antibody tests, based on the spike receptor binding domain and the nucleocapsid protein. Comprehens","2021","06","08","EBioMedicine","EBioMedicine","Antibody assay validation; Antigen purity; COVID-19; Dual-antigen testing; Kinetics of primary antibody response; SARS-CoV-2 neutralisation; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibodies, Viral; Binding Sites; CHO Cells; COVID-19; COVID-19 Serological Testing; Coronavirus Nucleocapsid Proteins; Cricetulus; Early Diagnosis; HEK293 Cells; Humans; Immunoglobulin G; Middle Aged; SARS-CoV-2; Sensitivity and Specificity; Spike Glycoprotein, Coronavirus; Young Adult","Klausberger","Miriam","Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU) Vienna, Muthgasse 18, 1190 Vienna, Austria",NA
"178","33903854","10.1016/j.htct.2021.03.004","Convalescent plasma therapy - a silver lining for COVID-19 management?","The COVID-19 pandemic has pushed the world towards social, economic, and medical challenges. Scientific research in medicine is the only means to overcome novel and complex diseases like COVID-19. To sum up the therapeutic wild-goose chase, many available antivirals and repurposed drugs have failed to show successful clinical evidence in patient recovery, several vaccine candidates are still waiting in the trial pipelines and a few have become available to the common public for administration in","2021","06","13","Hematol Transfus Cell Ther","Hematology, transfusion and cell therapy","COVID-19; COVID-19 Treatment; Convalescent Plasma Therapy; SARS-CoV2","Saha","Sumit","Advancells Group, Noida, India",NA
"179","33903149","10.1136/gutjnl-2021-324789","Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.","Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared with a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin ..4..7 monoclonal antib","2021","06","09","Gut","Gut","BNT162b2; CLARITY; COVID-19; ChAdOx1 nCoV-19; TNF; autoimmune disease; inflammatory bowel disease; inflammatory diseases; infliximab; vaccine; vedolizumab","Kennedy","Nicholas A","Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK",NA
"180","33902614","10.1186/s12941-021-00436-9","Novel coronavirus seropositivity and related factors among healthcare workers at a university hospital during the prevaccination period: a cross-sectional study.","This study aimed to investigate the specific risk factors for the transmission of novel coronavirus (SARS-CoV-2) among healthcare workers in different campuses of a university hospital and to reveal the risk factors for antibody positivity. In this retrospective cross-sectional study, 2988 (82%) of 3620 healthcare workers in a university hospital participated. The coronavirus disease 2019 (COVID-19) antibody was investigated using serum from healthcare workers who underwent COVID-19 antibody tes","2021","05","03","Ann Clin Microbiol Antimicrob","Annals of clinical microbiology and antimicrobials","Antibody; COVID-19; Pandemic; Antibodies, Viral; COVID-19; COVID-19 Serological Testing; Cross-Sectional Studies; Health Personnel; Hospitals, University; Humans; Retrospective Studies; SARS-CoV-2","Ogutlu","Aziz","Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Sakarya University, Sakarya, Turkey. drogutlu@hotmail","drogutlu@hotmail.com"
"181","33901607","10.1016/j.fct.2021.112239","SARS-CoV-2 inactivated vaccine (Vero cells) shows good safety in repeated administration toxicity test of Sprague Dawley rats.","The outbreak of COVID-19 has posed a serious threat to global public health. Vaccination may be the most effective way to prevent and control the spread of the virus. The safety of vaccines is the focus of preclinical research, and the repeated dose toxicity test is the key safety test to evaluate the vaccine before clinical trials. The purpose of this study was (i) to observe the toxicity and severity of an inactivated SARS-CoV-2 vaccine (Vero cells) in rodent Sprague Dawley rats after multiple","2021","05","27","Food Chem Toxicol","Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","COVID-19; Safety; The inactivated vaccine; The repeated administration toxicity; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Female; Male; Rats, Sprague-Dawley; Toxicity Tests; Vaccines, Inactivated","Huang","Zhangqiong","Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, 650118, China",NA
"182","33901420","10.1016/S0140-6736(21)00677-2","Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.","The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical trials and are now being used in national vaccination programmes in the UK and several other countries. Studying the real-world effects of these vaccines is an urgent requirement. The aim of our study was to investigate the association between the mass roll-out of the first doses of these COVID-19 vaccines and hospital admissions for COVID-19","2021","05","11","Lancet","Lancet (London, England)","Adolescent; Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Female; Hospitalization; Humans; Male; Mass Vaccination; Middle Aged; Pandemics; Prospective Studies; Risk Factors; Scotland; Social Class; Young Adult","Vasileiou","Eleftheria","Usher Institute, The University of Edinburgh, Edinburgh, UK",NA
"183","33900279","10.12659/MSM.932899","Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT).","During 2020 and 2021, the global pandemic of coronavirus disease 2019 (COVID-19) due to severe acute respi- ratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in high death rates and acute and chronic morbidity in all countries. The rapid development of new mRNA vaccines to SARS-CoV-2 brings hope that the spread of this virus can be controlled. The ChAdOx1 nCoV-19 vaccine developed by a collaboration between the University of Oxford and AstraZeneca showed efficacy in clinical trials, with a","2021","05","26","Med Sci Monit","Medical science monitor : international medical journal of experimental and clinical research","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Purpura, Thrombocytopenic, Idiopathic; RNA, Messenger; SARS-CoV-2","Parums","Dinah V","Science Editor, International Scientific Information, Cambridge, United Kingdom",NA
"184","33899040","10.1016/j.lanwpc.2021.100140","Impact of COVID-19 on routine immunisation in South-East Asia and Western Pacific: Disruptions and solutions.","Data on COVID-19-induced disruption to routine vaccinations in the South-East Asia and Western Pacific regions (SEAR/WPR) have been sparse. This study aimed to quantify the impact of COVID-19 on routine vaccinations by country, antigen, and sector (public or private), up to 1 June 2020, and to identify the reasons for disruption and possible solutions. Sanofi Pasteur teams from 19 countries in SEAR/WPR completed a structured questionnaire reporting on COVID-19 disruptions for 13-19 routinely del","2021","05","31","Lancet Reg Health West Pac","The Lancet regional health. Western Pacific","Asia; COVID-19; Disruption; Immunisation; Preventive care; Public health; Routine vaccination; Vaccination coverage rates; Vaccines","Harris","Rebecca C","Sanofi Pasteur, 38 Beach Road, #18-11 South Beach Tower, Singapore 189767, Singapore",NA
"185","33898273","10.1016/j.toxrep.2021.04.003","Safety of COVID-19 vaccines administered in the EU: Should we be concerned?","The COVID-19 pandemic has had an unprecedented and devastating impact on public health, society and economics around the world. As a result, the development of vaccines to protect individuals from symptomatic COVID-19 infections has represented the only feasible health tool to combat the spread of the disease. However, at the same time the development and regulatory assessment of different vaccines has challenged pharmaceutical industries and regulatory agencies as this process has occurred in t","2021","04","28","Toxicol Rep","Toxicology reports","Clinical trials; Covid-19; Public health; Safety; Side effects; Thrombosis; Vaccines","Hern..ndez","Antonio F","Department of Legal Medicine and Toxicology, University of Granada School of Medicine, Granada, Spain",NA
"186","33897702","10.3389/fimmu.2021.653974","To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis.","This study discusses substantive advances in T cell proliferation analysis, with the aim to provoke a re-evaluation of the generally-held view that Ki-67 is a reliable proliferation marker per se, and to offer a more sensitive and effective method for T cell cycle analysis, with informative examples in mouse and human settings. We summarize recent experimental work from our labs showing that, by Ki-67/DNA dual staining and refined flow cytometric methods, we were able to identify T cells ","2021","05","04","Front Immunol","Frontiers in immunology","DNA dye; Ki-67; T cells; cell cycle; flow cytometry; Animals; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Cell Cycle; Diabetes Mellitus, Type 1; Humans; Ki-67 Antigen; Mice; Neoplasms; SARS-CoV-2","Di Rosa","Francesca","Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), Rome, Italy",NA
"187","33897204","10.1016/j.jaim.2020.12.013","A Randomized open label parallel group pilot study to evaluate efficacy of Ayurveda interventions in the management of Asymptomatic and Mild COVID-19 patients-Experiences of a Lucknow based Level 2 hospital of Uttar Pradesh, India.","Sars Cov-2 has emerged as a global threat since its onset in December 2019. India has also been severely affected by the dreadful Corona Virus and is currently battling one of the worst pandemics of history. WHO and the world medical fraternity are putting their efforts to materialize a treatment or vaccine for this novel virus. A randomized open label parallel group study was designed in a Lucknow based level 2 COVID hospital to evaluate the efficacy of Ayurvedic interventions in the management","2021","04","28","J Ayurveda Integr Med","Journal of Ayurveda and integrative medicine","Agni; Ayurveda; Covid-19; Immunity; Randomized trial","Rais","Adil","Panchakarma Specialist, Panchakarma Unit, Lokbandhu Rajnarayan Combined Hospital, Lucknow, 226012",NA
"188","33896663","10.1016/j.vaccine.2021.04.017","Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.",NA,"2021","05","24","Vaccine","Vaccine","COVID-19; COVID-19 Vaccines; Humans; RNA, Viral; SARS-CoV-2; Viral Vaccines","Levin","Yotam","Advisor to Israel Institute for Biological Research (IIBR), Nes Ziona, Israel",NA
"189","33895322","10.1016/j.ymthe.2021.04.022","Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.","The coronavirus disease 2019 (COVID-19) pandemic caused by the emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health, and there is an urgent need to develop safe and effective vaccines. Here, we report the generation and the preclinical evaluation of a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike (S) protein of SARS-CoV-2. We show that our vaccine candidate, GRAd-COV2, is highly immunogenic","2021","05","07","Mol Ther","Molecular therapy : the journal of the American Society of Gene Therapy","COVID-19; SARS-CoV-2; gorilla adenovirus; immunogenicity; vaccine","Capone","Stefania","ReiThera Srl, Rome, Italy",NA
"190","33890580","10.2196/25271","The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study.","The COVID-19 pandemic has raised unprecedented challenges in the management of patients with cancer and has increased the demands for digital health tools that, for example, could facilitate remote monitoring of patients. Based on this, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) has recently developed a digital health tool dedicated to patients with hematologic malignancies: the GIMEMA-ALLIANCE platform. The main objectives of this web-based platform are to generate relevant ","2021","06","12","JMIR Res Protoc","JMIR research protocols","COVID-19; digital health; hematology; leukemia; lymphoma; multiple myeloma; patient-reported outcomes; quality of life; symptoms","Efficace","Fabio","Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy",NA
"191","33888900","10.1038/s41591-021-01330-9","Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.","An effective vaccine is needed to end the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we assess the preliminary safety, tolerability and immunogenicity data from an ongoing single-center (in Jiangsu province, China), parallel-group, double-blind phase 1 trial of the vaccine candidate BNT162b1 in 144 healthy SARS-CoV-2-naive Chinese participants. These participants are randomized 1:1:1 to receive prime and boost vaccinations of 10.....g or 30.....g BNT162b1 or pla","2021","04","23","Nat Med","Nature medicine",NA,"Li","Jingxin","NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China",NA
"192","33887209","10.1016/S1473-3099(21)00147-X","Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.","CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2. We present interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM vaccine with two different adjuvant formulations. This phase 1-2, randomised, double-blind study is being done in healthy, SARS-CoV-2-seronegative adults in ten clinical research centres in the USA. Participants were stratified by age (18-49 years and ...","2021","04","26","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Goepfert","Paul A","Department of Medicine, University of Alabama at Birmingham, AL, USA",NA
"193","33887208","10.1016/S1473-3099(21)00200-0","Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.","Given the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, and potential paediatric use. We aimed to assess the safety and immunogenicity of an MF59-adjuvanted subunit vaccine for COVID-19 based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a novel molecular clamp (spike glycoprot","2021","04","26","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Chappell","Keith J","School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia","k.chappell@uq.edu.au"
"194","33887070","10.1111/all.14868","Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe.","The ongoing COVID-19 pandemic caused by the SARS-CoV-2 coronavirus has affected the health of tens of millions of people worldwide. In particular, in elderly and frail individuals the infection can lead to severe disease and even fatal outcomes. Although the pandemic is primarily a human health crisis its consequences are much broader with a tremendous impact on global economics and social systems. Vaccines are considered the most powerful measure to fight the pandemic and protect people from CO","2021","05","22","Allergy","Allergy","COVID-19 pandemic; clinical trial; licensure; regulatory requirements; vaccine","Wagner","Ralf","Section for Viral Vaccines, Department of Virology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany",NA
"195","33883816","","Impact of meloxicam on respiratory virus titers and health outcomes when administered concurrently with a modified live respiratory vaccine in abruptly weaned beef steers.","Abruptly weaned crossbred steer calves (N = 271) were used in a randomized, blinded 2-arm clinical trial to assess the impact of a long-acting non-steroidal anti-inflammatory drug on bovine herpesvirus type 1, bovine respiratory syncytial virus, parainfluenza virus type 3, and coronavirus titers and health outcomes when administered concurrently with a modified live respiratory vaccine upon arrival at a feedlot. Treatment groups included a control (saline; n = 135) and an experimental group (inj","2021","04","23","Can J Vet Res","Canadian journal of veterinary research = Revue canadienne de recherche veterinaire","Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Viral; Cattle; Coronavirus, Bovine; Herpesvirus 1, Bovine; Male; Meloxicam; Parainfluenza Virus 3, Bovine; Respiratory Syncytial Virus, Bovine; Weaning","Homerosky","Elizabeth R","Veterinary Agri-Health Services, Ltd. 281121 Dickson Stevenson Trail, Rocky View County, Alberta T4B 4L5",NA
"196","33883675","10.1038/s42003-021-02025-0","SARS-CoV-2 shifting transmission dynamics and hidden reservoirs potentially limit efficacy of public health interventions in Italy.","We investigated SARS-CoV-2 transmission dynamics in Italy, one of the countries hit hardest by the pandemic, using phylodynamic analysis of viral genetic and epidemiological data. We observed the co-circulation of multiple SARS-CoV-2 lineages over time, which were linked to multiple importations and characterized by large transmission clusters concomitant with a high number of infections. Subsequent implementation of a three-phase nationwide lockdown strategy greatly reduced infection numbers an","2021","05","10","Commun Biol","Communications biology","COVID-19; Communicable Disease Control; Genome, Viral; Geography; Humans; Italy; Mutation; Pandemics; Phylogeny; Public Health; SARS-CoV-2","Giovanetti","Marta","Laborat..rio de Flaviv..rus, Instituto Oswaldo Cruz, Funda....o Oswaldo Cruz, Rio de Janeiro, Brazil",NA
"197","33882374","10.1016/j.ejca.2021.03.033","Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.","Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus. We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) in April 2020. The primary objective of the trial was to assess specific immune r","2021","05","28","Eur J Cancer","European journal of cancer (Oxford, England : 1990)","Cancer patients; Immune T cell response; SARS-CoV-2 antibodies; SARS-CoV-2 infection; Aged; Antibodies, Viral; COVID-19; Female; Humans; Male; Middle Aged; Neoplasms; SARS-CoV-2; T-Lymphocytes","Mansi","Laura","Department of Medical Oncology, University Hospital of Besan..on, France",NA
"198","33882225","10.1056/NEJMoa2101544","Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.","The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. In an international, randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned adult participants in a 1:1 ratio to receive a single dose of Ad26.COV2.S (5..10<sup>10</sup> viral particles) or placebo. The primary end points were vaccine effi","2021","06","11","N Engl J Med","The New England journal of medicine",NA,"Sadoff","Jerald","From Janssen Vaccines and Prevention, Leiden, the Netherlands (J. Sadoff, G. Shukarev, G. Scheper, M.L.G., H.S., J.V.H., M.D.)",NA
"199","33882211","10.1056/NEJMe2106836","Audio Interview: Covid-19 Vaccines and Pregnancy - A Conversation with CDC Director Rochelle Walensky.",NA,"2021","04","26","N Engl J Med","The New England journal of medicine","Adenovirus Vaccines; COVID-19; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; Epidemiological Monitoring; Female; Global Health; Health Equity; Humans; Immunogenicity, Vaccine; Interinstitutional Relations; Male; Patient Selection; Pregnancy; SARS-CoV-2; Thrombocytopenia; Thrombosis; United States; United States Food and Drug Administration","Rubin","Eric J",NA,NA
"200","33880481","10.1101/2021.04.16.21255614","Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection.","Although interim results from several large placebo-controlled phase 3 trials demonstrated high vaccine efficacy (VE) against symptomatic COVID-19, it is unknown how effective the vaccines are in preventing people from becoming asymptomatically infected and potentially spreading the virus unwittingly. It is more difficult to evaluate VE against SARS-CoV-2 infection than against symptomatic COVID-19 because infection is not observed directly but rather is known to occur between two antibody or RT","2021","04","21","medRxiv","medRxiv : the preprint server for health sciences",NA,"Lin","Dan-Yu",NA,NA
"201","33880468","10.1101/2021.04.13.439482","Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic that has led to more than 2.8 million deaths worldwide. Safe and effective vaccines are now available, including Moderna's COVID-19 vaccine (mRNA-1273) that showed 94% efficacy in prevention of symptomatic COVID-19 disease in a phase 3 clinical study. mRNA-1273 encodes for a prefusion stabilized full length spike (S) protein of the Wuhan-Hu-1 isolate. However, the emergence of SARS-CoV-2 vari","2021","04","21","bioRxiv","bioRxiv : the preprint server for biology",NA,"Wu","Kai",NA,NA
"202","33879208","10.1186/s13063-021-05250-4","The UPTAKE study: implications for the future of COVID-19 vaccination trial recruitment in UK and beyond.","Developing a safe and effective vaccine will be the principal way of controlling the COVID-19 pandemic. However, current COVID-19 vaccination trials are not adequately representing a diverse participant population in terms of age, ethnicity and comorbidities. Achieving the representative recruitment targets that are adequately powered to the study remains one of the greatest challenges in clinical trial management. To ensure accuracy and generalisability of the safety and efficacy conclusions ge","2021","04","23","Trials","Trials","BAME; COVID-19; Population survey; Vaccination trials; Vaccine; Adolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Pandemics; Patient Selection; Surveys and Questionnaires; United Kingdom; Vaccination; Young Adult","Sethi","Sonika","The Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton Road, Wolverhampton, West Midlands, WV10 0QP, UK. sonika.sethi1@nhs","sonika.sethi1@nhs.net"
"203","33877955","10.1080/21645515.2021.1909327","Prevalence and associated factors of intention of COVID-19 vaccination among healthcare workers in China: application of the Health Belief Model.","Healthcare workers (HCWs) are at an increased risk of coronavirus disease 2019 (COVID-19) and warrant COVID-19 vaccination to reduce nosocomial infections. This study investigated: (1) the prevalence of behavioral intention of COVID-19 vaccination (BICV) under eight scenarios combining vaccines' effectiveness/safety/cost, plus two general scenarios of free/self-paid vaccination given governmental/hospital recommendations, (2) perceptions involving preferred timing of COVID-19 vaccination and imp","2021","04","20","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","China; Vaccination; healthcare workers; intention; the Health Belief Model","Yu","Yanqiu","Centre for Health Behaviours Research, School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China",NA
"204","33877041","10.6002/ect.2021.0056","COVID-19 Vaccine Concerns: Fact or Fiction?","One year has elapsed since a team of Chinese scientists reported the first case of COVID-19 in Wuhan, China on January 8, 2020, after sequencing the first viral genetic material. Since then, many vaccines were rushed into testing, bypassing animal experimentations, with more than 200 pharma companies in different countries declaring the development of different vaccines, each with their own strategy for generating immunity, despite the arguments of many infectious disease experts that 18 months ","2021","04","20","Exp Clin Transplant","Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation",NA,"Barbari","Antoine","From the Rafik Hariri University Hospital, Bir Hassan, Beirut, Lebanon",NA
"205","33875420","10.3399/BJGP.2021.0028","Impact of COVID-19 on Migrants' Access to Primary Care and Implications for Vaccine Roll Out: A National Qualitative Study.","The COVID-19 pandemic has prompted considerable changes in delivery of UK primary care, including rapid digitalisation, yet the impact upon marginalised migrant groups is unknown. To understand the impact of the COVID-19 pandemic on migrants and their access to primary healthcare, and implications for COVID-19 vaccine roll out. Primary care professionals, administrative staff, and migrants (foreign born; &gt;18 years; &lt;10 years in UK), were recruited in three phases using purposive, convenien","2021","04","20","Br J Gen Pract","The British journal of general practice : the journal of the Royal College of General Practitioners","COVID-19 Vaccine; Delivery of Health Care Service delivery; Primary Health Care; Transients and Migrants","Knights","Felicity","St George's University of London Institute for Infection and Immunity, The Migrant Health Research Group, London, United Kingdom",NA
"206","33875266","10.1016/j.vaccine.2021.04.006","The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59..years: A phase I randomized, double-blinded, controlled trial.","This study examined the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine. In a phase I randomized, double-blinded, placebo-controlled trial involving 192 healthy adults 18-59..years old, two injections of three doses (50 EU, 100 EU, 150 EU) of an inactivated SARS-CoV-2 vaccine or placebo were administered intramuscularly at a 2- or 4-week interval. The safety and immunogenicity of the vaccine were evaluated. Vaccination was completed in 191 subjects. Forty-four adverse reactions oc","2021","05","06","Vaccine","Vaccine","Inactivated vaccine; Phase I; SARS-CoV-2; Adolescent; Adult; Antibodies, Viral; COVID-19; COVID-19 Vaccines; China; Double-Blind Method; Humans; Immunogenicity, Vaccine; Middle Aged; SARS-CoV-2; Vaccines; Young Adult","Pu","Jing","Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp",NA
"207","33873199","10.1038/s41586-021-03530-2","Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.","The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative<sup>1</sup>. Here we demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold (hereafter designated RBD-NP), to stimulate robust and durable neutralizing-antibody responses and protection against SARS-CoV-2 in rhesus macaques. We evaluated five adjuvants includin","2021","06","11","Nature","Nature",NA,"Arunachalam","Prabhu S","Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA",NA
"208","33871381","10.2196/21468","A Recursive Model of the Spread of COVID-19: Modelling Study.","The major medical and social challenge of the 21st century is COVID-19, caused by the novel coronavirus SARS-CoV-2. Critical issues include the rate at which the coronavirus spreads and the effect of quarantine measures and population vaccination on this rate. Knowledge of the laws of the spread of COVID-19 will enable assessment of the effectiveness and reasonableness of the quarantine measures used, as well as determination of the necessary level of vaccination needed to overcome this crisis. ","2021","04","28","JMIR Public Health Surveill","JMIR public health and surveillance","COVID-19; contagious; effective; epidemiology; infection; model; modelling; prediction; spread; transmission; COVID-19; COVID-19 Vaccines; Global Health; Humans; Models, Theoretical; Quarantine","Ilyin","Sergey O","AV Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Moscow, Russian Federation",NA
"209","33870886","","Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.","INTRODUCTION Prompted by reports of thromboembolic events - some with fatal outcomes - among people who had received the ChAdOx1 nCoV-19 (AZD1222) vaccine from Oxford-AstraZeneca against COVID-19, a number of European countries paused vaccination with this vaccine in early and mid-March 2021. Prior studies have suggested that vaccine willingness is highly dependent on public trust in the safety of vaccines. We therefore investigated whether vaccine willingness dropped in the wake of the reported","2021","04","22","Dan Med J","Danish medical journal","Aged; COVID-19; COVID-19 Vaccines; Denmark; Europe; Female; Humans; Longitudinal Studies; Male; Middle Aged; Pandemics; Patient Acceptance of Health Care; Pneumonia, Viral; SARS-CoV-2; Surveys and Questionnaires; Thromboembolism; Trust","S..nderskov","Kim Mannemar","soeoes@rm",NA
"210","33869552","10.3389/fsoc.2021.610297","The Role Played by Public Universities in Mitigating the Coronavirus Catastrophe in Brazil: Solidarity, Research and Support to Local Governments Facing the Health Crisis.","This study aims to assess the impacts of the Covid-19 pandemic in Brazil and how it has been dealt with by both the government and in civil society. To this end, we examine the Brazilian public health system and the measures taken by the Bolsonaro Government that led to Brazil being ranked second in overall Covid-19 infections in the world through August 2020. In the absence of national leadership facing the Covid-19 health crisis, we list a set of science-based initiatives promoted by Brazilian","2021","04","21","Front Sociol","Frontiers in sociology","federal universities; health crisis; impact of COVID-19; outreach; research; solidarity","Arrais","Cristiano Alencar","Faculdade de Hist..ria da Universidade Federal de Goi..s, Goi..nia, Brazil",NA
"211","33868906","10.1016/j.rinp.2021.104063","On the necessity of proper quarantine without lock down for 2019-nCoV in the absence of vaccine.","Presently the world is passing through a critical phase due to the prevalence of the Novel Corona virus, 2019-nCoV or COVID-19, which has been declared a pandemic by WHO. The virus transmits via droplets of saliva or discharge from the nose when an infected person coughs or sneezes. Due to the absence of vaccine, to prevent the disease, social distancing and proper quarantine of infected populations are needed. Non-resident citizens coming from several countries need to be quarantined for 14..da","2021","06","01","Results Phys","Results in physics","Diffusion model; Epidemic model; Phase plane analysis; Re-parametrisation; Reproductive rate; Wave speed","Sahoo","Prasanta","Department of Mathematics, Midnapore College (Autonomous), Midnapore 721 101, West Bengal, India",NA
"212","33868742","10.3126/nje.v11i1.36163","Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials.","To date, there is no comprehensive systematic review and meta-analysis to assess the suitability of COVID-19 vaccines for mass immunization. The current systematic review and meta-analysis was conducted to evaluate the safety and immunogenicity of novel COVID-19 vaccine candidates under clinical trial evaluation and present a contemporary update on the development and implementation of a potential vaccines. For this study PubMed, MEDLINE, and Embase electronic databases were used to search for e","2021","04","30","Nepal J Epidemiol","Nepal journal of epidemiology","COVID-19; Immunogenicity; Solicited and Unsolicited Systemic Adverse Events; candidate vaccines","Sathian","Brijesh","Rumailah Hospital, Hamad Medical Corporation, Doha, Qatar",NA
"213","33867618","10.1016/S0262-4079(21)00582-0","Covid-19 vaccines for kids.","Early trial results hint that vaccines could be safe for children, but how the virus behaves will determine their roll-out, reports Helen Thomson.","2021","04","19","New Sci","New scientist (1971)",NA,"Thomson","Helen",NA,NA
"214","33866000","10.1016/j.ijid.2021.04.047","Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers.","Concerns are prevailing about the safety and side effects of the BNT162b2 mRNA vaccine for coronavirus disease 2019 (COVID-19). A randomized, cross-sectional study was performed to investigate the side effects of the BNT162b2 vaccine using an independent online questionnaire gathering responses from healthcare workers (HCWs) with detailed review of organ systems. Of all HCWs, 87.98% (1245/1415) completed the survey. Of them, 64.5% (803/1245) received the BNT162b2 mRNA vaccine and reported at lea","2021","05","27","Int J Infect Dis","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","Acceptance; Adverse event; BNT162b2; COVID-19; Pfizer BioNtech; SARS-CoV-2; Side effect; mRNA vaccine; Activities of Daily Living; Adult; COVID-19 Vaccines; Cross-Sectional Studies; Fatigue; Health Personnel; Humans; RNA, Messenger; Self Report","Kadali","Renuka A K","Department of Internal Medicine, Central Harnett Hospital (affiliated with Cape Fear Valley Health System), Lillington, NC, USA","Renuka.Kadali@harnetthealth.org"
"215","33865031","10.1016/j.jcv.2021.104820","Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.","Neutralization tests (NT) are the gold standard for detecting and quantifying anti-SARS-CoV-2 neutralizing antibodies (NAb), but their complexity restricts them to research settings or reference laboratories. Antibodies against S protein receptor binding domain (RBD) have been shown to confer a neutralizing activity against SARS-CoV-2. Assays quantitatively measuring anti-S1-RBD-SARS-CoV-2 antibodies could be of great value for NAb screening of potential donors for convalescent-phase plasma ther","2021","05","31","J Clin Virol","Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology","Antibody; Electrochemiluminescence; Immunoassay; Neutralization; SARS-CoV-2; Antibodies, Viral; COVID-19; COVID-19 Serological Testing; High-Throughput Screening Assays; Humans; Immunoassay; Luminescent Measurements; Neutralization Tests; Spike Glycoprotein, Coronavirus","Resman Rus","Katarina","Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zalo..ka 4, 1000 Ljubljana, Slovenia",NA
"216","33864052","10.1038/s41591-021-01334-5","Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.","Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19)<sup>1</sup>, population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model<sup>2</sup>, which predicts the spread of SARS-CoV-2 infections, with a new data-based model that projects new cases onto casualties and healthcare system costs. Based on the Italian case study, we o","2021","04","17","Nat Med","Nature medicine",NA,"Giordano","Giulia","Department of Industrial Engineering, University of Trento, Trento, Italy. giulia.giordano@unitn","giulia.giordano@unitn.it"
"217","33861303","10.1182/blood.2021011568","Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.","Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 vaccine in patients with CLL. We evaluated humoral immune responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine in patients with CLL and compared responses with those obtained in age-matched healthy control subjects. Patients received 2 vaccine doses, 21 days apart, and antibody titers were measured by using ","2021","06","12","Blood","Blood","BNT162b2; CLL; COVID-19 vaccine; NEOPLASIA/Lymphoid leukemias; antibody response","Herishanu","Yair","Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel",NA
"218","33861165","10.1080/21645515.2021.1896319","Pediatricians' COVID-19 experiences and views on the willingness to receive COVID-19 vaccines: a cross-sectional survey in Turkey.","Developing an effective and safe vaccine against Covid-19 will facilitate return to normal. Due to hesitation toward the vaccine, it is crucial to explore the acceptability of the COVID-19 vaccine to the public and healthcare workers. In this cross-sectional survey, we invited 2251 pediatricians and 506 (22%) of them responded survey and 424 (84%) gave either nasopharyngeal swap or antibody assay for COVID-19 and 71 (14%) of them got diagnosis of COVID-19. If the effective and safe COVID-19 vacc","2021","04","16","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","COVID-19; Turkey; healthcare workers; pediatricians; vaccine acceptance; vaccine hesitancy","G..n..ll..","Erdem","Department of Pediatrics, ..sk..dar University Medical School, ..stanbul, Turkey",NA
"219","33860219","10.1021/acsptsci.1c00054","Toward the Next-Generation COVID-19 Vaccines That Circumvent Antigenic Drift while Defusing Viral Infection.","The emergence of vaccine-resistant variants suggests a complicated endemic scenario in the vaccination aftermath for COVID-19. The situation prompts us to enquire whether the antigen adopted by extant vaccines, the trimeric spike (S) protein, is the optimal in the sense of inducing an immunity that leaves the virus with no evolutionary route of evasion. The patterns of glycosylation camouflage suggest that the answer is negative while also suggesting an alternative antigen that appears to be bet","2021","04","17","ACS Pharmacol Transl Sci","ACS pharmacology &amp; translational science",NA,"Fern..ndez","Ariel","Daruma Institute for AI in Pharmaceutical Research, AF Innovation Pharma Consultancy, 4000 Pemberton Court, Winston-Salem, North Carolina 27106, United States",NA
"220","33858693","10.1016/j.therap.2021.03.005","Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy.",NA,"2021","04","18","Therapie","Therapie","Bell's palsy; COVID-19 vaccines; Pharmacovigilance; Phase 3 clinical trials; Type I interferons","Soeiro","Thomas","Aix-Marseille Universit.., Inserm, UMR 1106, 13005 Marseille, France",NA
"221","33857620","10.1016/j.tracli.2021.04.002","COVID-19 vaccination in the Indian blood donors: Adjudging the impact on the deferral period.","The only efficacious way to provide people with herd immunity against the novel corona virus [nCoV] is to administer an appropriate vaccine and help check the current pandemic. With the genetic sequence data of the nCoV already available since January 10, 2020, leading pharmaceutical companies, world over, in turn, have started working on the clinical trials to produce vaccines against this nCoV. In fact, many vaccines under the Phase III trial have claimed to demonstrate their efficacy to be as","2021","04","27","Transfus Clin Biol","Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","Blood donors; Blood safety; COVID-19; Deferral; Pandemic; Vaccine impact","Bansal","N","Department of transfusion medicine, VCSG government institute of medical science and research, Srinagar, Uttarakhand, India",NA
"222","33857453","10.1016/S2468-2667(21)00055-4","Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study.","The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in England. We aimed to investigate whether increases in the proportion of infections with this variant are associated with differences in symptoms or disease course, reinfection rates, or transmissibility. We did an ecological study to examine the association between the regional proportion of infections with the SARS-CoV-2 B.1.1.7 variant and reported symptoms, disease course, rates of reinfection, and transmissibility. Dat","2021","05","04","Lancet Public Health","The Lancet. Public health","Adolescent; Adult; Aged; COVID-19; Female; Humans; Male; Middle Aged; Reinfection; SARS-CoV-2; United Kingdom; Young Adult","Graham","Mark S","School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK. Electronic address: mark.graham@kcl.ac","mark.graham@kcl.ac.uk"
"223","33852237","10.36849/JDD.2021.6041","Global Recommendations on COVID-19 Vaccines and Soft Tissue Filler Reactions: A Survey-Based Investigation in Cooperation With the International Society for Dermatologic and Aesthetic Surgery (ISDS).","Recent reports have surfaced from the United States Food and Drug Administration hearings in December 2020 regarding the COVID-19 vaccines and study participants who developed facial and/or lip swelling after receiving the newly developed drug. Despite an incidence rate of 0.02% in the vaccine arm of the Moderna mRNA-1273 trial, concerns have been expressed about the association of adverse reactions following soft tissue filler injections and the COVID-19 vaccines. The International Society for ","2021","04","22","J Drugs Dermatol","Journal of drugs in dermatology : JDD","Adult; Aged; Aged, 80 and over; Biocompatible Materials; COVID-19 Vaccines; Dermatology; Edema; Face; Female; Humans; Incidence; Lip; Male; Middle Aged; Surgery, Plastic; Surveys and Questionnaires; Young Adult","Gotkin","Robert H",NA,NA
"224","33852219","","[Covid-19 vaccination and renal patients: overcoming unwarranted fears and re-establishing priorities].","The SARS-CoV-2 (Covid-19) has infected about 124 million people worldwide and the total amount of casualties now sits at a staggering 2.7 million. One enigmatic aspect of this disease is the protean nature of the clinical manifestations, ranging from total absence of symptoms to extremely severe cases with multiorgan failure and death. Chronic Kidney Disease (CKD) has emerged as the primary risk factor in the most severe patients, apart from age. Kidney disease and acute kidney injury have been ","2021","04","21","G Ital Nefrol","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","Covid-19; SARS-CoV-2; chronic kidney disease; exit-site infection; vaccines; Age Factors; Angiotensin-Converting Enzyme 2; COVID-19; COVID-19 Vaccines; Disease Susceptibility; Fear; Humans; Kidney; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Vaccination","Sciarrone Alibrandi","Maria Teresa","University Vita Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milano, Italia",NA
"225","33851143","10.1016/j.medj.2021.04.003","Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset.","RNA vaccines against Covid-19 have demonstrated ...95% efficacy in Phase III clinical trials. Although complete vaccination consisted of two-doses, the onset of protection for both licensed RNA vaccines was observed as early as 12 days after a single dose. The adaptive immune response that coincides with this onset of protection could represent the necessary elements of immunity against Covid-19. Serological and T cell analysis was performed in a cohort of 20 healthcare workers after receiving t","2021","04","20","Med (N Y)","Med (New York, N.Y.)","COVID-19; RNA vaccine; T cells; binding antibodies; neutralizing antibodies; vaccine efficacy","Kalimuddin","Shirin","Department of Infectious Diseases, Singapore General Hospital, Singapore 169856, Singapore",NA
"226","33849903","10.1136/bmj.n971","Covid-19: Moderna and Novavax vaccines to be tested in mixing vaccines trial.",NA,"2021","04","20","BMJ","BMJ (Clinical research ed.)",NA,"Mahase","Elisabeth","The BMJ",NA
"227","33849629","10.1186/s13063-021-05180-1","A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.","The primary objective is to evaluate the efficacy of an inactivated and aluminium hydroxide adsorbed SARS-CoV-2 vaccine (Sinovac, China) in voluntary participants after 14 days of the second dose against RT-PCR confirmed symptomatic COVID-19 cases. The secondary objectives include evaluating the efficacy after at least one dose of the vaccine against RT-PCR confirmed symptomatic COVID-19 cases; the efficacy of two doses of the vaccine on the rates of hospitalization and death; the safety of the ","2021","05","13","Trials","Trials","COVID-19; Turkey; double blind; inactivated vaccines; phase III clinical trial; protocol; randomised placebo controlled trial; vaccine; Animals; COVID-19; COVID-19 Vaccines; China; Chlorocebus aethiops; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Male; Pregnancy; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome; Vero Cells","Akova","Murat","Department of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Hacettepe Mh., 06230, Ankara, Turkey. makova@hacettepe.edu","makova@hacettepe.edu.tr"
"228","33846694","10.1016/j.imu.2021.100569","Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2.","The coronavirus disease 2019 (COVID-19) is an ongoing pandemic caused by an RNA virus termed as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 possesses an almost 30kbp long genome. The genome contains open-reading frame 1ab (ORF1ab) gene, the largest one of SARS-CoV-2, encoding polyprotein PP1ab and PP1a responsible for viral transcription and replication. Several vaccines have already been approved by the respective authorities over the world to develop herd immunity ","2021","04","19","Inform Med Unlocked","Informatics in medicine unlocked","ACE-2, Angiotensin-converting enzyme 2; COVID-19; COVID-19, coronavirus disease 2019; Cp, heat capacity; Gene silencing; ORF, open reading frame; Posttranscriptional regulation; RNAi Therapeutics; RNAi, RNA interference; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TMPRSS2, transmembrane protease serine 2; Tm, melting temperature; UTR, untranslated region; hsa-miR, human microRNA; miRNA; miRNA, microRNA; sgRNA, sub-genomic RNA; siRNA; siRNA, small interfering RNA","Hasan","Mahedi","Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh",NA
"229","33846122","10.1136/bmj.n937","Reporting of AstraZeneca studies may have caused vaccine reservations.",NA,"2021","04","26","BMJ","BMJ (Clinical research ed.)","Age Factors; Aged; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; European Union; Humans; Immunization Schedule; Mass Vaccination; Middle Aged; Norway; Patient Selection; Politics; Research Design; Risk Factors; Thromboembolism; United Kingdom","Bignardi","Giuseppe","Durham DH1 4LS, UK",NA
"230","33844797","10.4067/S0716-10182021000100088","[SARS CoV-2 Vaccine studies currently in phase III].","The coronavirus disease 2019, caused by the SARS-CoV2 virus, was declared a pandemic in March 2020 by the WHO. Protein S from the viral surface has been identified as the optimal antigen for vaccine development. In a pandemic, the traditional vaccine development process has had to be accelerated to advance in an adequate response to the problem, shortening the times. Safety, immunogenicity, protection against infection, antibody dependent enhancement phenomena and duration of protection are stud","2021","04","27","Rev Chilena Infectol","Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia","COVID-19; COVID-19 Vaccines; Humans; RNA, Viral; SARS Virus; SARS-CoV-2; Vaccines; Viral Vaccines","Ib....ez Guelfenbein","Carolina","Departamento de Pediatr..a, Facultad de Medicina, Universidad de Chile, Santiago, Chile",NA
"231","33844575","10.7326/M20-8149","A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.","Multiple candidate vaccines to prevent COVID-19 have entered large-scale phase 3 placebo-controlled randomized clinical trials, and several have demonstrated substantial short-term efficacy. At some point after demonstration of substantial efficacy, placebo recipients should be offered the efficacious vaccine from their trial, which will occur before longer-term efficacy and safety are known. The absence of a placebo group could compromise assessment of longer-term vaccine effects. However, by c","2021","05","14","Ann Intern Med","Annals of internal medicine",NA,"Follmann","Dean","National Institute of Allergy and Infectious Diseases, Bethesda, Maryland (D.F., J.F., M.P.F., M",NA
"232","33843251","10.1089/hum.2021.058","Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.","Advanced therapy medicinal products (ATMPs), such as gene therapies that consist of or contain genetically modified organisms (GMOs) need to comply with the European Union (EU) GMO legislation, as implemented in each EU Member State, before a clinical trial can commence. Complying with GMO requirements is complex, varies significantly across EU Member States and is leading to delays to clinical trials with ATMPs. Such delays and varying implementation of the GMO legislation makes the EU less att","2021","05","25","Hum Gene Ther","Human gene therapy","ATMP; EU; GMO","Beattie","Stuart","Biogen, Gene Therapy Regulatory Chemistry Manufacturing and Controls, Biogen, Innovation House, 70 Norden Road, Maidenhead, SL6 4AY, Berkshire, England, UK",NA
"233","33841038","10.1007/s10668-021-01373-5","An in silico approach to target RNA-dependent RNA polymerase of COVID-19 with naturally occurring phytochemicals.","The novel coronavirus disease 2019 (COVID-19) was firstly reported from Wuhan city of China and found as a highly contagious, transmittable and pathogenic viral infection. The World Health Organization declared COVID-19 as a pandemic since its emergence from China. The RNA-dependent RNA polymerase (nsp-12) is a complex with nsp-7 and nsp-8 cofactors and is a major constituent of viral replication and RNA synthesis machinery. In the current study, the RdRp of the virus was selected as a receptor ","2021","04","13","Environ Dev Sustain","Environment, development and sustainability","Molecular docking; Nsp-12; Phytochemicals; RNA-dependent RNA polymerase; SARS-CoV-2","Mahrosh","Hafiza Salaha","Department of Biochemistry, Government College University, Faisalabad, 38000 Pakistan",NA
"234","33840294","10.1177/08971900211009650","Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.","The United States Food and Drug Administration recently issued emergency use authorization for 2 mRNA vaccines for preventing COVID-19 disease caused by SARS-CoV-2 virus infections. BNT162b2 from Pfizer-BioNTech and mRNA-1273 by Moderna are planned for use in mass-immunization programs to curb the pandemic. A brief overview of COVID-19 mRNA vaccines is provided, describing the SARS-CoV-2 RNA, how mRNA vaccines work and the advantages of mRNA over other vaccine platforms. The Pfizer-BioNTech coll","2021","04","12","J Pharm Pract","Journal of pharmacy practice","COVID-19; messenger RNA; vaccination","Teo","Shyh Poh","Department of Internal Medicine, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital, Bandar Seri Begawan, Brunei Darussalam",NA
"235","33838657","10.1186/s12879-021-06045-3","Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.","Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. In this prospective triple-blinded ra","2021","04","13","BMC Infect Dis","BMC infectious diseases","COVID-19; Corticosteroid; Dexamethasone; Methylprednisolone; Randomized controlled trial; Adrenal Cortex Hormones; Adult; Aged; COVID-19; Dexamethasone; Female; Hospitalization; Humans; Iran; Length of Stay; Male; Methylprednisolone; Middle Aged; Prospective Studies; Respiration, Artificial; Treatment Outcome","Ranjbar","Keivan","Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran",NA
"236","33837790","10.1093/tbm/ibab029","Future directions of the National Institutes of Health Science of Behavior Change Program.","The National Institutes of Health Science of Behavior Change Common Fund Program has accelerated the investigation of mechanisms of behavior change applicable to multiple health behaviors and outcomes and facilitated the use of the experimental medicine approach to behavior change research. This commentary provides a brief background of the program, plans for its next phase, and thoughts about how the experimental medicine approach to behavior change research can inform future directions in two ","2021","05","04","Transl Behav Med","Translational behavioral medicine","COVID-19 vaccine uptake; Experimental medicine approach; Mechanisms of behavior change; NIH; Reproductive health; Science of behavior change","Keller","Chandra","National Institute on Aging, Bethesda, Maryland, USA",NA
"237","33836685","10.1186/s12879-021-06028-4","Effects of weather-related social distancing on city-scale transmission of respiratory viruses: a retrospective cohort study.","Unusually high snowfall in western Washington State in February 2019 led to widespread school and workplace closures. We assessed the impact of social distancing caused by this extreme weather event on the transmission of respiratory viruses. Residual specimens from patients evaluated for acute respiratory illness at hospitals in the Seattle metropolitan area were screened for a panel of respiratory viruses. Transmission models were fit to each virus to estimate the magnitude reduction in transm","2021","04","13","BMC Infect Dis","BMC infectious diseases","Epidemiology; Influenza, human; Non-Pharmaceutical Interventions; Respiratory syncytial virus, human; COVID-19; Cities; Epidemics; Humans; Incidence; Models, Theoretical; Physical Distancing; Respiratory Tract Infections; Retrospective Studies; Washington; Weather","Jackson","Michael L","Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. michael.l.jackson@kp",NA
"238","33836204","10.1016/j.virusres.2021.198421","SARS-CoV-2 presented moderately during two episodes of the infection with lack of antibody responses.","The world has gone through the critical phase of SARS-CoV-2 crisis caused by the new variants of the virus. The globally concerted effort to characterize viral genomic mutations across different clades has revealed several changes in the coding and also non-coding regions which might lead to a violent presentation or re-infection occurrence. Here, we studied a COVID-19 subject who represented the symptoms following the full recovery of the first infection. COVID-19 specific IgM and IgG were eval","2021","05","25","Virus Res","Virus research","COVID-19; Clade 20G; Mutation; Re-infection; SARS-CoV-2; Adult; Antibodies, Viral; COVID-19; Genome, Viral; Humans; Male; Mutation; Phylogeny; RNA, Viral; Reinfection; SARS-CoV-2","Salehi-Vaziri","Mostafa","COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran",NA
"239","33836013","10.1371/journal.pone.0250017","Knowledge, preventive behaviors and risk perception of the COVID-19 pandemic: A cross-sectional study in Turkish health care workers.","The coronavirus disease 2019 (COVID-19) outbreak spread to over 100 countries with a total of 100,000 cases during the first week of March 2020. Health care workers, as those on the frontline of the COVID-19 pandemic, are more susceptible to infection. Inadequate related knowledge and preventive behaviors among health care workers might lead to delayed treatment and result in the rapid spread of the infection. Therefore, this study evaluated the knowledge of health care workers with regard to CO","2021","04","19","PLoS One","PloS one","Adult; COVID-19; Cross-Sectional Studies; Female; Health Behavior; Health Knowledge, Attitudes, Practice; Health Personnel; Humans; Male; Middle Aged; Pandemics; SARS-CoV-2; Turkey","Arslanca","Tufan","Department of Obstetrics and Gynecology, Ufuk University, Ankara, Turkey",NA
"240","33835300","10.1208/s12249-021-01974-3","Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration.","The dire need for safe and effective coronavirus disease (COVID-19) vaccines is met with many vaccine candidates being evaluated in pre-clinical and clinical studies. The COVID-19 vaccine candidates currently in phase 3 or phase 2/3 clinical trials as well as those that recently received emergency use authorization (EUA) from the United States Food and Drug Administration (FDA) and/or other regulatory agencies worldwide require either cold (i.e., 2-8..C) or even freezing temperatures as low as -","2021","04","27","AAPS PharmSciTech","AAPS PharmSciTech","Cold chain; Dry powder; SARS-CoV-2; Thermostability; Vaccine; COVID-19; COVID-19 Vaccines; Drug Storage; Humans; Mass Vaccination; SARS-CoV-2","AboulFotouh","Khaled","Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA",NA
"241","33833104","10.1126/science.372.6538.116","Latest Russian vaccine comes with a big dose of mystery.",NA,"2021","04","23","Science","Science (New York, N.Y.)","Antibodies, Neutralizing; Antibodies, Viral; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Nucleocapsid Proteins; Drug Development; Humans; Russia; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Inactivated; Vaccines, Subunit","Dobrovidova","Olga","Olga Dobrovidova, a science journalist in Moscow, currently works at Skoltech, a private university not involved in the development of COVID-19 vaccines",NA
"242","33833099","10.1126/science.abi8397","The story behind COVID-19 vaccines.",NA,"2021","04","23","Science","Science (New York, N.Y.)","Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Humans; Interdisciplinary Research; Vaccinology; Viral Vaccines","Fauci","Anthony S","Anthony S. Fauci is director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. afauci@niaid.nih","afauci@niaid.nih.gov"
"243","33831583","10.1016/j.drudis.2021.03.029","Regulatory status quo and prospects for biosurfactants in pharmaceutical applications.","The concept of going 'green' and 'cold' has led to utilizing renewable resources for the synthesis of microbial biosurfactants that are both patient and eco-friendly. In this review, we shed light on the potential and regulatory aspects of biosurfactants in pharmaceutical applications and how they can significantly contribute to novel concepts for the Coronavirus 2019 (COVID-19) vaccine and future treatment. We emphasize that more specific guidelines should be formulated to regulate the approval","2021","04","22","Drug Discov Today","Drug discovery today","COVID-19; EMA; FDA; Microbial biosurfactants; Nanoformulations","Ismail","Ruba","Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, E..tv..s Str. 6, H-6720 Szeged, Hungary","ruba.ismail@szte.hu"
"244","33831450","10.1016/j.ijbiomac.2021.03.135","Antiviral potential of plant polysaccharide nanoparticles actuating non-specific immunity.","The development of high-end targeted drugs and vaccines against modern pandemic infections, such as COVID-19, can take a too long time that lets the epidemic spin up and harms society. However, the countermeasures must be applied against the infection in this period until the targeted drugs became available. In this regard, the non-specific, broad-spectrum anti-viral means could be considered as a compromise allowing overcoming the period of trial. One way to enhance the ability to resist the in","2021","06","10","Int J Biol Macromol","International journal of biological macromolecules","Antiviral activity; COVID-19; Immune modulator","Stovbun","Sergey V","N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia",NA
"245","33831133","10.1371/journal.ppat.1009431","High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19.","Tracking evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within infected individuals will help elucidate coronavirus disease 2019 (COVID-19) pathogenesis and inform use of antiviral interventions. In this study, we developed an approach for sequencing the region encoding the SARS-CoV-2 virion surface proteins from large numbers of individual virus RNA genomes per sample. We applied this approach to the WA-1 reference clinical isolate of SARS-CoV-2 passaged in vitro ","2021","04","19","PLoS Pathog","PLoS pathogens","COVID-19; Cell Line; Epitopes; Female; High-Throughput Nucleotide Sequencing; Humans; Immunity, Humoral; Male; Mutation; SARS-CoV-2; Spike Glycoprotein, Coronavirus","Ko","Sung Hee","Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America",NA
"246","33831032","10.1371/journal.pone.0248813","Prevalence of SARS-COV-2 positivity in 516 German intensive care and emergency physicians studied by seroprevalence of antibodies National Covid Survey Germany (NAT-COV-SURV).","Healthcare personnel are at risk to aquire the corona virus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated the prevalence of SARS-CoV-2 antibodies and positive nasopharyngeal reverse transcriptase polymerase-chain reaction (RT-PCR) tests in German intensive care and emergency physicians. Physicians attending intensive care and emergency medicine training courses between June 16th and July 2nd 2020 answered a questionnaire and were","2021","04","19","PLoS One","PloS one","Adult; Aged; Antibodies, Viral; COVID-19; COVID-19 Serological Testing; Critical Care; Female; Germany; Humans; Male; Middle Aged; Physicians; Prevalence; SARS-CoV-2; Seroepidemiologic Studies","Kindgen-Milles","Detlef","Dept. of Anesthesiology, University Hospital Duesseldorf, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany",NA
"247","33826784","10.1002/jcph.1868","Clinical Equipoise in COVID-19 Vaccine Candidates Trials.",NA,"2021","04","07","J Clin Pharmacol","Journal of clinical pharmacology","COVID-19; clinical equipoise; clinical trial; placebo; uncertainty; vaccine","Dal-R..","Rafael","Epidemiology Unit, Health Research Institute-Fundaci..n Jim..nez D..az University Hospital, Universidad Aut..noma de Madrid, Madrid, Spain",NA
"248","33824579","10.2147/DDDT.S301173","Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19.","The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), continues to spread around the world. While prophylactic vaccines against SARS-CoV-2 are making great progress, there is still a need to explore safe and effective therapies with biological products for COVID-19. Currently clinical trial efforts are planned and ongoing using different biological agents for anti-inflammatory therapies, immunomodulation, and therapeutic repair in CO","2021","04","14","Drug Des Devel Ther","Drug design, development and therapy","COVID-19; cytokine blockade; immunomodulation; therapeutic repair; Anti-Inflammatory Agents; Biological Products; COVID-19; Clinical Trials as Topic; Cytokines; Host-Pathogen Interactions; Humans; Immunologic Factors; Molecular Targeted Therapy; SARS-CoV-2; Treatment Outcome","Li","Chenghai","Stem Cell Program of Clinical Research Center, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, 450003, People's Republic of China",NA
"249","33824169","10.1212/WNL.0000000000011881","Guillain- Barr.. Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality.",NA,"2021","04","07","Neurology","Neurology",NA,"M..rquez Loza","Alejandra M","Department of Neurology, Brigham and Women's Hospital, Boston, MA",NA
"250","33824037","10.1016/j.vaccine.2021.03.076","Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study.","Evidence from COVID-19 outbreak shows that individuals with specific chronic diseases are at higher risk of severe prognosis after infection. Public health authorities are developing vaccination programmes with priorities that minimize the risk of mortality and severe events in individuals and communities. We propose an evidence-based strategy that targets the frailest subjects whose timely vaccination is likely to minimize future deaths and preserve the resilience of the health service by preve","2021","04","29","Vaccine","Vaccine","COVID vaccination; LASSO regression; Model selection; Public Health; Stratification for priorities; Adolescent; Adult; COVID-19; COVID-19 Vaccines; Cohort Studies; Humans; Middle Aged; SARS-CoV-2; Vaccination; Young Adult","Russo","Antonio Giampiero","Epidemiology Unit, Agency for Health Protection of the Metropolitan Area of Milan, Milan, Italy. Electronic address: agrusso@ats-milano",NA
"251","33822932","10.1093/intqhc/mzab062","Monitoring of three-phase variations in the mortality of COVID-19 pandemic using control charts: where does Pakistan stand?","At the end of December 2019, the world in general and Wuhan, the industrial hub of China, in particular, experienced the COVID-19 pandemic. Massive increment of cases and deaths occurred in China and 209 countries in Europe, America, Australia, Asia and Pakistan. Pakistan was first hit by COVID-19 when a case was reported in Karachi on 26 February 2020. Several methods were presented to model the death rate due to the COVID-19 pandemic and to forecast the pinnacle of reported deaths. Still, thes","2021","04","22","Int J Qual Health Care","International journal for quality in health care : journal of the International Society for Quality in Health Care"," c-chart; COVID-19 pandemic; EWMA chart; growth phases; mortality; run chart; COVID-19; Forecasting; Humans; Pakistan; Pandemics; Pneumonia, Viral; Population Surveillance; SARS-CoV-2","Mahmood","Yasar","School of Mathematical Sciences, Universiti Sains Malaysia, Penang, Malaysia",NA
"252","33822773","10.1172/jci.insight.149187","SARS-CoV-2 vaccines: a triumph of science and collaboration.","Roughly 1 year after the first case of COVID-19 was identified and less than 1 year after the sequencing of SARS-CoV-2, multiple SARS-CoV-2 vaccines with demonstrated safety and efficacy in phase III clinical trials are available. The most promising vaccines have targeted the surface glycoprotein (S-protein) of SARS-CoV-2 and achieved an approximate 85%-95% reduction in the risk of symptomatic COVID-19, while retaining excellent safety profiles and modest side effects in the phase III clinical t","2021","05","21","JCI Insight","JCI insight","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Global Health; Humans; Pandemics; Public-Private Sector Partnerships; SARS-CoV-2; Safety; Vaccination","Golob","Jonathan L","Division of Infectious Diseases",NA
"253","33822770","10.1172/JCI149335","SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.","Recent studies have shown T cell cross-recognition of SARS-CoV-2 and common cold coronavirus spike proteins. However, the effect of SARS-CoV-2 vaccines on T cell responses to common cold coronaviruses (CCCs) remains unknown. In this study, we analyzed CD4+ T cell responses to spike peptides from SARS-CoV-2 and 3 CCCs (HCoV-229E, HCoV-NL63, and HCoV-OC43) before and after study participants received Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) mRNA-based COVID-19 vaccines. Vaccine recipients","2021","05","25","J Clin Invest","The Journal of clinical investigation","COVID-19; T cells; Adult; CD4-Positive T-Lymphocytes; COVID-19 Vaccines; Coronavirus 229E, Human; Coronavirus NL63, Human; Coronavirus OC43, Human; Cross Reactions; Female; Humans; Male; Middle Aged; RNA, Messenger; SARS-CoV-2; Spike Glycoprotein, Coronavirus","Woldemeskel","Bezawit A",NA,NA
"254","33822361","10.1002/jmv.26996","Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.","There are concerns regarding the side effects of the new coronavirus disease 2019 (COVID-19) mRNA-1273 vaccine among healthcare workers (HCWs) in the United States. The objective of the study was to investigate the side effects of the mRNA-1273 vaccine with detailed review of organ systems. A randomized, cross-sectional study using an independent online survey questionnaire was conducted to collect responses from HCWs. Of all participants, 87.8% (1116/1271) provided complete responses. Of them, ","2021","06","08","J Med Virol","Journal of medical virology","COVID; COVID-19; Moderna; SARS-CoV-2; adverse events; mRNA-1273; side effects; symptoms; vaccine; Activities of Daily Living; Adult; Aged; Anaphylaxis; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Female; Fever; Health Personnel; Humans; Injection Site Reaction; Male; Middle Aged; SARS-CoV-2; Self Report; Sick Leave; Surveys and Questionnaires; Young Adult","Kadali","Renuka Ananth Kalyan","Department of Internal Medicine, Harnett Health System, Affiliated with Cape Fear Valley Health System, Lillington, North Carolina, USA",NA
"255","33821569","10.1002/eahr.500089","SARS-CoV-2 Human Challenge Trials: Rethinking the Recruitment of Healthy Young Adults First.","In the midst of the ongoing Covid-19 pandemic, researchers across the globe are still working to develop effective vaccines. To expedite this process even further, human challenge trials have been proposed by the World Health Organization (WHO) as an alternative to conventional approaches. In such trials, healthy volunteers are deliberately infected with the pathogen of interest, enabling scientists to study the infection process and facilitate further research on treatments or prophylactics, in","2021","05","31","Ethics Hum Res","Ethics &amp; human research","Covid-19; SARS-CoV-2; human challenge trials; human research ethics; human subjects research; research participants; research subject selection; Adult; Age Factors; Antiviral Agents; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Patient Selection; SARS-CoV-2; Young Adult","Matsui","Kenji","Director of the Division of Bioethics and Healthcare Law at the Center for Public Health Sciences at the National Cancer Center in Japan",NA
"256","33819751","10.1016/j.esmoop.2021.100100","COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?","High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients' needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: 'how ca","2021","05","13","ESMO Open","ESMO open","AIOM; COVID-19; cancer; treatment; vaccination; COVID-19; COVID-19 Vaccines; Central Venous Catheters; Clinical Trials as Topic; Humans; Influenza Vaccines; Neoplasms; Oncologists; Practice Guidelines as Topic; Societies, Medical","Silvestris","N","IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, Bari, Italy",NA
"257","33818952","10.22092/ari.2021.353761.1612","The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.","The Covid-19 pandemic has brought about rapid change in medical science. The production of new generation vaccines for this disease has surprised even their most optimistic supporters. Not only have these vaccines proven to be effective, but the importance of this disease and pandemic situation also significantly shortened the long-standing process of validating such products. Vaccination is a type of immunotherapy. Researchers have long been looking at vaccines as a possible treatment for cance","2021","04","16","Arch Razi Inst","Archives of Razi Institute","Vaccine; cancer; covid 19; Artificial Intelligence; COVID-19; COVID-19 Vaccines; Cancer Vaccines; Humans; Neoplasms; RNA, Messenger; SARS-CoV-2; Vaccines, Synthetic","Amanpour","S","Cancer Biology Research Center, Tehran University of Medical Sciences, Tehran, Iran",NA
"258","33818466","10.4103/ijmr.IJMR_2556_20","Emerging trends from COVID-19 research registered in the Clinical Trials Registry - India.","Since the beginning of the year, the deadly coronavirus pandemic, better known as coronavirus disease 2019 (COVID-19), brought the entire world to an unprecedented halt. In tandem with the global scenario, researchers in India are actively engaged in the conduct of clinical research to counter the pandemic. This review attempts to provide a comprehensive overview of the COVID-19 research in India including design aspects, through the clinical trials registered in the Clinical Trials Registry - I","2021","04","15","Indian J Med Res","The Indian journal of medical research","Ayurveda; COVID-19; CTRI-India; Homeopathy; Siddha; Unani; Yoga and Naturopathy; clinical trials; convalescent plasma therapy; drug trials; registration; vaccine trials; Biomedical Research; COVID-19; Clinical Trials as Topic; Humans; India; Registries","Rao","M Vishnu Vardhana","ICMR-National Institute of Medical Statistics, New Delhi, India",NA
"259","33817520","10.1021/acsomega.1c00404","Tamper-Proof Time-Temperature Indicator for Inspecting Ultracold Supply Chain.","In the precarious situation caused by the COVID-19 pandemic, the use of messenger ribonucleic acid (mRNA) vaccines is promising for prevention against the infection. However, this type of vaccine has not been effectively commercialized because it needs to be stored and transported at ultracold conditions. mRNA vaccines exposed to undesired temperatures may not show any visible changes but can deteriorate and cause negative effects. Consumers' demand for vaccine authenticity requires logistics to","2021","04","06","ACS Omega","ACS omega",NA,"Hao","Lam Tan","Research Center for Bio-based Chemistry, Korea Research Institute of Chemical Technology (KRICT), Ulsan 44429, Republic of Korea",NA
"260","33816087","10.1016/j.pmedr.2021.101350","Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants.","With the demand for rapid COVID-19 vaccine development and evaluation, this paper aimed to describe the prevalence and correlates of willingness to participate in COVID-19 vaccine trials among university students in China. A cross-sectional survey with 1912 Chinese university students was conducted during March and April 2020. Bivariate and multivariate analyses were performed to identify variables associated with willingness to participate. The majority of participants (64.01%) indicated willin","2021","04","07","Prev Med Rep","Preventive medicine reports","COVID-19; China; Vaccine hesitancy; Vaccine trials willingness; Young adult","Sun","Shufang","Brown University School of Public Health, Department of Behavioral and Social Sciences, United States",NA
"261","33815890","10.14336/AD.2020.1211","Global Sex Disparity of COVID-19: A Descriptive Review of Sex Hormones and Consideration for the Potential Therapeutic Use of Hormone Replacement Therapy in Older Adults.","The 2019-2020 SARS-related coronavirus-2 (SARS-CoV-2) pandemic has brought unprecedented challenges to healthcare sectors around the world. As of November 2020, there have been over 64 million confirmed cases and approaching 2 million deaths globally. Despite the large number of positive cases, there are very limited established standards of care and therapeutic options available. To date, there is still no Food and Drug Administration (FDA) approved vaccine for COVID-19, although there are seve","2021","04","06","Aging Dis","Aging and disease","COVID-19; SARS-CoV-2; older adults; sex hormones; sexual disparity","Okpechi","Samuel C","Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA",NA
"262","33815564","10.1016/j.nantod.2021.101142","Role of nanotechnology behind the success of mRNA vaccines for COVID-19.","The emergency use authorization (EUA) by the US-FDA for two mRNA-based vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) has brought hope of addressing the COVID-19 pandemic which has killed more than two million people globally. Nanotechnology has played a significant role in the success of these vaccines. Nanoparticles (NPs) aid in improving stability by protecting the encapsulated mRNA from ribonucleases and facilitate delivery of intact mRNA to the target site. The overwhelming suc","2021","06","12","Nano Today","Nano today","BNT162b2; COVID-19; Lipid nanoparticles; mRNA; mRNA-1273","Khurana","Amit","Centre for Biomedical Engineering (CBME), Indian Institute of Technology (IIT) Delhi, Hauz Khas, New Delhi 110016, India",NA
"263","33815415","10.3389/fimmu.2021.654165","Immunity to SARS-CoV-2: Lessons Learned.","In the year since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and with understanding of the etiology of the coronavirus disease 2019 (COVID-19) pandemic, it has become clear that most infected individuals achieve some form of immunity against the virus with relatively few reported reinfections. A number of vaccines have already achieved emergency use authorization based on data from large phase 3 field efficacy clinical trials. However, our knowledge about the e","2021","04","20","Front Immunol","Frontiers in immunology","COVID-19; SARS-CoV-2; duration of protection; immunity; receptor-binding domain; spike protein; systems serology; vaccination; Antibodies, Viral; COVID-19; Child; Female; Humans; Immunity, Cellular; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Protein Domains; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Vaccination","Fergie","Jaime","Department of Pediatric Infectious Diseases, Driscoll Children's Hospital, Corpus Christi, TX, United States",NA
"264","33815095","10.3389/fphar.2020.590154","A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.","The emergence of highly virulent CoVs (SARS-CoV-2), the etiologic agent of novel ongoing &quot;COVID-19&quot; pandemics has been marked as an alarming case of pneumonia posing a large global healthcare crisis of unprecedented magnitude. Currently, the COVID-19 outbreak has fueled an international demand in the biomedical field for the mitigation of the fast-spreading illness, all through the urgent deployment of safe, effective, and rational therapeutic strategies along with epidemiological cont","2021","04","06","Front Pharmacol","Frontiers in pharmacology","COVID-19; SARS-CoV-2; acute viral respiratory distress syndrome; epidemiology; pandemic; vaccines","Dash","Priyanka","Immunology and Molecular Medicine Laboratory, Department of Life Science, National Institute of Technology Rourkela, Odisha, India",NA
"265","33815034","10.1016/j.jtumed.2021.03.001","The willingness of the Saudi Arabian population to participate in the COVID-19 vaccine trial: A case-control study.","This study examines the Saudi Arabian population's willingness to participate in clinical trials for the coronavirus disease 2019 (COVID-19) vaccine, comparing recovered cases' willingness with that of healthy volunteers. A case-control study was conducted on the Saudi Arabian population during September 2020. The data were collected from recovered COVID-19 participants as the case group, and healthy volunteers as the control group. The data showed that 42.2% (n..=..315) of recovered COVID-19 ca","2021","04","09","J Taibah Univ Med Sci","Journal of Taibah University Medical Sciences","COVID-19; Clinical trial; Scientific developments; Vaccine; Willingness","Felemban","Rania M","Research Center, King Abdullah Medical City, Holy Capital, KSA",NA
"266","33813139","10.1016/j.ebiom.2021.103291","Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge.","Many milestones in medical history rest on animal modeling of human diseases. The SARS-CoV-2 pandemic has evoked a tremendous investigative effort primarily centered on clinical studies. However, several animal SARS-CoV-2/COVID-19 models have been developed and pre-clinical findings aimed at supporting clinical evidence rapidly emerge. In this review, we characterize the existing animal models exposing their relevance and limitations as well as outline their utility in COVID-19 drug and vaccine ","2021","05","17","EBioMedicine","EBioMedicine","Animal model; COVID-19; Clinical trial; Pandemic; Pre-clinical research; Vaccine; Age Factors; Animals; Antiviral Agents; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Cricetinae; Disease Models, Animal; Ferrets; Humans; Mice; Mutation; Primates; SARS-CoV-2","Winkler","Martin S","Department of Anesthesiology, Emergency and Intensive Care Medicine, University of G..ttingen, G..ttingen, Robert-Koch-Str. 40, 37085 G..ttingen, Germany",NA
"267","33812474","10.1016/S0140-6736(21)00624-3","COVID-19 vaccines in high-risk ethnic groups.",NA,"2021","04","23","Lancet","Lancet (London, England)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Ethnic Groups; Health Status Disparities; Healthy Volunteers; Humans; Minority Groups; Risk Factors; SARS-CoV-2; Social Determinants of Health","D'Souza","Rashmi S","Institute for Women's and Children's Health, King's College London, London SE1 7EU, UK. Electronic address: rashmi.d'souza@nhs","souza@nhs.net"
"268","33810902","10.1016/j.vaccine.2020.08.016","The safety of BCG revaccination: A systematic review.","Revaccination with Bacillus Calmette-Gu..rin (BCG) vaccine is not generally recommended due to a lack of proven efficacy of repeat doses for protection against tuberculosis. However, there is a growing interest in the use of BCG vaccine for its 'off-target' effects which might involve revaccination. We did a systematic review of the safety of BCG revaccination. MEDLINE (1946 to March 2020) and the BCG World Atlas (updated 2017) were searched, limiting to studies of BCG administration by the intr","2021","05","06","Vaccine","Vaccine","Adverse events; Bacillus Calmette-Gu..rin; Off-target effects; Safety; Tuberculosis; BCG Vaccine; Humans; Immunization, Secondary; Mycobacterium bovis; Tuberculosis; Vaccination","Bannister","Samantha","Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia",NA
"269","33807957","10.3390/v13030422","Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.","Although antibody levels progressively decrease following SARS-CoV-2 infection, the immune memory persists for months. Thus, individuals who naturally contracted SARS-CoV-2 are expected to develop a more rapid and sustained response to COVID-19 vaccines than na..ve individuals. In this study, we analyzed the dynamics of the antibody response to the BNT162b2 mRNA COVID-19 vaccine in six healthcare workers who contracted SARS-CoV-2 in March 2020, in comparison to nine control subjects without a pr","2021","04","19","Viruses","Viruses","BNT162b2 vaccine; COVID-19 vaccine; SARS-CoV-2; anti-spike RBD IgG antibody; immune response; immunogenicity; neutralizing antibody; reactogenicity; vaccination; vaccine doses; Adult; Antibodies, Viral; Antibody Formation; COVID-19; COVID-19 Vaccines; Female; Humans; Immunoglobulin G; Male; Middle Aged; RNA, Messenger; RNA, Viral; SARS-CoV-2","Gobbi","Federico","Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, I-37024 Negrar, Italy",NA
"270","33807839","10.3390/v13030418","Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.","The coronavirus SARS-CoV-2, which causes Coronavirus disease 2019 (COVID-19), has infected more than 100 million people globally and caused over 2.5 million deaths in just over one year since its discovery in Wuhan, China in December 2019. The pandemic has evoked widespread collateral damage to societies and economies, and has destabilized mental health and well-being. Early in 2020, unprecedented efforts went into the development of vaccines that generate effective antibodies to the SARS-CoV-2 ","2021","04","19","Viruses","Viruses","COVID-19; SARS-CoV-2; clinical trial; coronavirus; immune response; public health; target product profile; vaccine; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Pandemics; SARS-CoV-2","Funk","Colin D","Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada",NA
"271","33807787","10.3390/ijerph18052611","French Public Familiarity and Attitudes toward Clinical Research during the COVID-19 Pandemic.","The COVID-19 pandemic put clinical research in the media spotlight globally. This article proposes a first measure of familiarity with and attitude toward clinical research in France. Drawing from the &quot;Health Literacy Survey 2019&quot; (HLS19) conducted online between 27 May and 5 June 2020 on a sample of the French adult population (N = 1003), we show that a significant proportion of the French population claimed some familiarity with clinical trials (64.8%) and had positive attitudes (72%","2021","04","08","Int J Environ Res Public Health","International journal of environmental research and public health","COVID-19; clinical research; media coverage; pharmaceutical industry; public attitudes; survey; Adult; Attitude; COVID-19; Clinical Trials as Topic; Cross-Sectional Studies; France; Humans; Pandemics; SARS-CoV-2; Surveys and Questionnaires","Schultz","..milien","CEPED (UMR 196), Universit.. de Paris, IRD, 75006 Paris, France",NA
"272","33806148","10.3390/ijerph18073421","The Impact of the COVID-19 Pandemic on the Spectrum of Performed Dental Procedures.","The COVID-19 pandemic has significantly altered existing health care operations, including dentistry. The fear of SARS-CoV-2 infection and the need for increased protection measures have led to a reduction in the number of appointments and the range of performed procedures. Our study aimed to assess the impact of the COVID-19 pandemic (the pre-vaccine period) on the spectrum of performed dental services, with particular emphasis on the change in the proportion of conservative and surgical proced","2021","04","08","Int J Environ Res Public Health","International journal of environmental research and public health","COVID-19; SARS-CoV-2; conservative dentistry; dental procedures; dental services; dental surgery; dentistry; pandemic; tooth extraction; tooth restoration; COVID-19; Dentistry; Humans; Pandemics; Poland; SARS-CoV-2","Nijakowski","Kacper","Department of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, 60-812 Poznan, Poland",NA
"273","33805880","10.3390/vaccines9040310","Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice.","Theoretically, the subunit herpes zoster vaccine Shingrix<sup>TM</sup> could be used as a varicella vaccine that avoids the risk of developing shingles from vaccination, but bedside mixing strategies and the limited supply of the adjuvant component QS21 have made its application economically impracticable. With lipid nanoparticles (LNPs) that were approved by the FDA as vectors for severe acute respiratory syndrome coronavirus 2 vaccines, we designed a series of vaccines efficiently encapsulated","2021","05","15","Vaccines (Basel)","Vaccines","CpG ODN (CpG oligodeoxynucleotide); Poly I:C (polyinosinic-polycytidylic acid); cell-mediated immunity; chickenpox; herpes zoster; herpesvirus 3; human; humoral immunity; lipid nanoparticle; nucleic acid immunostimulator; shingles; varicella","Cao","Han","Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China",NA
"274","33804162","10.3390/microorganisms9030605","COVID-19: Insights into Potential Vaccines.","People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. The","2021","04","13","Microorganisms","Microorganisms","COVID-19; clinical trials; coronavirus (CoV); passive immunotherapies; vaccines","Loo","Ke-Yan","Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia",NA
"275","33802501","10.3390/ijerph18052497","A Two-Phase Stochastic Dynamic Model for COVID-19 Mid-Term Policy Recommendations in Greece: A Pathway towards Mass Vaccination.","From 7 November 2020, Greece adopted a second nationwide lockdown policy to mitigate the transmission of SARS-CoV-2 (the first took place from 23 March to 4 May 2020), just as the second wave of COVID-19 was advancing, as did other European countries. To secure the full benefits of mass vaccination, which started in early January 2021, it is of utmost importance to complement it with mid-term non-pharmaceutical interventions (NPIs). The objective was to minimize human losses and to limit social ","2021","04","08","Int J Environ Res Public Health","International journal of environmental research and public health","COVID-19; compartmental models; stochastic dynamic network; COVID-19; Communicable Disease Control; Europe; Greece; Humans; Mass Vaccination; Policy; SARS-CoV-2","Rachaniotis","Nikolaos P","Department of Industrial Management and Technology, University of Piraeus, 18534 Piraeus, Greece",NA
"276","33802467","10.3390/vaccines9030214","Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.","Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in clinical development and 173 are in the pre-clinical phase. Five types of vaccines are currently approved for emergency use in many countries (Inactivated, Sinopharm; Viral-vector, Astrazeneca, and Gamaleya Research Institute; mRNA, Moderna, and BioNTech/Pfizer). The main challenge in this pandemic was the availability to produce an effective vaccine to be distributed to the world's population in a short time. Her","2021","04","13","Vaccines (Basel)","Vaccines","SARS-CoV-2; efficacy; immunogenicity; pre-clinical study; vaccine safety","Kandeil","Ahmed","Center of Scientific Excellence for Influenza Virus, Environmental Research Division, National Research Centre, Giza 12622, Egypt",NA
"277","33801831","10.3390/vaccines9030238","Correlates of Vaccine-Induced Protection against SARS-CoV-2.","We are in the midst of a pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). SARS-CoV-2 has caused more than two million deaths after one year of the pandemic. The world is experiencing a deep economic recession. Safe and effective vaccines are needed to prevent further morbidity and mortality. Vaccine candidates against COVID-19 have been developed at an unprecedented speed, with more than 200 vaccine c","2021","04","13","Vaccines (Basel)","Vaccines","COVID-19; SARS-CoV-2; correlates of protection; immunogenicity; pandemic; vaccine","Koch","Till","Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany",NA
"278","33799289","10.1016/j.epidem.2021.100449","Modelling the early phase of the Belgian COVID-19 epidemic using a stochastic compartmental model and studying its implied future trajectories.","Following the onset of the ongoing COVID-19 pandemic throughout the world, a large fraction of the global population is or has been under strict measures of physical distancing and quarantine, with many countries being in partial or full lockdown. These measures are imposed in order to reduce the spread of the disease and to lift the pressure on healthcare systems. Estimating the impact of such interventions as well as monitoring the gradual relaxing of these stringent measures is quintessential","2021","06","12","Epidemics","Epidemics","Age-structured compartmental SEIR model; Hospitalization and mortality data; Markov Chain Monte Carlo (MCMC); Serial serological survey; Stochastic chain-binomial model","Abrams","Steven","Data Science Institute, Interuniversity Institute of Biostatistics and statistical Bioinformatics, UHasselt, Hasselt, Belgium","steven.abrams@uhasselt.be"
"279","33798717","10.1016/j.jbi.2021.103765","Creating and implementing a COVID-19 recruitment Data Mart.","The COVID-19 pandemic has resulted in an unprecedented strain on every aspect of the healthcare system, and clinical research is no exception. Researchers are working against the clock to ramp up research studies addressing every angle of COVID-19 - gaining a better understanding of person-to-person transmission, improving methods for diagnosis, and developing therapies to treat infection and vaccines to prevent it. The impact of the virus on research efforts is not limited to investigators and ","2021","05","19","J Biomed Inform","Journal of biomedical informatics","COVID-19; Clinical Research; REDCap; Research Recruitment","Helmer","Tara T","Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA",NA
"280","33798698","10.1016/j.cmi.2021.03.008","Acceptance of coronavirus disease 2019 vaccine among health-care personnel in India: a cross-sectional survey during the initial phase of vaccination.",NA,"2021","04","21","Clin Microbiol Infect","Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases",NA,"Singhania","Nikhil","Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: nikhil.singhania@yahoo.co","nikhil.singhania@yahoo.co.in"
"281","33798667","10.1016/j.jconrel.2021.03.043","The dawn of mRNA vaccines: The COVID-19 case.","In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for emergency use, while another mRNA vaccine, CVnCoV, progressed to phase 3 clinical testing. The COVID-19 mRNA vaccines represent a new class of vaccine products, which consist of synthetic mRNA strands encoding the SARS-CoV-2 Spike glycoprotein, packaged in lipid nanoparticles to deliver mRNA to cells. This review digs deeper into th","2021","05","17","J Control Release","Journal of controlled release : official journal of the Controlled Release Society",NA,"Verbeke","Rein","Ghent Research Group on Nanomedicines, Faculty of Pharmacy, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium",NA
"282","33798499","10.1016/S0140-6736(21)00628-0","Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.","A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. Volunteers (aged ...18 years) who were enrolled in phase 2/3 vaccine efficacy studies in the UK, and who were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, provided upper airway swabs on a we","2021","04","23","Lancet","Lancet (London, England)","Adolescent; Adult; Antibodies, Neutralizing; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Vaccines; Female; Humans; Male; Middle Aged; Nucleic Acid Amplification Techniques; Pandemics; SARS-CoV-2; Single-Blind Method; United Kingdom; Viral Load; Young Adult","Emary","Katherine R W","Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK",NA
"283","33797374","10.2174/1389557521666210401093948","Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management.","As winter is knocking the door, the risk of respiratory tract infection is increasing at present scenario due to no prophylaxis of Covid-19. So, no one is safe until everyone is safe. Worldwide researchers are looking for the vaccine to remove the need for social distancing, mask-wearing and social gathering. A vaccine is like many other outcomes if the vaccine would be available; we cannot say about the effectiveness of the vaccine. Several drugs are testing to save the people life from pandemi","2021","04","02","Mini Rev Med Chem","Mini reviews in medicinal chemistry","Azithromycin; Clinical trial; Covid-19; Cytokine storm; Immunomodulatory; Macrolides","Wahab","Shadma","Department of Pharmacognosy and Phytochemistry, King Khalid University, Abha. Saudi Arabia",NA
"284","33795692","10.1038/s41467-021-22236-7","Systems serology detects functionally distinct coronavirus antibody features in children and elderly.","The hallmarks of COVID-19 are higher pathogenicity and mortality in the elderly compared to children. Examining baseline SARS-CoV-2 cross-reactive immunological responses, induced by circulating human coronaviruses (hCoVs), is needed to understand such divergent clinical outcomes. Here we show analysis of coronavirus antibody responses of pre-pandemic healthy children (n...=...89), adults (n...=...98), elderly (n...=...57), and COVID-19 patients (n...=...50) by systems serology. Moderate levels ","2021","04","13","Nat Commun","Nature communications","Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Viral; Antibody Formation; COVID-19; COVID-19 Vaccines; Child; Child, Preschool; Cross Reactions; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Middle Aged; Receptors, IgG; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Young Adult","Selva","Kevin J","Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia",NA
"285","33794204","10.1016/S1470-2045(21)00131-5","Georgina Sposetti: trial recruitment revolutionary.",NA,"2021","04","15","Lancet Oncol","The Lancet. Oncology","Argentina; Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Peripheral Nervous System Diseases","Lucas","Catherine",NA,NA
"286","33793460","10.15585/mmwr.mm7013e3","Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.","Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Using prospective cohorts of health care personnel, first respond","2021","04","02","MMWR Morb Mortal Wkly Rep","MMWR. Morbidity and mortality weekly report","Adolescent; Adult; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Vaccines; Emergency Responders; Female; Health Personnel; Humans; Male; Middle Aged; Occupational Diseases; Occupations; Prospective Studies; United States; Vaccines, Synthetic; Young Adult","Thompson","Mark G",NA,NA
"287","33793189","10.1021/acsnano.1c01845","Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape.","At the time of preparing this Perspective, large-scale vaccination for COVID-19 is in progress, aiming to bring the pandemic under control through vaccine-induced herd immunity. Not only does this vaccination effort represent an unprecedented scientific and technological breakthrough, moving us from the rapid analysis of viral genomes to design, manufacture, clinical trial testing, and use authorization within the time frame of less than a year, but it also highlights rapid progress in the imple","2021","05","14","ACS Nano","ACS nano","Antibodies, Viral; COVID-19; COVID-19 Vaccines; Humans; Immunity, Cellular; Pandemics; SARS-CoV-2; Vaccination; Viral Vaccines","Nel","Andr.. E","Division of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, United States",NA
"288","33789273","10.1159/000513164","Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.","Since early 2020, COVID-19 has wreaked havoc in many societies around the world. As of the present, the SARS-CoV-2-borne disease is propagating in almost all countries, affecting hundreds of thousands of people in an unprecedented way. As the name suggests, the novel coronavirus, widely known as SARS-CoV-2, is a new emerging human pathogen. A novel disease of relatively unknown origin, COVID-19 does not seem to be amenable to the currently available medicines since there is no specific cure for ","2021","05","04","Blood Purif","Blood purification","Convalescent blood transfusion; Plasma; SARS-CoV-2/2019-nCoV/COVID-19; Serum (sera); Therapy","Sheervalilou","Roghayeh","Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran",NA
"289","33789019","10.1056/NEJMe2105496","Audio Interview: Delivering Covid-19 Vaccines to Minority Communities.",NA,"2021","04","12","N Engl J Med","The New England journal of medicine","Attitude to Health; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Communication; Health Services Accessibility; Healthcare Disparities; Humans; Information Dissemination; Minority Groups; Trust","Rubin","Eric J",NA,NA
"290","33786833","10.1111/ajd.13593","SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.","As the phase III COVID-19 vaccine trials excluded patients on immunosuppressive treatments, or patients with significant autoimmunity, the Australasian Medical Dermatology Group make the following preliminary recommendations around COVID-19 vaccination in dermatology patients on immunomodulatory and/or biologic agents. Vaccination against COVID-19 is strongly encouraged for all patients on immunomodulatory drugs and/or biologic agents. There are currently insufficient data to recommend one COVID","2021","05","31","Australas J Dermatol","The Australasian journal of dermatology","COVID-19; SARS-CoV-2; biologic therapies; dermatology; immunomodulatory therapies; immunosuppressive therapies; vaccine; Biological Products; COVID-19; COVID-19 Vaccines; Contraindications, Drug; Humans; Immunologic Factors; SARS-CoV-2; Skin Diseases; Vaccination","Wang","Charlie","Skin Health Institute, Carlton, Victoria, Australia",NA
"291","33785459","10.1016/j.ijid.2021.03.068","Emergence and outcomes of the SARS-CoV-2 'Marseille-4' variant.","In Marseille, France, following a first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in March-May 2020, a second epidemic phase occurred from June, involving 10 new variants. The Marseille-4 variant caused an epidemic that started in August and is still ongoing. The 1038 SARS-CoV-2 whole genome sequences obtained in our laboratory by next-generation sequencing with Illumina technology were analysed using Nextclade and nextstrain/ncov pipelines and IQ-TREE. A Marseille-4-","2021","06","04","Int J Infect Dis","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","COVID-19; Marseille-4; Molecular epidemiology; Mutations; SARS-CoV-2; Spike; Variant; Animals; COVID-19; Epidemics; France; Genome, Viral; Humans; Mink; Molecular Epidemiology; Mutation; Phylogeny; Reinfection; SARS-CoV-2; Whole Genome Sequencing","Fournier","Pierre-Edouard","IHU M..diterran..e Infection, Marseille, France",NA
"292","33783724","10.1007/s40271-021-00508-0","United States COVID-19 Vaccination Preferences (CVP): 2020 Hindsight.","Shortly after the 2020 US election, initial evidence on first-generation COVID-19 vaccines showed 70-95% efficacy and minimal risks. Yet, many US adults expressed reluctance. The aim of this study was to compare persons willing and unwilling to be vaccinated against COVID-19 and to estimate the effects of vaccination attributes on uptake: proof of vaccination, vaccination setting, effectiveness, duration of immunity, and risk of severe side effects. Between 9 and 11 November 2020, 1153 US adults","2021","05","12","Patient","The patient","Adolescent; Adult; Age Factors; Aged; COVID-19; COVID-19 Vaccines; Choice Behavior; Female; Humans; Male; Middle Aged; Models, Econometric; Patient Preference; SARS-CoV-2; Sex Factors; Socioeconomic Factors; United States; Young Adult","Craig","Benjamin Matthew","Department of Economics, University of South Florida, CMC206A, 4202 E. Fowler Avenue, Tampa, FL, 33620, USA. bcraig@usf","bcraig@usf.edu"
"293","33780993","10.1055/a-1375-4471","[SARS-CoV-2 vaccines - what the nephrologist should know].","Only fifteen months after the beginning of the COVID-19 pandemic, several vaccines are already available for clinical use. While the spike protein of SARS-CoV-2 constitutes the main target of all predominant SARS-CoV-2 vaccines, they work by different mechanisms (mRNA-based vaccines vs. vector-based vaccines vs. protein-based vaccines).Though there are slight differences regarding the level of protection against mild COVID-19, all five vaccines that have been through phase 3 trials were nearly 1","2021","04","05","Dtsch Med Wochenschr","Deutsche medizinische Wochenschrift (1946)","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Immunosuppression; Immunosuppressive Agents; RNA, Messenger; Renal Insufficiency, Chronic; Uremia; Vaccines, Synthetic","Heine","Gunnar H","Medizinische Klinik II, AGAPLESION MARKUS KRANKENHAUS, Frankfurt",NA
"295","33778462","10.1016/j.jtauto.2021.100097","Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab.","The number of confirmed cases of infection with SARS-CoV-2, the virus causing Coronavirus disease 2019 (COVID-19), continues to increase and is associated with substantial morbidity and mortality in virtually every country in the world. Although in the long-term mass vaccinations remains the most promising approach to control the pandemic, evidence suggests that new variants of the virus have emerged that may be able to evade the immune responses triggered by current vaccines. Therefore despite ","2021","04","13","J Transl Autoimmun","Journal of translational autoimmunity","Coronavirus-disease-2019-(COVID-19); Extracorporeal-membrane-oxygenation-(ECMO); Leronlimab; SARS-CoV-2","Elneil","Sohier","University College London, National Hospital for Neurology and Neurosurgery, London, UK",NA
"296","33778130","10.1007/s13337-020-00650-7","Vaccines and drugs under clinical trials for prevention and treatment of COVID-19.","The uncertainty related to prevention and treatment of Coronavirus disease 2019 due to lack of effective vaccine candidates or drug molecules has resulted in extensive spread of infection and mortality worldwide. Although the asymptomatic or mild patients are becoming healthy with regular over-the-counter medicines and proper rest and care, for the severe patients, in the absence of definite cure, different drug combinations are being used to treat on trial basis without the assurance of efficac","2021","03","30","Virusdisease","Virusdisease","COVID19; Coronavirus; Pandemic; SARS-CoV-2; Severe acute respiratory syndrome; Vaccines","Yadav","Umesh C S","Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India",NA
"297","33773276","10.1016/j.ejca.2021.02.024","Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.","Coronavirus disease (COVID-19) is interfering heavily with the screening, diagnosis and treatment of cancer patients. Better knowledge of the seroprevalence and immune response after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in this population is important to manage them safely during the pandemic. 922 cancer patients, 100 non-cancer patients and 94 health care workers (HCW) attending the Multidisciplinary Oncology Unit of Antwerp University Hospital from 24th of Mar","2021","05","07","Eur J Cancer","European journal of cancer (Oxford, England : 1990)","COVID-19; Cancer; Health care workers; Immunoglobulin G; SARS-CoV-2; Seroconversion; Adolescent; Aged; Ambulatory Care; Antibodies, Viral; Belgium; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Case-Control Studies; Child; Child, Preschool; Cohort Studies; Female; Health Personnel; Humans; Immunoglobulin G; Male; Middle Aged; Neoplasms; Oncology Service, Hospital; Prospective Studies; Reagent Kits, Diagnostic; Reproducibility of Results; SARS-CoV-2; Seroconversion; Seroepidemiologic Studies","van Dam","Peter","Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Wilrijkstraat 10, Edegem, B-2650, Belgium","peter.vandam@uza.be"
"298","33773131","10.1016/S1473-3099(21)00159-6","Behind Cuba's successful pandemic response.",NA,"2021","04","14","Lancet Infect Dis","The Lancet. Infectious diseases","Biotechnology; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Cuba; Drug Development; Humans; International Cooperation; Intersectoral Collaboration; Mass Vaccination; Pandemics","Burki","Talha",NA,NA
"299","33773111","10.1016/S1473-3099(21)00127-4","Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.","Although several COVID-19 vaccines have been developed so far, they will not be sufficient to meet the global demand. Development of a wider range of vaccines, with different mechanisms of action, could help control the spread of SARS-CoV-2 globally. We developed a protein subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen. We aimed to assess the safety and immunogenicity of this vaccine, ZF2001, and determine","2021","03","29","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Yang","Shilong","Anhui Zhifei Longcom Biopharmaceutical, Hefei, China",NA
"300","33772572","10.1093/intimm/dxab013","Development of COVID-19 vaccines utilizing gene therapy technology.","There is currently an outbreak of respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) is caused by infection with SARS-CoV-2. Individuals with COVID-19 have symptoms that are usually asymptomatic or mild in most initial cases. However, in some cases, moderate and severe symptoms have been observed with pneumonia. Many companies are developing COVID-19 vaccine candidates using different technologies that are classified in","2021","05","04","Int Immunol","International immunology","SARS-CoV-2; gene therapy; virus vector","Nakagami","Hironori","Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Yamada-oka, Suita, Osaka, Japan",NA
"301","33772240","10.1038/d41586-021-00576-0","Scandal over COVID vaccine trial at Peruvian universities prompts outrage.",NA,"2021","04","14","Nature","Nature","Politics; Public health; SARS-CoV-2; Vaccines; COVID-19 Vaccines; Clinical Protocols; Clinical Trials, Phase III as Topic; Family Health; Federal Government; Female; Humans; Male; Peru; Politics; Public Opinion; Research Personnel; Trust; Universities","Taylor","Luke",NA,NA
"302","33771665","10.1016/j.annonc.2021.03.199","Immunotherapy use outside clinical trial populations: never say never?","Based on favourable outcomes in clinical trials, immune checkpoint inhibitors (ICIs), most notably programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors, are now widely used across multiple cancer types. However, due to their strict inclusion and exclusion criteria, clinical studies often do not address challenges presented by non-trial populations. This review summarises available data on the efficacy and safety of ICIs in trial-ineligible patients, inc","2021","06","09","Ann Oncol","Annals of oncology : official journal of the European Society for Medical Oncology","CTLA-4; PD-1; checkpoint inhibitors; immunotherapy; special populations; Aged; COVID-19; Child; Humans; Immunologic Factors; Immunotherapy; Neoplasms; SARS-CoV-2","Rzeniewicz","K","Warwick Medical School, University of Warwick, Warwick, UK",NA
"303","33771391","10.1016/j.vaccine.2021.02.056","Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use.","Multiple candidates of COVID-19 vaccines have entered Phase III clinical trials in the United States (US). There is growing optimism that social distancing restrictions and face mask requirements could be eased with widespread vaccine adoption soon. We developed a dynamic compartmental model of COVID-19 transmission for the four most severely affected states (New York, Texas, Florida, and California). We evaluated the vaccine effectiveness and coverage required to suppress the COVID-19 epidemic ","2021","04","15","Vaccine","Vaccine","COVID-19 vaccine; Face mask use; Social distancing; Vaccine coverage; Vaccine effectiveness; COVID-19; COVID-19 Vaccines; California; Florida; Humans; Masks; Models, Theoretical; New York; Physical Distancing; Texas; United States","Shen","Mingwang","China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China",NA
"304","33770576","10.1016/j.ejca.2021.01.046","SARS-CoV-2 vaccines for cancer patients: a call to action.","Coronavirus disease 2019 (COVID-19) has affected more than 96 million people worldwide, leading the World Health Organization (WHO) to declare a pandemic in March 2020. Although an optimal medical treatment of COVID-19 remains uncertain, an unprecedented global effort to develop an effective vaccine hopes to restore pre-pandemic conditions. Since cancer patients as a group have been shown to be at a higher risk of severe COVID-19, the development of safe and effective vaccines is crucial. Howeve","2021","05","07","Eur J Cancer","European journal of cancer (Oxford, England : 1990)","Advocacy; COVID-19; Cancer; Pandemics; Public health; Sars-CoV-2; Trial; Vaccine; COVID-19; COVID-19 Vaccines; Drug Approval; Drug Development; Humans; Neoplasms; SARS-CoV-2; Vaccines, Attenuated; Vaccines, Inactivated; Vaccines, Subunit; Vaccines, Synthetic; Vaccines, Virus-Like Particle","Corti","Chiara","Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy",NA
"305","33768743","","Human Challenge Trials: Ethical and Legal Issues for COVID-19 Research.","COVID-19 has generated a new and distinctive focus on the use of human challenge studies, also known as controlled human infection trials. The first such trial was authorised in England in February 2021. Although vaccines are now available for COVID-19, there remain multiple deficits in knowledge in respect of treatment and prevention of the infection and a powerful impetus for solutions given the level of its global morbidity and mortality. Thus, there are potent incentives for unorthodox accel","2021","03","29","J Law Med","Journal of law and medicine","COVID-19; clinical research; consent; controlled human infection trials; ethics; human challenge trials; COVID-19; England; Ethics, Research; Humans; Research Design; SARS-CoV-2","Freckelton","Ian","Barrister, Castan Chambers, Melbourne, Victoria, Australia",NA
"306","33767619","10.3389/fphar.2021.583387","Plant Products as Inhibitors of Coronavirus 3CL Protease.","Background: The ongoing COVID-19 pandemic has created an alarming situation due to extensive loss of human lives and economy, posing enormous threat to global health security. Till date, no antiviral drug or vaccine against SARS-CoV-2 has reached the market, although a number of clinical trials are under way. The viral 3-chymotrypsin-like cysteine protease (3CL<sup>pro</sup>), playing pivotal roles in coronavirus replication and polyprotein processing, is essential for its life cycle. In ","2021","03","27","Front Pharmacol","Frontiers in pharmacology","3-chymotrypsin-like cysteine protease; SARS-CoV-2; coronavirus disease 2019; main protease; plant products; plant-derived 3CLpro inhibitors","Mandal","Anirban","Department of Microbiology, Mrinalini Datta Mahavidyapith, Kolkata, India",NA
"307","33767200","10.1038/s41541-021-00313-8","The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization.","Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7-2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical ","2021","06","04","NPJ Vaccines","NPJ vaccines",NA,"Zou","Jing","Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA",NA
"308","33766863","10.1126/science.371.6536.1294","New problems erode confidence in AstraZeneca's vaccine.",NA,"2021","04","12","Science","Science (New York, N.Y.)","Blood Coagulation Disorders; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Drug Industry; Europe; Humans; Immunization Programs; Immunogenicity, Vaccine; United States","Vogel","Gretchen",NA,NA
"309","33764580","10.1002/hpm.3156","Decreasing transmission and initiation of countrywide vaccination: Key challenges for future management of COVID-19 pandemic in Bangladesh.","With a fragile healthcare system, Bangladesh, much like other countries in South East Asia, struggled during the early days of COVID-19 pandemic. In following months several encouraging initiatives were undertaken including nationwide lockdown, maintaining social distancing and setting up COVID-19 dedicated laboratories and hospitals. Despite fear of an escalation in COVID-19 transmission during the winter months like their European counterparts, fortunately infection rates subsided and Banglade","2021","03","25","Int J Health Plann Manage","The International journal of health planning and management","Bangladesh; COVID-19; ICU; PCR; SARS-CoV-2; vaccination","Molla","Md Maruf Ahmed","Department of Virology, National Institute of Laboratory Medicine and Referral Center, Dhaka, Bangladesh",NA
"310","33761791","10.1177/2515690X211003727","A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.","Currently, the coronavirus disease 2019 (COVID-19) is a big challenge to the healthcare systems in the world. Several researchers in the world have immediately carried out clinical investigations for the discovery of vaccines and drugs. Different studies have shown that antiviral measures including small bioactive compounds targeting multifaceted molecular communications take in COVID-19 infection. The drug development archived in this review emphasizes mainly on drugs that are effective for the","2021","04","05","J Evid Based Integr Med","Journal of evidence-based integrative medicine","antiviral drugs; coronavirus; vaccines; Antibodies, Viral; Antiviral Agents; COVID-19; Humans; Middle East Respiratory Syndrome Coronavirus; SARS Virus; SARS-CoV-2; Viral Vaccines","Kifle","Zemene Demelash","2057University of Gondar, College of Medicine and Health Sciences, Gondar, Ethiopia",NA
"311","33760277","10.1111/bcp.14828","Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?",NA,"2021","04","30","Br J Clin Pharmacol","British journal of clinical pharmacology","AstraZeneca vaccine; COVID-19; SARS-CoV-2; efficacy; elderly; placebo-controlled trials","Dal-R..","Rafael","Health Research Institute-Fundaci..n Jim..nez D..az University Hospital, Universidad Aut..noma de Madrid, Madrid, Spain",NA
"312","33758378","10.1038/s41571-021-00503-2","Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.",NA,"2021","05","26","Nat Rev Clin Oncol","Nature reviews. Clinical oncology",NA,"Desai","Aakash","Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA",NA
"313","33758124","10.1097/CRD.0000000000000386","The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5.",NA,"2021","04","14","Cardiol Rev","Cardiology in review","Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; COVID-19; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Glucocorticoids; Humans; Janus Kinase Inhibitors; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides","Frishman","William H","Department of Cardiology and Medicine, New York Medical College, Westchester Health Care System, Valhalla, NY, William.Frishman@wmchealth","William.Frishman@wmchealth.org"
"314","33757958","10.1136/bmj.n807","Covid-19: Officials query data from AstraZeneca's US vaccine trial.",NA,"2021","03","25","BMJ","BMJ (Clinical research ed.)",NA,"Kmietowicz","Zosia","The BMJ",NA
"315","33755218","10.1002/jmv.26954","Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients.","As public distribution of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is underway, prevention of coronavirus disease 2019 (COVID-19) relies on minimizing spread. In this study, chlorhexidine gluconate was investigated as a topical antimicrobial agent against SARS-CoV-2. This was a randomized, prospective cohort study using chlorhexidine as an oral rinse and posterior oropharyngeal spray in hospitalized COVID-19 patients. The primary outcome was presence or absen","2021","06","08","J Med Virol","Journal of medical virology","COVID-19; SARS-CoV-2; antiviral agents; coronavirus; disinfectants; dissemination; epidemiology; shedding; Adult; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; Chlorhexidine; Female; Humans; Male; Middle Aged; Mouthwashes; Prospective Studies; SARS-CoV-2; Young Adult","Huang","Y Hanna","Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA",NA
"316","33755190","10.1002/jcp.30367","Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.","The evolution of the SARS-CoV-2 new variants reported to be 70% more contagious than the earlier one is now spreading fast worldwide. There is an instant need to discover how the new variants interact with the host receptor (ACE2). Among the reported mutations in the Spike glycoprotein of the new variants, three are specific to the receptor-binding domain (RBD) and required insightful scrutiny for new therapeutic options. These structural evolutions in the RBD domain may impart a critical role t","2021","03","23","J Cell Physiol","Journal of cellular physiology","KD..(dissociation constant); MD simulation; SARS-CoV-2; new variants; protein-protein docking","Khan","Abbas","Department of Bioinformatics and Biological Statistics, Shanghai Jiao Tong University, Shanghai, P.R. China",NA
"317","33754539","","SARS-CoV2 Outbreak: Emergence, transmission and clinical features of human coronaviruses.","The novel coronavirus was emerged from China Wuhan city and spread around the globe within a few days. COVID-19 is rapidly transmitted from one human to another, and it is also a highly pathogenic infection. Genetic analysis confirmed that SARS-CoV 2 is phenotypically related to SARS-CoV; therefore, the possible reservoir for SARS-CoV 2 could be bats. According to WHO more than 20 million individuals infected with SARS-CoV 2 while more than 700,000 peoples lost their lives due to COVID-19 as of ","2021","04","05","J Ayub Med Coll Abbottabad","Journal of Ayub Medical College, Abbottabad : JAMC"," Human Coronavirus; SARS-CoV 2; Transmission of COVID-19; Treatment of coronavirus; Vaccine; COVID-19; Disease Transmission, Infectious; Global Health; Humans; Pandemics; RNA, Viral; SARS-CoV-2","Imran","Muhammad","College of Physicians &amp",NA
"318","33753733","10.1038/s41467-021-22102-6","A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies.","Better diagnostic tools are needed to combat the ongoing COVID-19 pandemic. Here, to meet this urgent demand, we report a homogeneous immunoassay to detect IgG antibodies against SARS-CoV-2. This serological assay, called SATiN, is based on a tri-part Nanoluciferase (tNLuc) approach, in which the spike protein of SARS-CoV-2 and protein G, fused respectively to two different tNLuc tags, are used as antibody probes. Target engagement of the probes allows reconstitution of a functional luciferase i","2021","04","07","Nat Commun","Nature communications","Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Testing; Enzyme-Linked Immunosorbent Assay; HEK293 Cells; Humans; Immunoassay; Immunoglobulin G; Immunoglobulin M; Luciferases; SARS-CoV-2; Spike Glycoprotein, Coronavirus","Yao","Zhong","Donnelly Centre, University of Toronto, Toronto, ON, Canada",NA
"319","33753421","10.1136/gutjnl-2021-324388","Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.","Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections. Antibody responses in participants treated with infliximab were compared with a reference cohort treated with vedolizumab, a gut-selective anti-integrin ..4..7 monoclonal ant","2021","04","15","Gut","Gut","COVID-19; autoimmune disease; clarity; inflammatory bowel disease; inflammatory diseases; infliximab; vedoluzimab; Adult; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Antibody Formation; COVID-19; Female; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Male; Middle Aged; Prospective Studies; SARS-CoV-2; Serologic Tests; United Kingdom","Kennedy","Nicholas A","Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK",NA
"320","33751699","10.1111/jeb.13771","Variable routes to genomic and host adaptation among coronaviruses.","Natural selection operating on the genomes of viral pathogens in different host species strongly contributes to adaptation facilitating host colonization. Here, we analyse, quantify and compare viral adaptation in genomic sequence data derived from seven zoonotic events in the Coronaviridae family among primary, intermediate and human hosts. Rates of nonsynonymous (dN ) and synonymous (dS ) changes on specific amino acid positions were quantified for each open reading frame","2021","03","31","J Evol Biol","Journal of evolutionary biology","coronaviruses; genomics; molecular evolution; role of selection in host switches; spike protein; viral adaptation; zoonoses","Montoya","Vincent","British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada",NA
"321","33749864","10.5694/mja2.50991","The evolution of clinical trials in response to COVID-19.",NA,"2021","04","28","Med J Aust","The Medical journal of Australia","COVID-19; Clinical trials as topic; Infectious diseases; Respiratory tract infections; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Pandemics; Research Design; SARS-CoV-2","Sarah","Alana","University Hospital Geelong, Barwon Health, Geelong, VIC",NA
"322","33748858","10.1093/jtm/taab040","Morocco achieves the highest COVID-19 vaccine rates in Africa in the first phase: what are reasons for its success?",NA,"2021","06","02","J Travel Med","Journal of travel medicine",NA,"Drissi Bourhanbour","Asmaa","Laboratory of Immunology, Ibn Rochd University Hospital Center, 20000 Casablanca, Morocco",NA
"323","33748833","10.1093/eurheartj/ehab133","Influenza vaccination: a 'shot' at INVESTing in cardiovascular health.","The link between viral respiratory infection and non-pulmonary organ-specific injury, including cardiac injury, has become increasingly appreciated during the current coronavirus disease 2019 (COVID-19) pandemic. Even prior to the pandemic, however, the association between acute infection with influenza and elevated cardiovascular risk was evident. The recently published results of the NHLBI-funded INfluenza Vaccine to Effectively Stop CardioThoracic Events and Decompensated (INVESTED) trial, a ","2021","05","27","Eur Heart J","European heart journal","Cardiovascular prevention; Heart failure; Influenza vaccination; Myocardial infarction; COVID-19; Humans; Influenza Vaccines; Influenza, Human; Pandemics; SARS-CoV-2; Vaccination","Bhatt","Ankeet S","Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Sreet, Boston, MA 02115, USA",NA
"324","33748805","10.1016/j.idnow.2021.03.001","Mosaic vaccination schedule: An unexpected card to play against SARS-CoV-2?",NA,"2021","05","11","Infect Dis Now","Infectious diseases now","Clinical trial; Coronavirus; Covid-19; SARS-CoV-2; Vaccine candidates; Vaccine development","Ricco","Matteo","AUSL-IRCCS di Reggio Emilia, Servizio di Prevenzione e Sicurezza negli ambienti di Lavoro (SPSAL), Via Amendola n.2, Reggio Emilia (RE), Italy. Electronic address: matteo.ricco@ausl.re","matteo.ricco@ausl.re.it"
"325","33748571","10.1021/acsomega.0c05163","SARS-CoV-2 Genome from the Khyber Pakhtunkhwa Province of Pakistan.","Among viral outbreaks, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the deadliest ones, and it has triggered the global COVID-19 pandemic. In Pakistan, until 5th September 2020, a total of 6342 deaths have been reported, of which 1255 were from the Khyber Pakhtunkhwa (KPK) province. To understand the disease progression and control and also to produce vaccines and therapeutic efforts, whole genome sequence analysis is important. In the current investigation, we sequ","2021","03","23","ACS Omega","ACS omega",NA,"Khan","Muhammad Tahir","Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, KM Defence Road, Lahore 58810, Pakistan",NA
"326","33746660","10.1007/s10989-021-10196-x","In-Silico Drug Designing of Spike Receptor with Its ACE2 Receptor and Nsp10/Nsp16 MTase Complex Against SARS-CoV-2.","The realm Riboviria constitutes Coronaviruses, which led to the emergence of the pandemic COVID 19 in the twenty-first century affected millions of lives. At present, the management of COVID 19 largely depends on antiviral therapeutics along with the anti-inflammatory drug. The vaccine is under the final clinical phase, and emergency use is available. We aim at ACE2 and Nsp10/Nsp16 MTase as potential drug candidate in COVID 19 management in the present work. For drug designing, various computati","2021","03","23","Int J Pept Res Ther","International journal of peptide research and therapeutics","Molecular docking; Molecular dynamics; Nsp10/Nsp16 complex; Scoring functions; Spike protein","Siddiqa","M A","Department of Biotechnological, Acharya Nagarjuna University, Guntur, Andhra Pradesh India",NA
"327","33746095","10.1016/j.ijid.2021.03.050","Interim estimates in null models of COVID-19 vaccine effectiveness.","Recently released interim numbers from advanced vaccine candidate clinical trials suggest that a COVID-19 vaccine effectiveness (VE) of &gt;90% is achievable. However, SARS-CoV-2 transmission dynamics are highly heterogeneous and exhibit localized bursts of transmission, which may lead to sharp localized peaks in the number of new cases, often followed by longer periods of low incidence. Here we show that, for interim estimates of VE, these characteristic bursts in SARS-CoV-2 infection may intro","2021","06","04","Int J Infect Dis","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","COVID-19; SARS-CoV-2; Vaccine; Vaccine candidate; Vaccine effectiveness; Bias; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Models, Statistical; SARS-CoV-2; Statistical Distributions","Lisewski","Andreas Martin","Department of Life Sciences and Chemistry/Focus Area Health, Jacobs University Bremen, 28759 Bremen, Germany. Electronic address: a.lisewski@jacobs-university",NA
"328","33745730","10.1016/j.vaccine.2021.03.036","The social experience of participation in a COVID-19 vaccine trial: Subjects' motivations, others' concerns, and insights for vaccine promotion.","Vaccine hesitancy could undermine the effectiveness of COVID-19 vaccination programs. Knowledge about people's lived experiences regarding COVID-19 vaccination can enhance vaccine promotion and increase uptake. To use COVID-19 vaccine trial participants' experiences to identify key themes in the lived experience of vaccination early in the vaccine approval and distribution process. We interviewed 31 participants in the Iowa City, Iowa US site of the Pfizer/BioNTech COVID-19 vaccine phase 3 clini","2021","04","28","Vaccine","Vaccine","Clinical trial; Covid-19; Qualitative research; Vaccine hesitancy; Vaccine uptake; COVID-19; COVID-19 Vaccines; Humans; Iowa; Motivation; SARS-CoV-2; Vaccines","Wentzell","Emily","Department of Anthropology, 114 Macbride Hall, The University of Iowa, Iowa City, IA 52242-1322, USA. Electronic address: emily-wentzell@uiowa","wentzell@uiowa.edu"
"329","33744042","10.1016/j.vaccine.2021.03.039","Natural unblinding of BCG vaccination trials.","There is significant public and clinical interest in the potential for Bacillus Calmette-Gu..rin (BCG) vaccination to protect against type 2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) induced COVID-19. This question could be best answered by blinded and placebo controlled clinical trials. However, a skin reaction occurs within days at the site of BCG injection, making it rather challenging to blind this vaccination. Here, we examined registered clinical trials in ClinicalTrials.g","2021","04","15","Vaccine","Vaccine","BCG; Blinding; COVID-19; Clinical trial; Placebo; BCG Vaccine; COVID-19; Clinical Trials as Topic; Double-Blind Method; Humans; Research Design; Single-Blind Method; Vaccination","Szigeti","Reka","Department of Pathology &amp",NA
"330","33743992","10.1016/j.identj.2021.01.013","Fear of COVID-19 in Madrid. Will patients avoid dental care?","The objective of this research is to describe how perceived infectability, germ aversion, and fear of COVID-19 in adults in Madrid have changed from the beginning of the pandemic until the lockdown exit phase and their influence on dental care behaviour. Some 961 participants were monitored in a study in Madrid at 2 time points: before lockdown (T0) and after completion of the total lockdown (T1). A questionnaire that included basic sociodemographic variables, the perceived vulnerability to dise","2021","03","25","Int Dent J","International dental journal","Anxiety; COVID-19; Coronavirus infections; Disease avoidance; Perceived fear to disease","Gonz..lez-Olmo","Mar..a Jos..","Dentistry Department, Rey Juan Carlos University, Madrid, Spain. Electronic address: mariajose.gonzalez@urjc","mariajose.gonzalez@urjc.es"
"331","33743846","10.1016/S1473-3099(21)00079-7","The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.","In response to the COVID-19 pandemic, the UK first adopted physical distancing measures in March, 2020. Vaccines against SARS-CoV-2 became available in December, 2020. We explored the health and economic value of introducing SARS-CoV-2 immunisation alongside physical distancing in the UK to gain insights about possible future scenarios in a post-vaccination era. We used an age-structured dynamic transmission and economic model to explore different scenarios of UK mass immunisation programmes ove","2021","03","26","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Sandmann","Frank G","Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene &amp","frank.sandmann@phe.gov.uk"
"332","33743214","10.1016/j.puhe.2021.01.011","Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes.","Public health professionals and clinicians, in many countries, are immersed in the ongoing and upcoming vaccination programmes for COVID-19. Published information from vaccine trials is complex. There are important and helpful insights about the nature of the available and forthcoming vaccines, immune responses and side-effects from phase II trials. We have systematically summarised information from 10 such trials on the nature of the vaccines, exclusions from the trials, immunological effects a","2021","05","13","Public Health","Public health","COVID-19; Public health; SARS-CoV-2; Vaccination; Vaccine; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase II as Topic; Humans; Immunization Programs; Public Health","Bhopal","Sunil S","Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK. Electronic address: sunil.bhopal@newcastle.ac","sunil.bhopal@newcastle.ac.uk"
"333","33741502","10.1016/j.jclinepi.2021.03.006","New placebo-controlled Covid-19 vaccine trials are ethically questionable; it's now about comparative effectiveness and availability of registered vaccines.",NA,"2021","06","03","J Clin Epidemiol","Journal of clinical epidemiology","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Comparative Effectiveness Research; Humans; Placebos; Vaccination","Knottnerus","J Andr..","Department of General Practice, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University/Maastricht University Medical Centre+, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Electronic address: andre.knottnerus@maastrichtuniversity","andre.knottnerus@maastrichtuniversity.nl"
"334","33738620","10.1007/s10096-021-04221-6","Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran.","COVID-19 immunity in infected individuals may not be persistent. The specific response wanes in patients who have recovered from this infection. Nevertheless, it has not been fully understood whether true re-infection occurs or the viral reactivation. In this study, we investigated three COVID-19 patients who represented the symptoms after recovery. Chest CT scan was applied to assess the patients along with the viral samples from oropharyngeal/nasopharyngeal which were subjected to RT-PCR. The ","2021","03","21","Eur J Clin Microbiol Infect Dis","European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology","COVID-19; Re-infection; Reactivation; SARS-CoV-2","Salehi-Vaziri","Mostafa","COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran",NA
"335","33737439","10.1136/bmjopen-2020-044899","COVID-19 symptom surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study.","To describe the frequency of symptoms compatible with SARS-CoV-2 infection in immunocompromised children and young people in the UK during the SARS-CoV-2 pandemic. To describe patient/parent anxiety regarding SARS-CoV-2 infection in this cohort. A prospective observational cohort study. 46 centres across the UK between 16 March and 4 July 2020. A weekly online questionnaire based on the International Severe Acute Respiratory and emerging Infections Consortium-WHO Case Report Form was used to col","2021","03","23","BMJ Open","BMJ open","COVID-19; immunology; paediatric infectious disease &amp; immunisation; paediatrics; Adolescent; Anxiety; COVID-19; COVID-19 Testing; Child; Female; Humans; Male; Prospective Studies; State Medicine; United Kingdom","Shaunak","Meera","NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK",NA
"336","33737373","10.1542/peds.2020-038356","Early Life RSV: Can Vaccines Help Fix Societal Ills?",NA,"2021","03","19","Pediatrics","Pediatrics",NA,"Caserta","Mary T","Division of Infectious Diseases, Departments of Pediatrics and mary_caserta@urmc.rochester","caserta@urmc.rochester.edu"
"337","33737124","10.1016/j.gene.2021.145574","Epidemiological transcriptomic data supports BCG protection in viral diseases including COVID-19.","Epidemiological and clinical evidence suggests that Bacille Calmette-Gu..rin (BCG) vaccine induced trained immunity protects against non-specific infections. Multiple clinical trials are currently underway to assess effectiveness of the vaccine in the coronavirus disease 2019 (COVID-19). However, the durability and mechanism of BCG trained immunity remain unclear. Here, an integrative analysis of available epidemiological transcriptomic data related to BCG vaccination and respiratory tract viral","2021","04","14","Gene","Gene","BCG vaccine; COVID-19; Gene expression; Trained immunity; Transcriptome; Adult; Antiviral Agents; BCG Vaccine; COVID-19; Child; Datasets as Topic; Gene Expression Profiling; Humans; Immunity, Innate; Infant; Respiratory Tract Infections; Transcriptome; Virus Diseases","Sharma","Abhay","CSIR-Institute of Genomics and Integrative Biology, Sukhdev Vihar, Mathura Road, New Delhi 110025 India. Electronic address: abhaysharma@igib.res","abhaysharma@igib.res.in"
"338","33734524","10.1002/uog.23631","Benefits...and...potential...harms...of...COVID-19 vaccination during pregnancy: evidence summary for patient counseling.",NA,"2021","05","12","Ultrasound Obstet Gynecol","Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology","Adult; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Counseling; Female; Humans; Infectious Disease Transmission, Vertical; Patient Education as Topic; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome","Kalafat","E","Koc University, School of Medicine, Department of Obstetrics and Gynaecology, Istanbul, Turkey",NA
"339","33734072","","[Development and use of vaccines from the 18th century to the SARS-CoV 2 period].","This review is about the development and use of vaccines from the early smallpox vaccine in the 18th century to the forthcoming SARS-CoV 2 vaccines. Immunisations have been of paramount importance for childhood mortality and public health in general, but some obstacles have also been encountered such as vaccine failures and vaccine scepticism. This calls for continued emphasis on large phase three studies not only for demonstration of efficacy but also for safety and possible side effects. The r","2021","03","25","Ugeskr Laeger","Ugeskrift for laeger","COVID-19; COVID-19 Vaccines; Child; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; Humans; SARS-CoV-2; Smallpox Vaccine; Vaccines","Skinh..j","Peter","skinh..j@dadlnet","skinh..j@dadlnet.dk"
"340","33733663","10.1093/trstmh/trab045","COVID-19 vaccines for low- and middle-income countries.","The COVID-19 pandemic is the biggest threat to public health in a century. Through hard work and ingenuity, scientists have developed a number of safe and effective vaccines against COVID-19 disease. However, demand far outstrips supply and countries around the world are competing for available vaccines. This review describes how low- and middle-income countries access COVID-19 vaccines, what is being done to distribute vaccines fairly, as well as the challenges ahead.","2021","05","27","Trans R Soc Trop Med Hyg","Transactions of the Royal Society of Tropical Medicine and Hygiene","2019 novel coronavirus disease clinical trial; COVID-19; low- and middle-income countries; severe acute respiratory syndrome coronavirus 2; vaccines; COVID-19; COVID-19 Vaccines; Developing Countries; Humans; Pandemics; SARS-CoV-2","Choi","Edward M","Department of Clinical Research, London School of Hygiene &amp",NA
"341","33732150","10.3389/fphar.2021.576448","A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management.","The 2019 novel coronavirus (2019-nCoV), commonly known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19), was first revealed in late 2019 in Wuhan city, Hubei province, China. It was subsequently spread globally and thereby declared as a pandemic by WHO in March 2020. The disease causes severe acute respiratory illness and is highly contagious due to the fast-onward transmission. As of the mid of November 2020, the disease has affected 220 cou","2021","03","20","Front Pharmacol","Frontiers in pharmacology","COVID-19; SARS-CoV-2; azithromycin; coronavirus; dexamethasone; hydroxychloroquine; remdesivir; vaccines","Shoaib","Muhammad Harris","Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan",NA
"342","33731687","10.1038/s41398-021-01279-w","Psychiatric symptoms and behavioral adjustment during the COVID-19 pandemic: evidence from two population-representative cohorts.","This study examined prevalences of anxiety and depression and their correlations with daily routines among Hong Kong Chinese during the COVID-19 pandemic. Random digit dialing recruited two population-representative samples of 6029 residents during a period of low infection and limited intervention (survey 1: n...=...4021) and high incidence and intensive measures (survey 2: n...=...2008). Prevalence of anxiety for survey 1 and survey 2 were 14.9% and 14% and depression were 19.6% and 15.3%, res","2021","03","29","Transl Psychiatry","Translational psychiatry","Adaptation, Psychological; Adolescent; Adult; Aged; Anxiety; COVID-19; COVID-19 Vaccines; Cohort Studies; Communicable Disease Control; Depression; Disinfection; Female; Hand Disinfection; Health Behavior; Hong Kong; Humans; Male; Masks; Middle Aged; Physical Distancing; Prevalence; Young Adult","Hou","Wai Kai","Department of Psychology, The Education University of Hong Kong, Hong Kong, SAR, China. wkhou@eduhk","wkhou@eduhk.hk"
"343","33731427","10.9778/cmajo.20200290","Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study.","Emergency physicians lack high-quality evidence for many diagnostic and treatment decisions made for patients with suspected or confirmed coronavirus disease 2019 (COVID-19). Our objective is to describe the methods used to collect and ensure the data quality of a multicentre registry of patients presenting to the emergency department with suspected or confirmed COVID-19. This methodology study describes a population-based registry that has been enrolling consecutive patients presenting to the e","2021","03","25","CMAJ Open","CMAJ open","COVID-19; Canada; Data Accuracy; Data Collection; Data Management; Emergency Medicine; Emergency Service, Hospital; Evidence-Based Emergency Medicine; Follow-Up Studies; Humans; Information Storage and Retrieval; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Registries; Retrospective Studies; SARS-CoV-2; Telephone","Hohl","Corinne M","Department of Emergency Medicine (Hohl, Taylor, Andolfatto, Ting, Brar, Stachura), University of British Columbia","corinne.hohl@ubc.ca"
"344","33730597","10.1016/j.cell.2021.02.037","Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.","The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. These variants have multiple changes in the immunodominant spike protein that facilitates viral cell entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Mutations","2021","05","13","Cell","Cell","ACE2; B.1.351; SARS-CoV-2; South Africa; antibody; escape; neutralization; receptor-binding domain; vaccine; variant; Animals; Antibodies, Monoclonal; COVID-19; COVID-19 Vaccines; Chlorocebus aethiops; Clinical Trials as Topic; HEK293 Cells; Humans; Immunization, Passive; Models, Molecular; Mutation; Neutralization Tests; Protein Binding; SARS-CoV-2; Vero Cells","Zhou","Daming","Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK",NA
"345","33730580","10.1016/j.celrep.2021.108852","Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies.","As the global COVID-19 pandemic progresses, it is paramount to gain knowledge on adaptive immunity to SARS-CoV-2 in children to define immune correlates of protection upon immunization or infection. We analyzed anti-SARS-CoV-2 antibodies and their neutralizing activity (PRNT) in 66 COVID-19-infected children at 7 (..2) days after symptom onset. Individuals with specific humoral responses presented faster virus clearance and lower viral load associated with a reduced in..vitro infectivity. We dem","2021","04","01","Cell Rep","Cell reports","Ab-mediated neutralization activity; COVID-19; SARS-CoV-2; anti-SARS-CoV-2 antibodies; antigen-specific B cells; antigen-specific CD4 T..cells; pediatric COVID-19; proteomic profiling; Adaptive Immunity; Antibodies, Neutralizing; Antibodies, Viral; B-Lymphocytes; CD4-Positive T-Lymphocytes; COVID-19; Child; Humans; Immunity, Humoral; Proteome; SARS-CoV-2; Signal Transduction; Viral Load","Cotugno","Nicola","Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Ges.. Children's Hospital, IRCCS, 00165 Rome, Italy",NA
"346","33730471","10.1056/NEJMc2102179","Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.",NA,"2021","05","11","N Engl J Med","The New England journal of medicine","Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Humans; Mutation; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Statistics, Nonparametric; Vaccines, Synthetic","Wu","Kai","Moderna, Cambridge, MA",NA
"347","33728277","10.2147/ITT.S280706","Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches.","Coronavirus disease 2019 (Covid-19), caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can range in severity from asymptomatic to severe/critical disease. SARS-CoV-2 uses angiotensin-converting enzyme 2 to infect cells leading to a strong inflammatory response, which is most profound in patients who progress to severe Covid-19. Recent studies have begun to unravel some of the differences in the innate and adaptive immune response to SARS-CoV-2 in patie","2021","03","18","Immunotargets Ther","ImmunoTargets and therapy","SARS-CoV-2; autoantibodies; cytokines; immune regulation; inflammation; neutralizing antibodies; type I interferon","Hasan","Amal","Department of Immunology and Microbiology, Research Division, Dasman Diabetes Institute, Dasman, Kuwait City, Kuwait",NA
"348","33728098","10.4110/in.2021.21.e5","Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.","Coronavirus disease 2019 (COVID-19) has developed as a pandemic, and it created an outrageous effect on the current healthcare and economic system throughout the globe. To date, there is no appropriate therapeutics or vaccines against the disease. The entire human race is eagerly waiting for the development of new therapeutics or vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Efforts are being taken to develop vaccines at a rapid rate for fighting against the ongo","2021","03","18","Immune Netw","Immune network","COVID-19; Clinical trial; Repurposed vaccines; SARS-CoV-2; Vaccines","Chakraborty","Chiranjib","Department of Biotechnology, School of Life Science &amp",NA
"349","33727699","10.1038/s41591-021-01299-5","Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.",NA,"2021","04","28","Nat Med","Nature medicine","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Placebo Effect; SARS-CoV-2; World Health Organization","Singh","Jerome Amir","Howard College School of Law, University of KwaZulu-Natal, Durban, South Africa. singhj9@ukzn.ac","singhj9@ukzn.ac.za"
"350","33727379","10.46747/cfp.6703185","COVID-19 vaccine fast facts.",NA,"2021","03","23","Can Fam Physician","Canadian family physician Medecin de famille canadien","Adult; Adverse Drug Reaction Reporting Systems; Aged; COVID-19; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Female; Humans; Immunization Schedule; Male; Middle Aged; Randomized Controlled Trials as Topic; United States; Vaccination","Kolber","Michael R","Professor in the Department of Family Medicine at the University of Alberta in Edmonton",NA
"351","33725432","10.1056/NEJMoa2102214","Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.","Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa. We conducted a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not inf","2021","05","25","N Engl J Med","The New England journal of medicine","Adenoviridae; Adolescent; Adult; Antibodies, Neutralizing; COVID-19; COVID-19 Serological Testing; COVID-19 Vaccines; Double-Blind Method; Humans; Immunogenicity, Vaccine; Middle Aged; SARS-CoV-2; South Africa; T-Lymphocytes; Treatment Failure; Vaccine Potency; Young Adult","Madhi","Shabir A","From the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (S.A.M., V.B., A.L.K., G.K., S.B., J.P., A.J., M.L., S.M., A.M., C.T., A.T., A.I.), African Leadership in Vaccinology Expertise (C.L.C.), Wits Reproductive Health and HIV Institute (L.F., E.H., M. Masenya, F.P., S.E.), the Antibody Immunity Research Unit, School of Pathology (J.N.B., C.K.W., P.L.M.), and the Perinatal HIV Research Unit (C.B.), Faculty of Health Sciences, and the Department of Science and Innovation/National Research Foundation South African Research Chair Initiative in Vaccine Preventable Diseases Unit (S.A.M., V.B., A.L.K., G.K., S.B., A.I.), University of the Witwatersrand, and the National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS) (J.N.B., C.K.W., P.L.M.), Johannesburg, Setshaba Research Centre, Tshwane (S.D.P., K.A., M. Malahleha, M. Masilela, K.M.), the Division of Pulmonology, Groote Schuur Hospital and the University of Cape Town (K.D., A.E., S.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics, University of Stellenbosch (S.L.B., M.G., L.R.), Cape Town, Soweto Clinical Trials Centre, Soweto (Q.E.B., A.E.B.), and the Africa Health Research Institute (S.-H.H., H.R., A.S.) and the KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu-Natal (S.P., H.T., T.O., A.S.), Durban - all in South Africa",NA
"352","33724440","10.1002/14651858.CD003427.pub5","Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.","Sickle cell disease (SCD) is a group of inherited disorders that result in haemoglobin abnormalities and other complications. Injury to the spleen, among other factors, contribute to persons with SCD being particularly susceptible to infection. Infants and very young children are especially vulnerable. The 'Co-operative Study of Sickle Cell Disease' observed an incidence rate for pneumococcal septicaemia of 10 per 100 person-years in children under the age of three years. Vaccines, including cus","2021","03","24","Cochrane Database Syst Rev","The Cochrane database of systematic reviews","Age Factors; Anemia, Sickle Cell; Antibiotic Prophylaxis; Bias; Child, Preschool; Hemoglobin SC Disease; Homozygote; Humans; Incidence; Infant; Medication Adherence; Penicillins; Pneumococcal Infections; Randomized Controlled Trials as Topic; Streptococcus pneumoniae; beta-Thalassemia","Rankine-Mullings","Angela E","Sickle Cell Unit, Caribbean Institute for Health Research, University of the West Indies, Kingston, Jamaica",NA
"353","33723914","10.1002/eahr.500088","Human Infection Challenge Experiments: Then and Now.","In the midst of the Covid-19 pandemic, ethicists, researchers, and journalists have recommended studies that deliberately infect healthy volunteers with the coronavirus as a scientific means of expediting vaccine development. In this essay, we trace the history of infection challenge experiments and reflect on the Nuremberg Code of 1947, issued in response to brutal human experiments conducted by Nazi investigators in concentration camps. We argue that the Code continues to offer valuable guidan","2021","05","31","Ethics Hum Res","Ethics &amp; human research","Nuremberg Code; human research ethics; human subjects research; independent review; infection challenge experiments; research risks; social value; COVID-19; Clinical Trials as Topic; History, 20th Century; History, 21st Century; Human Experimentation; Humans; National Socialism; SARS-CoV-2","Miller","Franklin G","Professor of medical ethics in medicine at Weill Cornell Medical College",NA
"354","33723528","10.1016/j.isci.2021.102298","Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.","We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established Vero cell platform to produce large-scale GMP-grade highly purified inactivated antigen. Product development and manufacturing process were carried out in a BSL-3 facility. Immunogenicity and safety were determined","2021","04","28","iScience","iScience","Immune Response; Immunology; Virology","Ganneru","Brunda","Bharat Biotech International Ltd, Hyderabad (BBIL), Telangana 500 078, India",NA
"355","33723483","10.1016/j.nurpra.2021.02.010","COVID-19 Management in Pediatrics.","Coronavirus disease 2019 (COVID-19) is a deadly global pandemic, with scientific efforts improving our understanding of this novel coronavirus. No proven disease-specific therapies exist, although 2 vaccines have been recently approved by the United States Food and Drug Administration under emergency use authorization, and several others are in development or phase III clinical trial testing. COVID-19 presents in greater severity in the medically fragile, obese, elderly, and socially disadvantag","2021","06","01","J Nurse Pract","The journal for nurse practitioners : JNP","COVID-19 pandemic; diagnosis; infectious disease; management; pediatric nurse practitioner; treatment","Alcindor","Magalie L",NA,NA
"356","33723371","10.1038/s41571-021-00487-z","COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.","Emerging efficacy data have led to the emergency use authorization or approval of COVID-19 vaccines in several countries worldwide. Most trials of COVID-19 vaccines excluded patients with active malignancies, and thus data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited. Given the risk posed by the COVID-19 pandemic, decisions regarding the use of vaccines against COVID-19 in patients participating in trials of investigational anticancer the","2021","05","10","Nat Rev Clin Oncol","Nature reviews. Clinical oncology","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Neoplasms; Patient Selection; SARS-CoV-2; Vaccination","Desai","Aakash","Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA",NA
"357","33722288","10.1186/s13073-021-00859-1","SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription.","ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28..kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glycoprotein gene. We used direct RNA sequencing to analyse transcript expression from the ChAdOx1 nCoV-19 genome in human MRC-5 and A549 cell lines that are non-permissive for vector replication alongside the repli","2021","03","29","Genome Med","Genome medicine","COVID-19; COVID-19 Vaccines; Cell Line; Cells, Cultured; Gene Expression; Gene Expression Profiling; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Polyadenylation; Proteomics; RNA, Messenger; RNA, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Transcription, Genetic","Almuqrin","Abdulaziz","School of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of Bristol, Bristol, BS8 1TD, UK",NA
"358","33721882","10.1093/ecco-jcc/jjab046","SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges.","Since the beginning of the pandemic, patients with inflammatory bowel diseases (IBD) have been considered at high-risk for infection and complications of COVID-19. However, IBD patients and patients taking immunosuppressive therapy were excluded from clinical phase III vaccine trials, complicating the assessment of effectiveness of these new vaccines. From past experience we know that adapted vaccination strategies may be appropriate in some IBD patients to optimize immunogenicity. We review cur","2021","04","02","J Crohns Colitis","Journal of Crohn's &amp; colitis","SARS-CoV-2; immunogenicity; inflammatory bowel disease; vaccination strategies","Wellens","Judith","Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford",NA
"359","33721697","10.1016/j.rmed.2021.106355","SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.","Non-pharmacological interventions and tracing-testing strategy proved insufficient to reduce SARS-CoV-2 spreading worldwide. Several vaccines with different mechanisms of action are currently under development. This review describes the potential target antigens evaluated for SARS-CoV-2 vaccine in the context of both conventional and next-generation platforms. We reported experimental data from phase-3 trials with a focus on different definitions of efficacy as well as factors affecting real-lif","2021","05","26","Respir Med","Respiratory medicine","COVID-19; Primary prevention; SARS-CoV-2; Vaccination; COVID-19; COVID-19 Vaccines; Humans; Immunity, Herd; Pandemics; SARS-CoV-2; Vaccination","Blasi","Francesco","Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy",NA
"360","33721548","10.1080/13543784.2021.1901883","The time to offer treatments for COVID-19.","Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy relies solely on vaccines to prevent disease.Methods: We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results.Results: As of 2/15/2021, we found 111 publications repor","2021","05","07","Expert Opin Investig Drugs","Expert opinion on investigational drugs","SARS-Cov-2; convalescent plasma; covid-19; favipiravir; hcq; interferon-..-1; interferon-..; ivermectin; remdesivir; synthetic anti-spike protein antibodies","Ngo","Binh T","Department of Internal Medicine, Eastern Virginia Medical School, Pulmonary and Critical Care Medicine, Norfolk, USA",NA
"361","33720612","10.26442/00403660.2020.11.000713","[Umifenovir and coronavirus infections: a review of research results and clinical practice].","Coronaviruses are known to cause acute respiratory infections. Antiviral therapy, including for COVID-19, is based on clinical practice, experimental data and trial results. The purpose of this review is to: provide and systematize actual preclinical data, clinical trials results and clinical practice for antiviral agent umifenovir (Arbidol). Databases Scopus, Web of Science, RSCI and medRxiv were used for publication searching from 2004. A meta-analysis of clinical trials results was performed.","2021","03","17","Ter Arkh","Terapevticheskii arkhiv","COVID-19; SARS-CoV-2; antiviral therapy; coronaviruses; review; umifenovir; Animals; Antiviral Agents; COVID-19; Coronavirus Infections; Humans; Indoles; SARS-CoV-2; Spike Glycoprotein, Coronavirus","Leneva","I A","Mechnikov Research Institute for Vaccines and Sera",NA
"362","33719950","10.2174/2589977513666210315094752","A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2.","The novel coronavirus disease 2019 (COVID-19), emerged in Wuhan, China in December 2019 and then spread worldwide rapidly. The records from World Health Organisation (WHO), Centres of Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) backup the fact that no medications have proven to be completely effective for prevention or treatment of SARS-CoV-2. The clinical trials are underway for many repurposed, investigational drugs and vaccine candidates. BioNTech and Pfizer In","2021","03","15","Curr Drug Res Rev","Current drug research reviews","Antivirals; COVID-19; Drug repurposing; Novel Coronavirus; SARS CoV-2; Vaccine","Khanna","Nikita","University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014. India",NA
"363","33719885","10.1080/10810730.2021.1871985","Creating a Robust Digital Communications Strategy for the US Department of Health &amp; Human Services.","The US Department of Health and Human Services (HHS) has developed and is implementing an agency-wide Digital Communications Strategy. A robust strategy to coordinate digital communications is vital at times of crisis, such as the COVID-19 pandemic - and will be needed as part of an effective HHS campaign to motivate individuals who are hesitant to accept coronavirus vaccines. Using science-based principles of systems change, a four-phase approach was developed in alignment with the 21st Century","2021","04","01","J Health Commun","Journal of health communication","COVID-19; Health Communication; Humans; Program Development; United States; United States Dept. of Health and Human Services","Weber","Mark A","College of Social &amp",NA
"364","33719877","10.1080/10810730.2020.1864520","Health Communication and Decision Making about Vaccine Clinical Trials during a Pandemic.","The COVID-19 pandemic has magnified the importance of clinical trials for finding a safe and effective vaccine to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. Although communication about vaccines and vaccine hesitancy were challenges long before COVID-19, the twin facts of a pandemic and an &quot;infodemic&quot; of health information, misinformation, and disinformation have raised new challenges for vaccine-related communication a","2021","04","01","J Health Commun","Journal of health communication","Adult; COVID-19; COVID-19 Vaccines; Decision Making; Health Communication; Health Knowledge, Attitudes, Practice; Health Literacy; Humans; Intention; Patient Selection; Randomized Controlled Trials as Topic; Research Subjects","Langford","Aisha T","Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA",NA
"365","33718854","10.1016/j.eclinm.2021.100780","Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members.",NA,"2021","04","02","EClinicalMedicine","EClinicalMedicine",NA,"Hotez","Peter","Texas Children's Center for Vaccine Development, Baylor College of Medicine, Houston, TX, USA",NA
"366","33717077","10.3389/fimmu.2021.598778","A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.","Emerging infectious diseases (EIDs) caused by viruses are increasing in frequency, causing a high disease burden and mortality world-wide. The COVID-19 pandemic caused by the novel SARS-like coronavirus (SARS-CoV-2) underscores the need to innovate and accelerate the development of effective vaccination strategies against EIDs. Human leukocyte antigen (HLA) molecules play a central role in the immune system by determining the peptide repertoire displayed to the T-cell compartment. Genetic polymo","2021","03","18","Front Immunol","Frontiers in immunology","SARS-CoV-2; T-cell epitope; emerging-infectious disease; epitope discovery; ethnicity; immunoinformatics; vaccine design; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Communicable Diseases, Emerging; Epitopes, T-Lymphocyte; Ethnic Groups; HLA Antigens; Humans; Immunogenicity, Vaccine; Medical Informatics Applications; Pandemics; Polymorphism, Genetic; Protein Binding; Proteomics; SARS-CoV-2; Software; Spike Glycoprotein, Coronavirus","Oyarzun","Patricio","Facultad de Ingenier..a y Tecnolog..a, Universidad San Sebasti..n, Sede Concepci..n, Concepci..n, Chile",NA
"367","33711296","10.1016/S0140-6736(21)00503-1","Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development.","The research and development (R&amp;D) ecosystem has evolved over the past decade to include pandemic infectious diseases, building on experience from multiple recent outbreaks. Outcomes of this evolution have been particularly evident during the COVID-19 pandemic with accelerated development of vaccines and monoclonal antibodies, as well as novel clinical trial designs. These products were developed, trialled, manufactured, and authorised for use in several countries within a year of the pandem","2021","04","07","Lancet","Lancet (London, England)","Global Health; Humans; International Cooperation; Models, Organizational; Pandemics; Research","Lurie","Nicole","Coalition for Epidemic Preparedness Innovations, Oslo, Norway",NA
"368","33711085","10.2196/22470","Predicting Health Disparities in Regions at Risk of Severe Illness to Inform Health Care Resource Allocation During Pandemics: Observational Study.","Pandemics including COVID-19 have disproportionately affected socioeconomically vulnerable populations. Our objective was to create a repeatable modeling process to identify regional population centers with pandemic vulnerability. Using readily available COVID-19 and socioeconomic variable data sets, we used stepwise linear regression techniques to build predictive models during the early days of the COVID-19 pandemic. The models were validated later in the pandemic timeline using actual COVID-1","2021","03","15","JMIRx Med","JMIRx med","COVID-19; SARS-CoV-2; coronavirus; health care resource allocation; pandemic; predictive model; socioeconomic status","Fusillo","Tara","John F Kennedy High School Bellmore, NY United States",NA
"369","33709292","10.1007/s11695-021-05339-4","Eighty-Seven Consecutive Sleeve Gastrectomies Between the Two Peaks of the Covid-19 Pandemic. An Opening-Phase Experience.","During the Covid-19 pandemic, the outcome of symptomatic Covid-19 infection occurring early after elective operations is reportedly associated with fatalities. Incidence is unknown and data on bariatric practice is scarce. Covid-19 exposure status and outcomes of sleeve gastrectomy (SG) between the first two peaks of the pandemic are prospectively evaluated. During our &quot;opening-phase,&quot; candidates for SG were enrolled after written informed consent was obtained which specifically emphas","2021","06","07","Obes Surg","Obesity surgery","Covid-19; SARS-CoV-2; complication; elective surgery; sleeve gastrectomy; COVID-19; Gastrectomy; Humans; Obesity, Morbid; Pandemics; SARS-CoV-2; Treatment Outcome","Yerdel","Mehmet Ali","..stanbul Bariatrics, Obesity and Advanced Laparoscopy Center, Fulya Mah. Ye..il..imen Sok. 12/407 34394, ..i..li, ..stanbul, Turkey. yerdel@yerdel","yerdel@yerdel.com"
"370","33707061","10.1016/j.vaccine.2021.02.007","A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.","Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike protein of SARS-CoV-2. This phase 2, randomized, observer-blind, placebo-controlled trial was conducted at 8 sites in the USA, in healthy adults aged.....18..years with no known history or risk of SARS-CoV-2 infection, and had not previously received an investiga","2021","05","06","Vaccine","Vaccine","COVID-19; Immunogenicity; Phase 2; SARS-CoV-2; Safety; Vaccine; mRNA-1273; Adolescent; Adult; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Double-Blind Method; Humans; Immunization, Passive; Immunogenicity, Vaccine; RNA, Messenger; SARS-CoV-2; Vaccines","Chu","Laurence","Benchmark Research, 3100 Red River St #2, Austin, TX 78705, United States",NA
"371","33705727","10.1016/S1473-3099(21)00070-0","Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.","BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 ..g or 6 ..g) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-blind, multicentre, randomised, controlled phase 1 trial on the safety and immunogenicity of three different formulations of BBV152 (3 ..g with Algel-IMDG, 6 ..g with Algel-IMDG, or 6 ..g with Algel) and one Algel-only control (no antigen), with the first dose administered on day 0 and the","2021","03","11","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Ella","Raches","Bharat Biotech, Hyderabad, India",NA
"372","33705636","10.3906/sag-2012-310","CURRENT COMMUNITY TRANSMISSION AND FUTURE PERSPECTIVES ON THE COVID-19 PROCESS.","COVID-19 syndrome due to the SARS-CoV-2 virus is a currently challenging situation ongoing Worldwide. Since the current pandemic of the SARS-CoV-2 virus is a great concern for everybody in the World, the frequently asked question is how and when the COVID-19 process will be concluded. The aim of this paper is to propose hypotheses in order to answer this essential question. As recently demonstrated, SARS-CoV-2 RNAs can be reverse-transcribed and integrated into the human genome. Our main hypothe","2021","03","15","Turk J Med Sci","Turkish journal of medical sciences","COVID-19; Genomic integration; SARS-CoV-2; Virobiota","T..rk","Seyhan",NA,NA
"373","33704435","10.1093/cid/ciab229","Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening.","Several vaccines are now clinically available under emergency use authorization in the United States and have demonstrated efficacy against symptomatic COVID-19. The impact of vaccines on asymptomatic SARS-CoV-2 infection is largely unknown. We conducted a retrospective cohort study of consecutive, asymptomatic adult patients (n = 39,156) within a large United States healthcare system who underwent 48,333 pre-procedural SARS-CoV-2 molecular screening tests between December 17, 2020 and February ","2021","04","02","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Asymptomatic; COVID-19; SARS-CoV-2; vaccination","Tande","Aaron J","Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA",NA
"374","33704352","10.1001/jama.2021.3645","Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.","Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson &amp; Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses. Twenty-five participants were enrolled from July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was completed on October 3, 2020; fol","2021","05","03","JAMA","JAMA","Adult; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Double-Blind Method; Female; Humans; Immunity, Cellular; Immunity, Humoral; Immunogenicity, Vaccine; Male; Middle Aged; Vaccine Potency; Young Adult","Stephenson","Kathryn E","Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts",NA
"375","33693552","10.1093/cid/ciab213","Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines.","COVID-19 vaccine trials provide valuable insight into the safety and efficacy of vaccines, with individually-randomized, placebo-controlled trials being the gold standard in trial design. However, a myriad of variables must be considered as clinical trial data are interpreted and used to guide policy decisions. These variables include factors such as the characteristics of the study population and circulating SARS-CoV-2 strains, the force of infection, the definition and ascertainment of endpoin","2021","04","02","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","COVID-19; SARS-CoV-2; clinical trial; efficacy; vaccine","Rapaka","Rekha R","University of Maryland Center for Vaccine Development and Global Health, University of Maryland School of Medicine",NA
"376","33693529","10.1093/cid/ciab226","Evaluating the Long-Term Efficacy of COVID-19 Vaccines.","Large-scale deployment of safe and durably effective vaccines can curtail the COVID-19 pandemic.1-3 However, the high vaccine efficacy (VE) reported by ongoing phase 3 placebo-controlled clinical trials is based on a median follow-up time of only about two months4-5 and thus does not pertain to long-term efficacy. To evaluate the duration of pro- tection while allowing trial participants timely access to efficacious vaccine, investigators can sequentially cross participants over from the placebo","2021","04","22","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","SARS-CoV-2; booster vaccination; durability of vaccine efficacy; phase 3 trials; severe COVID-19; waning efficacy","Lin","Dan-Yu","Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA",NA
"377","33692215","10.1128/JVI.00194-21","Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19.","Within a year after its emergence, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 100 million people worldwide with a death toll over 2 million. Vaccination remains the best hope to ultimately put this pandemic to an end. Here, using Trimer-Tag technology, we produced both wild-type (WT) and furin site mutant (MT) S-Trimers for COVID-19 vaccine studies. Cryo-EM structures of the WT and MT S-Trimers, determined at 3.2 .. and 2.6 .. respectively, revealed that b","2021","03","11","J Virol","Journal of virology",NA,"Ma","Jiahao","Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China",NA
"378","33691913","","Efficacy and safety of COVID-19 vaccines: a systematic review.","To evaluate systematically the efficacy and safety of COVID-19 vaccines. PubMed, Embase, Cochrane Library, Clinicaltrial.gov, CNKI, Wanfang Data, China Biomedical Literature Service System, and China Clinical Trial Registry were searched for randomized controlled trials of COVID-19 vaccines published up to December 31, 2020. The Cochrane bias risk assessment tool was used to assess the quality of studies. A qualitative analysis was performed on the results of clinical trials. Thirteen randomized","2021","03","12","Zhongguo Dang Dai Er Ke Za Zhi","Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics","Aged; COVID-19; COVID-19 Vaccines; China; Humans; SARS-CoV-2; Vaccines","Xing","Kai","Department of Pediatrics, Renmin Hospital of Wuhan University, Wuhan 430060, China",NA
"379","33691737","10.1186/s12985-021-01525-z","Optimal preparation of SARS-CoV-2 viral transport medium for culture.","The sudden arrival of the COVID-19 pandemic placed significant stresses on supply chains including viral transport medium (VTM). The VTM that was urgently required needed to support viral replication, as well as other routine diagnostic approaches. We describe the preparation and validation testing of VTM for rapidly expanding diagnostic testing, where the capacity of the VTM to preserve viral integrity, for culture, isolation and full sequence analysis, was maintained. VTM was prepared using di","2021","03","22","Virol J","Virology journal","Culture; Diagnosis; SARS-CoV-2; Transport media; VTM; Animals; Anti-Bacterial Agents; COVID-19; COVID-19 Testing; Cell Line; Chlorocebus aethiops; Culture Media; Humans; RNA, Viral; SARS-CoV-2; Specimen Handling; Vero Cells","McAuley","Julie","Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, 3000, Australia",NA
"380","33689074","10.1134/S1607672921010129","Thermovaccination: Thermoheliox as an Immune Response Stimulant. Kinetics of Antibodies and C-Reactive Protein Synthesis in Coronaviral Infection.","The high efficiency of using thermoheliox (inhalation with a high-temperature mixture of helium and oxygen) in the treatment of patients affected by COVID-19 was shown. The dynamics of accumulation of IgG, IgM, and C-reactive protein (CRP) in patients with coronavirus infection in the &quot;working&quot; and control groups was studied experimentally. It was shown that thermoheliox intensifies the synthesis of IgG, IgM, and CRP antibodies, while eliminating the induction period on the kinetic cur","2021","03","22","Dokl Biochem Biophys","Doklady. Biochemistry and biophysics","C-reactive protein; coronavirus; immunoglobulin G; immunoglobulin M; kinetic model; thermoheliox; thermovaccination; Antibodies, Viral; C-Reactive Protein; COVID-19; Humans; Immunity; Kinetics; Spike Glycoprotein, Coronavirus; Vaccination","Varfolomeev","S D","Department of Chemistry, Moscow State University, 119991, Moscow, Russia",NA
"381","33688668","10.1101/2021.02.26.21252483","Mathematical modeling to inform vaccination strategies and testing approaches for COVID-19 in nursing homes.","Nursing home residents and staff were included in the first phase of COVID-19 vaccination in the United States. Because the primary trial endpoint was vaccine efficacy (VE) against symptomatic disease, there are limited data on the extent to which vaccines protect against SARS-CoV-2 infection and the ability to infect others (infectiousness). Assumptions about VE against infection and infectiousness have implications for possible changes to infection prevention guidance for vaccinated population","2021","06","08","medRxiv","medRxiv : the preprint server for health sciences",NA,"Kahn","Rebecca","Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts",NA
"382","33688588","10.35772/ghm.2021.01010","COVID-19 vaccines: implementation, limitations and opportunities.","The speed of development and the magnitude of efficacy of recently developed vaccines directed against SARS-CoV-2 has been truly remarkable. This editorial will not summarize the highly publicized and reviewed information about the design and clinical trial results of these vaccines. Rather, I will speculate about several issues regarding i) considerations of the rollout and implementation of the multiple vaccines, ii) the use of the vaccines in ways different from those used in th","2021","03","12","Glob Health Med","Global health &amp; medicine","COVID-19; SARS-CoV-2; vaccine","Richman","Douglas D","University of California San Diego, Distinguished Professor of Pathology and Medicine (Active Emeritus)",NA
"383","33688540","10.4103/jehp.jehp_457_20","Review of investigational drugs for coronavirus disease 2019.","In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became evident in Wuhan, China, and then spread rapidly worldwide. Numerous drugs and vaccines are under clinical trial pipeline for investigation against coronavirus disease 2019 (COVID-19) infection. The aim of this systematic review was to discuss about investigational new as well as repurposed drugs currently under trial for COVID-19 infection. An exhaustive search was carried out for this review article inclu","2021","03","12","J Educ Health Promot","Journal of education and health promotion","Coronavirus; Solidarity trial; coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2","Sharma","Dhruva","Department of Cardiothoracic and Vascular Surgery, SMS Medical College and Attached Hospitals, Jaipur, Rajasthan, India",NA
"384","33688448","10.1007/s40005-021-00520-4","Potential therapeutic and pharmacological strategies for SARS-CoV2.","At the end of 2019, the new Coronavirus disease 2019 (COVID-19) strain causing severe acute respiratory syndrome swept the world. From November 2019 till February 2021, this virus infected nearly 104 million, with more than two million deaths and about 25 million active cases. This has prompted scientists to discover effective drugs to combat this pandemic. Drug repurposing is the magic bullet for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Therefore, several drugs have","2021","03","12","J Pharm Investig","Journal of pharmaceutical investigation","COVID-19; Camostat; Hydroxychloroquine; Indomethacin; Teicoplanin; Tocilizumab","Ghareeb","Doaa A","Biological Screening and Preclinical Trial Laboratory, Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt",NA
"385","33688023","10.1136/jitc-2021-002489","Perspectives on COVID-19 and cancer immunotherapy: a review series.",NA,"2021","03","22","J Immunother Cancer","Journal for immunotherapy of cancer","COVID-19; COVID-19; Disease Management; Humans; Immunotherapy; Neoplasms; SARS-CoV-2","Goldman","Jason D","Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, WA, USA",NA
"386","33686064","10.1038/s41392-021-00525-3","The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity.","The adaptive immunity that protects patients from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is not well characterized. In particular, the asymptomatic patients have been found to induce weak and transient SARS-CoV-2 antibody responses, but the underlying mechanisms remain unknown; meanwhile, the protective immunity that guide the recovery of these asymptomatic patients is elusive. Here, we characterized SARS-CoV-2-specific B-cell","2021","03","22","Signal Transduct Target Ther","Signal transduction and targeted therapy","Adaptive Immunity; Adult; B-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; Female; Humans; Male; SARS-CoV-2; Severity of Illness Index; Th1 Cells","Gao","Leiqiong","Institute of Immunology, Third Military Medical University, Chongqing, China",NA
"387","33685939","10.1136/bmj.n605","Racial and ethnic health disparities in healthcare settings.",NA,"2021","03","19","BMJ","BMJ (Clinical research ed.)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Community Participation; Continental Population Groups; Culturally Competent Care; Ethnic Groups; Health Services Research; Health Status Disparities; Healthcare Disparities; Humans; Minority Groups; Patient Selection; United Kingdom","Gardiner","Tom","London North West University Healthcare NHS Trust, London, UK thomas.gardiner@nhs","thomas.gardiner@nhs.net"
"388","33685502","10.1186/s13063-021-05139-2","Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.","The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is associated with a decrease in viral load of SARS-CoV-2 compared with placebo. FLARE is a phase IIA randomised, double-blind, 2x2 factorial placebo-controlled, interventional trial. This trial is being conducted in the United Kingdom, with Royal Free Hospital, London as the lead site. Participant","2021","03","18","Trials","Trials","COVID-19; antivirals; combination therapy; early treatment; factorial design; favipiravir; lopinavir/ritonavir; placebo-controlled trial; protocol; randomised controlled trial; Ambulatory Care; Amides; Antiviral Agents; COVID-19; Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Early Medical Intervention; Humans; Lopinavir; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; United Kingdom; Viral Load","Brown","Li-An K","UCL Institute of Immunity and Transplantation, Royal Free Hospital, Pond Street, London, NW3 2QG, UK",NA
"389","33684351","10.1016/S0140-6736(21)00384-6","Sex-disaggregated data in COVID-19 vaccine trials.",NA,"2021","03","26","Lancet","Lancet (London, England)","COVID-19 Vaccines; Clinical Trials as Topic; Data Analysis; Female; Humans; Male; Sex Factors","Vijayasingham","Lavanya","Gender and Health Hub United Nations University-International Institute for Global Health, UKM Medical Centre, 56000 Kuala Lumpur, Malaysia. Electronic address: vijayasingham@unu","vijayasingham@unu.edu"
"390","33683637","10.1007/s40265-021-01480-7","BNT162b2 mRNA COVID-19 Vaccine: First Approval.","BNT162b2 (Comirnaty<sup>..</sup>; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. BNT162b2 encodes the SARS-CoV-2 spike protein, the expression of which elicits immune responses against the antigen in recipients. In early December 2020, BNT162b2 received a temporary emergency use authorization (EUA) in the ","2021","03","25","Drugs","Drugs","Bahrain; COVID-19; COVID-19 Vaccines; Canada; Clinical Trials as Topic; Drug Approval; Drug Development; European Union; Humans; Mexico; SARS-CoV-2; Saudi Arabia; Spike Glycoprotein, Coronavirus; Switzerland; United Kingdom; United States; Vaccines, Synthetic; World Health Organization","Lamb","Yvette N","Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis","dru@adis.com"
"391","33683337","10.1182/bloodadvances.2020003880","Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias.","Patients with plasma cell dyscrasias (PCDs) experience an increased burden of influenza, and current practice of single-dose annual influenza vaccination yields suboptimal protective immunity in these patients. Strategies to improve immunity to influenza in these patients are clearly needed. We performed a randomized, double-blind, placebo-controlled clinical trial comparing tandem Fluzone High-Dose influenza vaccination with standard-of-care influenza vaccination. Standard-of-care vaccination w","2021","03","16","Blood Adv","Blood advances","Adult; Aged; Aged, 80 and over; Double-Blind Method; Humans; Influenza Vaccines; Influenza, Human; Middle Aged; Paraproteinemias","Branagan","Andrew R","Yale Cancer Center, New Haven, CT",NA
"392","33683080","10.36849/JDD.5899","Coronavirus Vaccination Adverse Reactions and the Role of the Dermatologist.",NA,"2021","03","16","J Drugs Dermatol","Journal of drugs in dermatology : JDD","COVID-19; COVID-19 Vaccines; Dermatologists; Female; Health Knowledge, Attitudes, Practice; Humans; Injection Site Reaction; Male; Patient Education as Topic; Physician's Role; Randomized Controlled Trials as Topic; Skin Diseases; Spike Glycoprotein, Coronavirus; Vaccines, Synthetic","Pulsipher","Kayd J",NA,NA
"393","33682615","10.1080/19390211.2021.1890662","Trace Minerals, Vitamins and Nutraceuticals in Prevention and Treatment of COVID-19.","Coronavirus disease 2019 (COVID-19) was first officially diagnosed in the city of Wuhan, China in January 2020. In reality, the disease was identified in December 2019 in the same city where patients began showing symptoms of pneumonia of unidentified origin. Very soon the disease became a global pandemic due to the suppression of information in the country of origin and inadequate testing for the COVID-19 virus. Currently, &gt; 101 million people have been found positive for this virus and &gt;","2021","05","08","J Diet Suppl","Journal of dietary supplements","COVID-19; SARS-CoV-2; cepharanthine; coagulopathy; curcumin; cytokine storm; elderberry; iron transport polyethylene glycol succinate; lactoferrin; metalocomplex curcuminoids; nutraceuticals; trace minerals; vitamins","Srivastava","Ajay","Vets Plus Inc, Menomonie, WI, USA",NA
"394","33682603","10.1080/17512433.2021.1900728","How do nocebo effects in placebo groups of randomized controlled trials provide a possible explicative framework for the COVID-19 pandemic?","Introduction: Randomized clinical trials (RCTs) are useful to study the role of individual and contextual factors in which therapies vs placebos are administered and to provide an important perspective for understanding the phenomenon of nocebo-related risks.Areas covered: The results of nocebo effects in RCT placebo groups, measured in terms of adverse events (AEs) and dropouts, will be presented as an explicative framework for the COVID-19 pandemic. Currently, SARS-CoV-2 vaccines","2021","05","10","Expert Rev Clin Pharmacol","Expert review of clinical pharmacology","Adverse events; COVID-19; aging; nocebo effect; randomized clinical trials; COVID-19; COVID-19 Vaccines; Europe; Humans; Medication Adherence; Nocebo Effect; Patient Dropouts; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Vaccination Refusal","Amanzio","Martina","Department of Psychology, University of Turin, Turin, Italy",NA
"395","33681861","10.1016/j.idnow.2021.02.007","COVID-19 vaccines: Frequently asked questions and updated answers.","At the end of December 2019, China notified the World Health Organization about a viral pneumonia epidemic soon to be named COVID-19, of which the infectious agent, SARS-CoV-2, was rapidly identified. Less than one year later, published phase 3 clinical trials underlined the effectiveness of vaccines utilizing hitherto unusual technology consisting in injection of the messenger RNA (m-RNA) of a viral protein. In the meantime, numerous clinical trials had failed to identify a maximally effective ","2021","05","11","Infect Dis Now","Infectious diseases now","COVID-19; Review; SARS-CoV-2; Vaccine","Lefebvre","M","Service des maladies infectieuses et tropicales, centre de pr..vention des maladies infectieuses et transmissibles, centre hospitalo-universitaire H..tel-Dieu, Inserm CIC1413, 1, place Alexis-Ricordeau, 44000 Nantes, France. Electronic address: maeva.lefebvre@chu-nantes",NA
"396","33681731","10.1016/j.eclinm.2021.100773","Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.","Treatment options for outpatients with COVID-19 could reduce morbidity and prevent SARS-CoV-2 transmission. In this randomized, double-blind, three-arm (1:1:1) placebo-equivalent controlled trial conducted remotely throughout the United States, adult outpatients with laboratory-confirmed SARS-CoV-2 infection were recruited. Participants were randomly assigned to receive hydroxychloroquine (HCQ) (400..mg BID x1day, followed by 200..mg BID x9days) with or without azithromycin (AZ) (500..mg, then 2","2021","04","02","EClinicalMedicine","EClinicalMedicine","Azithromycin; COVID-19; Coronavirus; Early treatment; Hydroxychloroquine; Randomized controlled trial; Remote enrollment; SARS-CoV-2","Johnston","Christine","Division of Allergy and Infectious Diseases, University of Washington, United States",NA
